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Japanese encephalitis virus (JEV) is one of the primary global causes of viral encephalitis, with 
approximately 68,000 clinical cases and 20,000 deaths attributed to the virus annually. 
Between 30% and 50% of survivors suffer from debilitating neurological sequelae. Despite 
being a vaccine-preventable disease, no antiviral treatments are licensed and commercially 
available to counteract JEV infection. In order to quantify the neutralising antibody response 
raised against antigenic epitopes on flavivirus prME glycoproteins, conventional serological 
assays such as the plaque reduction neutralisation test (PRNT) can be employed. However, 
these assays often necessitate the handling of pathogenic wild-type virus in expensive high-
biosafety laboratories, restricting the scope of their application, particularly in resource-
deprived areas. Chimeric, replication-deficient pseudotype viruses can offer a solution to this 
problem, as they mimic wild-type virus entry mechanisms, enabling their use in pseudotype 
virus neutralisation assays (PVNAs). PVNAs bypass high biosafety requirements and permit 
vaccine evaluation and serosurveillance studies with no risk of inadvertent infection.  
This project focuses on the production of functional pseudotype viruses displaying the prM 
and E surface glycoproteins of the JEV flavivirus, for utilisation in serological neutralisation 
assays. Subcloning of the prME gene into an appropriate eukaryotic expression vector and 
insertion mutagenesis to produce prME with 15- and 24-residue upstream signal peptides are 
shown, before production of JEVpp with either HIV or MLV cores is attempted, via the 
conventional multi-plasmid co-transfection approach or the utilisation of constitutive gag-pol 
expressing cell lines. The impact of additional plasmid-derived furin protease expression and 
low glucose culture medium, as well as the construction of JEV/VSV chimeric prME 
glycoproteins and the introduction of Kozak consensus sequences upstream of the prME gene, 
to enhance the efficiency of JEVpp generation is also explored. Finally, the infectivity of 
lentiviral pseudotype viruses following lyophilisation, storage and reconstitution is confirmed, 
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Chapter 1 Introduction①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.1 Japanese encephalitis virus①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.1.1 HistorǇ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.33 
1.1.2 PhylogenǇ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.① ①?①?①? 
1.1.3 Transmission and epidemiologǇ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.1.4 Clinical manifestation and disease symptomƐ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.1.5 Virion and genomĞ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.①?①?①? 
1.1.5.1 C proteiŶ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
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1.1.5.2 pr and M proteinƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?    ? ? 
1.1.5.3 E proteiŶ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.5.4 Non-structural proteinƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6 Virus life cyclĞ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.1.6.1 Attachment, entry and cellular receptorƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.1 Glycosaminoglycans (GAGs) and heparan sulfatĞ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.2 CLEC5A ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.3 High affinity laminin receptor ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.4 Heat shock protein 70 (HSP70) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.5 Vimentin ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.1.6 Integrin ɲVɴ3 ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?  
1.1.6.1.7 Nucleolin ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.6.2 Fusion, expression, assembly and egresƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.7 Immunity ĂŶĚƉĂƚŚŽŐĞŶĞƐŝƐ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?Q.①?①?①? 
1.1.7.1 Humoral immunitǇ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
1.1.7.2 Cell-mediated immunitǇ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.8 Vaccines①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.①?①?①? 
1.1.9 Antivirals①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?① ①?①?①?①?①?①?①? 
1.1.10 Diagnosis and serology①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①?①?①?①?①? 
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1.1.10.1 Detection of JEV IgM antibodies ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?..71  
1.1.10.2 Detection of JEV IgG antibodies ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.1.10.3 Haemagglutination inhibition (HI) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
1.1.10.4 Plaque reduction neutralisation test (PRNT) ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
1.2 Surrogate virus particles for flavivirus serology①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
1.2.1 Genetically ŵŽĚŝĨŝĞĚĂŶĚƌĞĐŽŵďŝŶĂŶƚǀŝƌƵƐĞƐ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①?①?①?①?①?  
1.2.2 Reporter virus particles①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q①?①?①? 
1.2.3 Virus-like particles produced in insect cells①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q①Q?①?①? 
1.3 Pseudotype viruses①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?  




Chapter 2 General materials and ŵĞƚŚŽĚƐ①?①?①?①?①?①?①?①?①?①?①?①?①?①?..①?①?88 
2.1 DŽůĞĐƵůĂƌďŝŽůŽŐǇ①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?88 
2.1.1 Plasmids①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①?88 
2.1.2 Liquid and solid bacterial media①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q91 
2.1.3 Transformation of chemically competent E. coli cells①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①?91 
2.1.4 Plasmid DNA purification from bacterial culture①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..92 
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2.1.5 Calculation of nucleic acid concentration①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q①Q93 
2.1.6 Oligonucleotide primers for molecular biology and sequencing purposes①?①?①?①?①?①?①?①?①? 
2.1.7 Sanger chain termination sequencing①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q①Q①Q①Q94 
2.1.8 Polymerase chain reactions①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..95 
2.1.9 Restriction endonuclease digestion of DNA①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①?①?96 
2.1.10 DNA ligation①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.97 
2.1.11 Colony polymerase chain reaction for screening of recombinant clones①?①?①?①?①?①?①Q①?①?98 
2.1.12 Gel electrophoresis of DNA①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q98 
2.1.13 Polymerase chain reaction and restriction digest purification of DNA fragments①?①?100 
2.1.14 Agarose gel extraction of DNA fragments①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①?100 
2.1.15 Site-directed mutagenesis of DNA using Q5 polymerase①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q101 
2.2 Cell culture①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..103 
2.2.1 Maintenance and characteristics of cell lines①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q103 
2.2.2 Freezing and thawing of cell lines①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①?①?104 
2.3 Pseudotype production①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..105 
2.3.1 Plasmids used for pseudotype production①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①?①?105 
2.3.2 Protocol for pseudotype production①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q106 
2.3.3 Titration assay for pseudotype viruses①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..107 
2.3.4 Pseudotype virus neutralisation assay①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..108 
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2.4.2 SDS-PAGE and Western blotting①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①Q①Q①Q①?110 
Chapter 3 Manipulating transfection and assay parameters to attempt 
production of functional retroviral pseudotypes bearing JEV envelope 
glycoproteins①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
3.1 Introduction①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
3.2 Materials and Methods①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?..116 
3.2.1 Molecular biology①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?Q①Q①?116 
3.2.1.1 Genes ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.2 Restriction digests ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.3 Gel electrophoresis ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?116 
3.2.1.4 PCR purifications and gel extractions ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?117 
3.2.1.5 Ligations ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
 ? ? ? ? ? ? ?dƌĂŶƐĨŽƌŵĂƚŝŽŶƐ ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.7 Colony PCR ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.8 Overnight cultures ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.9 Plasmid purification ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.2.1.10 Site-directed mutagenesis ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
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3.2.2 Production of pseudotype viruses and pseudotype-based assays①?①?①?①?①?①?①?①?①?①?①Q①?①?122 
3.2.2.1 Multi-plasmid co-transfection to produce pseudotype viruses ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
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3.2.3.1 Immunofluorescence ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ?
3.2.3.2 SDS-PAGE and Western blotting ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? ? 
3.3 Results①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①? 
3.3.1 Subcloning of 15SPprME gene into pCAGGS expression vector①?①?①?①?①?①?①?①?①?①Q①Q①Q①Q124 
3.3.2 Site-directed insertion mutagenesis to create 24SPprME①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?①?.126 
3.3.3 Production of JEV pseudotype viruses with HIV and MLV cores①?①?①?①?①?①?①?①?①?①?①?①Q①?①?127 
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3.3.5 Low glucose environment for generating JEV pseudotype viruses①?①?①?①?①?①?①?①?①?①Q①Q①?132 
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cGP  Chimeric glycoprotein 
CHO  Chinese hamster ovary 
CLEC5A  C-type lectin domain family 5 member A 
CLR  C-type lectin receptor 
CMC  Carboxymethylcellulose 
CME  Clathrin-mediated endocytosis 
CMV  Cytomegalovirus 
CNS  Central nervous system 
CO2  Carbon dioxide 
COOH  Carboxylic acid 
CPCV  Cacipacore virus 
CPE  Cytopathic effect 
cPPT  Central polypurine tract cis-active sequence 
CPRG  Chlorophenol red-ɴ-d-galactopyranoside 
CRD  Carbohydrate recognition domain 
CrFK  Crandell-Rees feline kidney 
CSF  Cerebrospinal fluid 
C-terminus  Carboxyl terminus 
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CY  Cytoplasmic 
DAP12  DNAX-activating protein 12kDa 
DAPI  4',6-diamidino-2-phenylindole 
DC  Dendritic cell 
DC-SIGN Dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin 
DC-SIGNR Closely related homologue of DC-SIGN 
DENV  Dengue virus 
DMEM  ƵůďĞĐĐŽ①?ƐŵŽĚŝĨŝĞĚĞĂŐůĞŵĞĚŝƵŵ 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
dNTP  Deoxynucleotide triphosphate 
E  Envelope gene/protein 
E.coli  Escherichia coli 
EDTA  Ethylenediaminetetraacetic acid 
EG  Envelope glycoprotein 
eGFP  Enhanced green fluorescent protein 
EIAV  Equine infectious anemia virus 
ELISA  Enzyme-linked immunosorbent assay 
ER  Endoplasmic reticulum 
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ERA  Evelyn Rokitniki Abseleth 
F  Fusion 
Fab  Fragment antigen-binding  
Fas  First apoptosis signal 
FasL  First apoptosis signal ligand 
FAVN  Fluorescent antibody virus neutralization 
FBS  Foetal bovine serum 
Fc  Fragment crystallization region 
&Đɶ  Fc-gamma receptor 
FFU/ml  Focus forming units per millilitre 
FITC  Fluorescein isothiocyanate 
FMDV  Foot and mouth disease virus 
Fwd  Forward 
g  Grams or g-force 
GAG  Glycosaminoglycan 
GFP  Green fluorescent protein 
GI  JEV genotype I 
GII  JEV genotype II 
GIII  JEV genotype III 
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GIV  JEV genotype IV 
GV  JEV genotype V 
H+L  Heavy and light chain 
HA  Haemagglutinin 
HCV  Hepatitis C virus 
HEK293T Human embryonic kidney 293 T  
HEK293T/17 Human embryonic kidney 293 T clone 17 
HFV  Human foamy virus 
HI  Haemagglutination inhibition 
HIV  Human immunodeficiency virus 
HMM  Hidden Markov model 
HN  Haemagglutinin-neuraminidase 
HPIV-3  Human parainfluenza virus type 3 
HSC70  Heat shock cognate protein 70 
HSP70  Heat shock protein 70 
HSV-1  Herpes simplex virus type 1 
HxNx  Haemagglutinin-neuraminidase (influenza subtype) 
IC50  Half maximal inhibitory concentration 
IC90  90% inhibitory concentration 
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IE  Immediate-early 
IF  Immunofluorescence 
IFA  Indirect fluorescent antibody 
IFN  Interferon 
IFN-ɶ  Interferon gamma 
IgG  Immunoglobulin G 
IgM  Immunoglobulin M 
IL-10  Interleukin 10 
IL-4  Interleukin 4 
ITAM  Immunoreceptor tyrosine-based activation motif 
JAK-STAT Janus kinase/signal transducers and activators of transcription 
JEV  Japanese encephalitis virus 
kb  Kilobase 
KCl  Potassium chloride 
kDa  Kilodalton 
KLD  Kinase-ligase-DpnI 
KOUV  Koutango virus 
Koz  Kozak (consensus sequence) 
KUNV  Kunjin virus 
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L  Litre 
LB  Luria Bertani 
LBV  Lagos bat virus 
LC-MS/MS Liquid chromatography tandem-mass spectrometry 
log   Logarithm 
L-SIGN  Liver/lymph node-specific intercellular adhesion molecule-3-grabbing integrin 
LTR  Long tandem repeat 
Luc  Luciferase 
Lys  Lysine 
M  Molar or membrane gene/protein 
Mab/mAb Monoclonal antibody 
MAC-ELISA IgM capture enzyme-linked immunosorbent assay 
MALDI-TOF Matrix-assisted laser desorption/ionization-time of flight 
MARV  Marburg virus 
mBar  Millibar 
MCS  Multiple cloning site 
MERS  Middle East respiratory syndrome 
mg  Milligram 
Mg2+  Magnesium ion 
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MgCl2  Magnesium chloride 
MgSO4  Magnesium sulphate 
ml  Millilitre 
MLV  Murine leukaemia virus 
mM  Millimolar 
MOKV  Mokola virus 
MVEV  Murray Valley encephalitis virus  
MW  Molecular weight 
MɴCD  Methyl-beta-cyclodextrin 
NaCl  Sodium chloride 
NC  Nucleocapsid 
NDV  Newcastle disease virus 
ng  Nanogram 
NLS  Nuclear localization signal 
nm  Nanometer 
nmol  Nanomolar 
NS1  Non-structural gene/protein 1 
NS2A  Non-structural gene/protein 2A 
NS2B  Non-structural gene/protein 2B 
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NS3  Non-structural gene/protein 3 
NS4A  Non-structural gene/protein 4A 
NS4B  Non-structural gene/protein 4B 
NS5  Non-structural gene/protein 5 
nt  Nucleotide 
N-terminus Amino terminus 
NTPase  RNA nucleoside triphosphatase 
NY-1  New York-1 hantavirus 
ONPG  O-nitrophenyl-ɴ-d-lactopyranoside 
p  Plasmid 
PAGE  Polyacrylamide gel electrophoresis 
PBMC  Peripheral blood mononuclear cell 
PBS  Phosphate buffered saline 
PCR  Polymerase chain reaction 
PDL  Poly-D-lysine 
PEI  Polyethylenimine 
PFU/ml  Plaque forming units per millilitre 
pH  Power/potential of hydrogen 
PIP  Pseudo-infectious particle 
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pmol  Picomolar 
PNA  Pseudotype neutralisation assay 
pp  Pseudotype particle 
prM  Pre-membrane gene/protein 
prME  Pre-membrane-envelope gene/protein 
PRNT  Plaque reduction neutralisation test 
PV  Pseudotype virus 
PVDF  Polyvinylidene fluoride 
PVNA  Pseudotype virus neutralisation assay 
R.luc  Renilla luciferase 
RABV  Rabies virus 
RdRp  RNA-dependent RNA polymerase 
RER  Rough endoplasmic reticulum 
Rev  Reverse 
RFP  Red fluorescent protein 
RH  Relative humidity 
RLU/ml  Relative luminescent units per millilitre 
RNA  Ribonucleic acid 
RNAse A Endoribonuclease A 
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rNDV  Recombinant Newcastle disease virus 
rpm  Revolutions per minute 
rRNA  Ribosomal RNA 
RSV  Respiratory syncytial virus 
RT-PCR  Reverse transcription polymerase chain reaction 
RVP  Reporter virus particle 
Zɲ,  Rabbit anti-horse 
SARS  Severe acute respiratory syndrome 
SD  Standard deviation 
SDM  Site-directed mutagenesis 
SDS  Sodium dodecyl sulphate 
SDS-PAGE Sodium dodecyl sulphate-polyacrylamide gel electrophoresis 
SEAP  Secreted alkaline phosphatase 
Sf9  Spodoptera frugiperda 9 cells 
SFFV  Spleen focus forming virus 
SFV  Semliki forest virus 
SGR  Subgenomic replicon 
SLEV  Saint Louis encephalitis virus 
SOC  Super optimal broth with catabolite expression 
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SRIP  Single-round infectious particle 
SV40  Simian vacuolating virus 40 
SVP  Subviral particle 
T cell  T lymphocyte 
T=3  Triangulation number 3 
T7  T7 bacteriophage 
Ta  Annealing temperature 
TAE  Tris-acetate-ethylenediaminetetraacetic acid 
Taq  Thermus aquaticus 
TBEV  Tick-borne encephalitis virus 
TBS-T  Tris buffered saline-Tween 20 
TGN  Trans-Golgi network 
Th  T helper cell 
Tm  Melting temperature 
TM  Transmembrane  
TMD  Transmembrane domain 
TNFɲ  Tumour necrosis factor alpha 
TRIM5ɲ Tripartite motif 5 alpha 
U  Unit 
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UC11   Unique segment C 11 
USUV  Usutu virus 
UV  Ultraviolet 
V  Volt 
V/O  Vector only 
v/v  Volume/volume 
VLP  Virus-like particle 
VNAb  Virus neutralizing antibody 
VOPBA  Virus overlay protein binding assay 
VSV  Vesicular stomatitis virus 
VSV-G  Vesicular stomatitis virus glycoprotein 
w/v  Weight/volume 
WNV  West Nile virus 
WPRE  Woodchuck hepatitis virus post-transcriptional regulatory element 
X-gal  5-bromo-4-chloro-3-indolyl-ɴ-d-galactopyranoside 
YAOV  Yaounde virus 





1.1 Japanese encephalitis virus 
Japanese encephalitis virus (JEV) is one of the most prominent causes of viral encephalitis 
worldwide, with approximately 68,000 symptomatic cases and 20,000 deaths, primarily in 
children, attributed to the virus each year (Campbell et al, 2011; WHO, 2014a). Of those who 
survive, almost half suffer from irreversible and life-altering neurological damage (Solomon et 
al, 2000). Since its discovery in Japan in the 1870s, JEV has spread considerably and is now 
endemic across the majority of Asia, putting between 3 and 4 billion people at a tangible risk of 
infection (Ghosh and Basu, 2009; Yun and Lee, 2014). Despite outbreaks in the Western 
hemisphere remaining uncommon, rapid globalisation and climate change are respectively 
facilitating international travel and expanding the habitats of JEV mosquito vectors, thus  
increasing the likelihood of JEV emerging in geographical regions that were previously 
unburdened by the virus (Nett et al, 2009). The introduction and spread of the 
phylogenetically similar West Nile virus (WNV) throughout North America since 1999 serves to 
testify that the threat of the global circulation of JEV has never been more serious, and should 
not be underestimated (Lanciotti et al, 1999; LaBeaud, 2008).  
1.1.1 History 
Genetic sequence alignment studies predict that JEV originally evolved from an ancestral 
flavivirus, probably several millennia ago, in the region of the Malay archipelago (Solomon et 
al, 2003; Erlanger et al, 2009). However, clinical records of the virus only date back to the early 
1870s, when regular summer outbreaks of encephalitis indicative of JEV infection were 
described in Japan, with substantial incidents occurring periodically at an approximate rate of 




6000 cases and a mortality rate greater than 60% (Miyake, 1964; Solomon et al, 2000; Erlanger 
et al, 2009). This outbreak stimulated an increased effort to characterise the pathology and 
establish the agent responsible for causing the disease.  In 1933, pathogen filtered from 
infected neuronal matter was able to be transmitted to monkeys causing encephalitic 
symptoms. Soon after this, the virus was successfully isolated from the brain tissue of a fatal 
Japanese case, and was then officially named the prototype Nakayama strain of JEV in 1935 
(Mitamura et al, 1936; Miyake, 1964). Subsequently in 1938, JEV was also isolated from Culex 
tritaenniorynchus mosquitoes, alluding to the role this species plays as a primary vector for 
virus transmission (Mitamura et al, 1938). As it spread to the Korean peninsula and China by 
1940, then through many other countries in south east Asia and the Indian subcontinent in the 
following decades (Figure 1), knowledge of the ecology of JEV and its zoonotic transmission 
cycles was elucidated (Buescher et al, 1959a-b; Scherer et al, 1959a-b). By the time the first 
clinical cases of JEV were recorded in Papua New Guinea and Australia in the mid-1990s, much 
ŵŽƌĞŝŶĨŽƌŵĂƚŝŽŶĂďŽƵƚƚŚĞǀŝƌƵƐ①?ďŝŽůŽŐǇǁĂƐĞƐƚĂďůŝƐŚĞĚ①?ŝŶĐůƵĚŝŶŐŝƚƐĐĂƚĞŐŽƌŝƐĂƚŝŽŶƐĞǀĞƌĂů
years earlier as a member of the Flavivirus genus, within the Flaviviridae family (Westaway et 





Figure 1. Spread of JEV throughout Asia and Australasia during the 20
th
 century. A choropleth 
map displaying the years in which the first clinical cases of JEV were reported in Asian and 
Australasian countries between 1920 and 1999. Clinical case data taken from Erlanger et al, 




The Flaviviridae family encompasses a wide range of human and animal viral pathogens, and is 
divided into four genera: Flavivirus, Pestivirus, Hepacivirus and Pegivirus (Lindenbach et al, 
2007). The Flavivirus genus is the largest of the four with 74 members, including clinically 
important viruses such as dengue virus (DENV), yellow fever virus (YFV), tick-borne 
encephalitis virus (TBEV) and WNV (Kuno et al, 1998). Despite the fact that all flaviviruses 
share common group-reactive epitopes, the genus can be further segregated into 9 antigenic 
complexes based on serological cross-neutralisation studies, and JEV ①W another flavivirus ①W 
lends it name to one of these (Figure 2). The Japanese encephalitis serocomplex itself 
comprises nine virus species: Alfuy virus (ALFV), Cacipacore virus (CPCV), JEV, Koutango virus 
(KOUV), Murray Valley encephalitis virus (MVEV), Saint Louis encephalitis virus (SLEV), Usutu 
virus (USUV), WNV (including the Kunjin virus clade (KUNV)) and Yaounde virus (YAOV) 
(Poidinger et al, 1996, Mackenzie et al, 2002; Thiel et al, 2005). Of these viruses, four (JEV, 
MVEV, SLEV and WNV) are capable of causing severe encephalitic symptoms in humans, and as 
a collective, the virus members of the JEV serocomplex are geographically distributed across 
every continent except Antarctica. Despite existing as a single serotype, JEV still exhibits 
antigenic variation at the more specific classification of immunotype. Initially, the presence of 
immunological variation amongst JEV strains was demonstrated by Hale and Lee in 1954, who 
isolated six Malaysian Japanese encephalitis virus strains (as confirmed by histopathological 
examination of neuronal tissue) before assessing them in a series of cross-neutralisation and 
complement fixation experiments. In the following years, further investigations were 
conducted, which immunologically distinguished between the prototype Nakayama strain and 
the then-recently-isolated G-1 strain of JEV, using the intracerebral protection test, as well as a 
variety of serological assays. It was concluded that these two strains of the virus may belong in 
distinct immunotype categories (Kobayashi, 1959; Ogata, 1970). This finding was later 
corroborated in a study which analysed 26 strains of Japanese encephalitis virus isolated from 
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Japan and the countries of the Malaya region between 1935 and 1966. Following both 
conventional haemagglutination inhibition (HI) and antibody-absorption HI testing, as well as 
the complement-fixation assay, two distinct immunotypes were identified, represented by the 
Nakayama and Beijing-1 JEV strains (Okuno et al, 1968).  Since then, a more extensive degree 
of immunotype diversity has been identified between strains of the virus, with a number of 
monoclonal antibody-based analytical studies demonstrating at least five distinct antigenic 
subgroups (Kobayashi et al, 1984; Kedarnath et al, 1986).   
Additionally, JEV exhibits a significant level of genomic variation (Figure 3). The virus can be 
divided into five different genotypes (GI-V) ①W four of these genotypes (GI-IV) were originally 
elucidated by nucleotide sequence analysis of the highly variable prM gene, which was 
subsequently ratified by similar, more phylogenetic studies involving the E gene and the full-
length JEV genome (Chen et al, 1990; Chen et al, 1992; Williams et al, 2000; Solomon et al, 
2003). Until more recently, the only JEV isolate to fall into GV was the Muar strain in 1952, as 
determined by E gene phylogeny. As no other strain with particularly high levels of genotypic 
resemblance to this was isolated for decades afterwards, and also because a confirmatory 
sequence of a JEV virus of the same strain was absent, virologists working in the discipline 
were unsure if the distinct diversity of the Muar strain could be attributed to original 
sequencing errors in a region of its E gene sequence that was actually conserved with other 
JEV strains from different genotypes (Gould et al, 2004). However, in 2009 the JEV strain 
XZ0934 was isolated from Culex tritaenniorynchus mosquitoes in China ①W structural gene and 
complete genome phylogenetic analysis confirmed that this strain also belonged to GV, thus 
ratifying the authenticity of the genotype, as well as its re-emergence as a circulating genotype 
of JEV (Uchil and Satchidanandam, 2001; Li et al, 2011). Another virus isolate of genotype V 
JEV was also isolated from a related culicine mosquito species in the Republic of Korea in 2010 
(Takhampunya et al, 2011).  
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A correlation is also thought to exist between the presence of particular JEV genotypes in 
certain geographical regions and climates, and the activity of the virus.  Despite some 
exceptions to this pattern, it is generally observed that JEV strains belonging to GI and GIII 
circulate primarily in more northern, temperate areas of Asia, whereas GII and GIV strains of 
JEV are predominantly located in more tropical regions and closer to the equator. 
Furthermore, the majority of seasonal, summer epidemics of JEV take place in the 
temperature regions where the virus circulates, and conversely the tropical countries where 
JEV is present often experience more endemic strains of JEV. This observation potentially 
alludes to the fact that particular JEV genotypes could display either epidemic or endemic 
activity (Chen et al, 1990; Chen et al, 1992). This geographical pattern of JEV genotypic 
distribution was also presented in a 2013 study, which also concluded that the products of a 
division of genotype I into two separate clusters, GI-a and GI-b, were found in geographically 
distant areas from one another, with GI-a residing primarily in tropical regions and GI-b in 
countries with more temperate climates (Schuh et al, 2013).  
It is evident that JEV continues to display a high level of genetic diversity, seeing as since the 
turn of the 21st century, GI has split into differentiable sub-genotype clusters as well as 
replacing GIII as the dominant circulating JEV genotype in Asia, and GV has also re-emerged as 
a circulating genotype (Li et al, 2011; Pan et al, 2011; Schuh et al, 2013; Han et al, 2014). This 
consistent viral evolution poses significant public health risks, especially to the countries in 
which JEV circulates, as existing vaccines may become less effective and vulnerable 





Figure 2. Phylogenetic tree of medically important tick- and mosquito-borne flaviviruses. 
Complete polyprotein sequences were aligned, prior to performing phylogenetic 
reconstruction using PAUP v.4.0b10 and maximum likelihood analysis (figure sourced from 




Figure 3. Phylogenetic tree of Japanese encephalitis virus strains. Phylogenetic relationships 
were predicted using E gene sequence information, and genotypic classifications are indicated 
(G1-G4). Tree construction was carried out in ClustalX using the neighbour-joining method, 
and percentage bootstrap calculations are shown at each branch node. The scale at the 
bottom left hand side of the figure refers to the number of nucleotide substitutions per site. In 
order to root the tree, E gene sequence information for the KUNV clade was used (figure 
sourced from Mackenzie et al, 2007). 
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1.1.3 Transmission and epidemiology 
JEV is a mosquito-borne arbovirus, sustained within an enzootic cycle between aquatic birds 
and pigs, and transmitted through the bite of an infected culicine mosquito, primarily the Culex 
tritaeniorrhynchus species (Buescher et al, 1959a; Endy and Nisalak, 2002; van den Hurk et al, 
2009). Pigs and aquatic birds are crucial members of this transmission cycle because they act 
as asymptomatic amplifying hosts for the virus, which means they develop prolonged and high 
levels of viraemia sufficient for previously uninfected Culex mosquitoes to take up JEV during a 
blood meal (Buescher et al, 1959b; Scherer et al, 1959a; Le Flohic et al, 2013). Furthermore, 
water fowl are responsible for efficiently disseminating the virus to new geographical areas, 
and both pigs and these birds produce a large number of offspring, thus consistently supplying 
new amplifying hosts to continue the JEV enzootic cycle (Solomon et al, 2000). Humans, 
amongst several other animals, can also be infected with JEV but are considered coincidental 
①‘ĚĞĂĚ-ĞŶĚ①?ŚŽƐƚƐ①?ĂƐǀŝƌĂĞŵŝĂŝƐŐĞŶĞƌĂůůǇƚŽŽůŽǁĂŶĚƚƌĂŶsient to subsequently uphold the 
virus transmission cycle (Scherer et al, 1959b; Le Flohic et al, 2013; Figure 4).  
Human cases of JEV infection mostly appear in rural or periurban areas of Asia, where 
communities live in closer proximity to farmland, rice paddy fields and similar environments 
cohabited by the animals primarily involved in the natural transmission cycle of the virus (Daly 
and Solomon, 2010).  Fluctuations in the numbers of people infected by JEV occur on a 
seasonal basis in endemic regions ①W following the monsoon season across large parts of South 
East Asia, breeding rates of many mosquitoes, including those in the Culex genus, increase 
significantly due to the sudden abundance of standing or stagnant water sites that serve as 
breeding grounds. Mosquito populations proliferate, leading to accordant rises in amplifying 
host infection prevalence (Solomon et al, 2000). This combination of factors inevitably results 




Figure 4. Diagram of the enzootic transmission cycle of JEV. This diagram shows the interaction 
between the different organisms that primarily constitute the enzootic transmission cycle of Japanese 
encephalitis virus. The cycle is sustained between culicine mosquitoes, which act as a primary vector 
and reservoir host, as well as pigs and ardeid bird species, which respectively fulfil the roles of 
amplifying and maintenance hosts. Humans can only contract JEV through incidental infection and are 
ƌĞŐĂƌĚĞĚĂƐ①‘ĚĞĂĚ-ĞŶĚ①?ŚŽƐƚƐ①?ŵĞĂŶŝŶŐƚŚĂƚƚŚĞůĞǀĞůƐŽĨǀŝƌĂĞŵŝĂŝŶŝŶĨĞĐƚĞĚŝŶĚŝǀŝĚƵĂůƐĂƌĞŶŽƚ




(https://uk.pinterest.com/pin/179651472613171341/).    
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1.1.4 Clinical manifestation and disease symptoms 
Except for rare, occasional cases of laboratory-acquired infection, contraction of Japanese 
encephalitis virus is almost invariably caused by the bite of an infected culicine mosquito. At 
the point of initial infection, JEV breaches dendritic cells (DCs) within the dermis, in close 
proximity to the bite location. From here, the virus is carried in the antigen-presenting DCs to 
the peripheral lymph nodes, where the infection spreads to macrophages and other cells of 
the lymphatic system. A short-lived viraemia of approximately one week subsequently occurs, 
which is accountable for the generic febrile symptoms characteristic of the initial incubation 
period of JEV infection (Mackenzie et al, 2007). In the vast majority of cases, the virus is 
cleared by the host immune response at this stage of infection. However, in between 1:200 
and 1:2000 cases, JEV manages to cross the blood-brain barrier via penetration of the vascular 
endothelium, thus gaining entry to the central nervous system (CNS) (Ghosh and Basu, 2009). 
hƉŽŶďĞŝŶŐƉƌĞƐĞŶƚŝŶƚŚĞE^①?ƚŚĞǀŝƌƵƐĐĂŶŝŶǀĂĚĞƚŚĞƐǇƐƚĞŵ①?ƐŶĞƵƌŽŶĂůĂŶĚƉŚĂŐŽĐǇƚŝĐ
cells, consequentially affecting several tissues in the brain, including central cerebral structures 
such as the hippocampus, thalamus, substantia nigra and brainstem. Late-stage JEV infection is 
also witnessed in the temporal lobe and cerebellum, as well as the anterior horn cells of the 
upper spinal cord. Oedema and an inflammatory infiltrate containing elevated levels of B and T 
lymphocytes and macrophages are often observed in these infected neuronal regions, and 
alongside other factors such as neuronal apoptotic activity, these inflammatory responses 
contribute significantly to the cerebral damage and hallmark neurological presentation of JEV 
(Mackenzie et al, 2007). 
In populations where the virus circulates regularly and is considered endemic, symptomatic 
JEV infection is primarily witnessed in children, since adults have usually developed immunity 
against the virus throughout their childhood. However, the elderly also display a heightened 
propensity to develop symptoms attributed to JEV and other flaviviral infections, such as WNV 
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and MVEV, in comparison to healthy adult cohorts. Furthermore, amongst travellers or those 
who are newly residing in high-risk regions, the virus can infect individuals regardless of age, 
due to their naïve immunity.  
The clinical disease caused by JEV infection can be neatly ordered into three distinct 
categories, which can be separated and distinguished between by their levels of severity. As 
expected, in each category, the symptoms described closely correspond to the clinical 
pathologies observed during each stage of viral development in an infected patient.  
The first of these categories covers non-encephalitic disease: in the vast majority of instances, 
JEV infection is considered asymptomatic in patients, or they experience a non-specific febrile 
illness, which is characteristically mild but with the potential to progress into headache, 
vomiting, diarrhoea and convulsions. This level of illness is almost always self-limiting, and is 
ĂůƐŽŬŶŽǁŶĂƐ①‘ĂďŽƌƚŝǀĞĞŶĐĞƉŚĂůŝƚŝƐ①?①?/ƚŝƐďĞůŝĞǀĞĚƚŚĂƚƚŚŝƐŵŝůĚ①?ĨĞďƌŝůĞŝůůŶĞƐƐĂƚƚƌŝďƵƚĞĚƚŽ
JEV may well be underdiagnosed, because of the fact that the symptoms appear to resemble 
several other infections, in both clinical and serological respects, meaning that infection with 
JEV may not be considered by physicians during diagnosis (Watt and Jongaskul, 2003).  
However, in approximately 1 in every 250 cases, acute encephalitic symptoms manifest 
themselves subsequent to the milder initial presentation, usually after an incubation period of 
between 7 and 14 days (WHO, 2014a). In these patients, the progression of the disease is 
characterised by a sudden onset of a more severe fever, and other common symptoms include 
neck stiffness, convulsions and cranial nerve palsies, which cause a vacant, expressionless face 
with staring eyes (Figure 5). This clinical presentation links closely to a bad prognosis, with 
many such cases developing into late-onset encephalitic disease.  
Many patients that display the early disease symptoms of encephalitis caused by JEV often 
progress on to a more severe and life-threatening late-stage encephalitis. Additional 
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symptoms also emerge in these instances, such as tremor, hypertonia and cogwheel rigidity, as 
well as a range of motor neuron failures such as erratic facial contortions, twitching and 
blinking, cerebellar ataxia and seizures. Ultimately, the widespread viral infection throughout 
the brain causes flaccid paralysis, coma and subsequent respiratory failure (Solomon et al, 
2000). Between 20% and 30% of those who suffer with this severe encephalitis succumb to the 
disease, even if the most sophisticated medical facilities are at hand. For the remainder of 
patients that manage to survive late-onset Japanese encephalitis, the path to recovery is 
complicated and neurological impairments can take months to subside. Up to 50% of survivors 
develop and suffer from lifelong neurological sequelae, of which the effects can be twofold: 
often, physical sequelae are reported, such as varying degrees of paralysis, nerve palsies, 
blindness, epilepsy, movement disorders and parkinsonism; however, behavioural sequelae 
can also occur, such as an impaired memory, a loss of the ability to speak, uncharacteristic 





Figure 5. Japanese encephalitis symptoms. A breakdown of the hallmark symptoms of 
the disease caused by the flavivirus, ranging from the initial non-encephalitic disease, 
through the acute and late stages of encephalitis to the progression of long-lasting 
neurological sequelae.  
Non-encephalitic disease 
Non-specific febrile illness ①W coryza, rigors, headache; 
diarrhoea; vomiting; minor convulsions followed by a 
reduced level of consciousness 
 
Acute encephalitic stage 
Severe fever; neck stiffness; convulsions; aseptic 
meningitis; cranial nerve palsies; vacant, 
expressionless face; staring eyes  
 
Late-stage encephalitis 
Tremor; hypertonia; cogwheel rigidity; motor neuron 
failures ①W erratic facial contortions, twitching and 
blinking; cerebellar ataxia; tonic-clonic and focal motor 
seizures; erratic facial contortions; flaccid paralysis; 
coma; respiratory failure; death 
Neurological sequelae 
Physical ①W partial or complete paralysis, nerve palsies, 
blindness, epilepsy, movement disorders, 
parkinsonism; behavioural ①W impaired memory, 




1.1.5 Virion and genome 
JEV virions are approximately 50nm in diameter and exist as spherical enveloped particles 
(Figure 6). The surface of the mature virion contains two proteins ①W the envelope (E; ~53kDa) 
and membrane (M; ~8kDa) proteins (Lindenbach and Rice, 2003; Gubler et al, 2007). Within 
the virus envelope, a 30nm diameter nucleocapsid contains the viral genetic material.  The 
~10.9kb JEV genome exists as a single-stranded, positive-sense RNA molecule, which is 
processed as one open reading frame and encodes a single polyprotein (Mukhopadhyay et al, 
2005). The three JEV structural proteins are located at the N-terminus of this genome ①W capsid 
(C), premembrane (prM ①W expressed initially with a precursor element) and envelope (E) 
proteins ①W upstream of seven non-structural proteins which are crucial for virus replication 
(Figure 6).   
1.1.5.1 C protein 
The C protein is one of the smallest expressed in the JEV genome, with a length of 
approximately 120 amino acids and a predicted molecular weight (MW) of 12-14 kDa 
(Chambers et al, 1990). It is a basic, highly positively charged protein, with C-terminal and 
central hydrophobic domains that surround a hydrophilic sequence of amino acids. These 
regions of strong hydrophobicity or hydrophilicity within the protein are generally conserved 
among flaviviruses (Abraham et al, 2011). It possesses a dimeric structure, with each monomer 
ĐŽŶƚĂŝŶŝŶŐĨŽƵƌĐŽŶŶĞĐƚĞĚɲ-helices. The two monomers sit in an anti-parallel orientation, with 
ƚŚĞɲ①?ĂŶĚɲ①?ŚĞůŝĐĞƐŽĨĞĂĐŚŵŽŶŽŵĞƌƉŽƐŝƚŝŽŶĞĚĂĚũĂĐĞŶƚƚŽĞĂĐŚŽƚŚĞƌ①?ĐŽŵƉůĞƚŝŶŐƚŚĞ
protein dimer. The function of the capsid protein concerns early JEV assembly, via the 
formation of the nucleocapsid (NC) core and the packaging of the viral genome into the NC 
(Mukhopadhyay et al, 2005). Also, nuclear localisation of the C protein in infected mammalian 
and insect cells plays a crucial role in JEV replication and pathogenesis (Mori et al, 2005).  
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1.1.5.2 pr and M proteins 
The prM protein (~240 amino acids; predicted MW 18.1-19.0 kDa) is a glycoprotein precursor 
to the structural M protein found in mature JEV virions (Chambers et al, 1990). During the 
early stages of progeny virus biosynthesis and assembly, prM and E form a heterodimeric 
complex. Within this complex, prM has already acquired its completely folded structure and 
acts as a chaperone for the folding of the E protein, as well as protecting it from premature, 
irreversible conformational changes induced by acidic pH as it transits through the intracellular 
trans-Golgi network (TGN) (Lorenz et al, 2002; Heinz and Allison, 2003). Shortly before virus 
exocytosis and egress from the cell, the prM protein undergoes a proteolytic cleavage step 
vital for virion maturation. Cleavage is directed to occur immediately after the Arg-X-Arg/Lys-
Arg motif in the prM amino acid sequence, which corresponds to the cleavage site of the 
cellular protease furin, an enzyme which concentrates in the proximity of the TGN. The low-pH 
environment of the TGN stimulates a conformational change in the prM-E heterodimers of the 
immature JEV virion, which is generally thought to expose this furin cleavage site, enabling 
progeny virus maturation to be completed (Mukhopadhyay et al, 2005). prM is cleaved into a 
discarded precursor (pr; ~165 amino acids) fragment and a small, mature membrane (M; ~75 
amino acids) protein. In the surface structure of the mature JEV virion, the M protein is 
partially embedded into the outer lipid membrane of the virus, and possesses a very small 
ectodomain in comparison with E (Heinz and Allison, 2003; Mukhopadhyay et al, 2005). 
Another important motif in the prM protein is a single N-linked glycosylation site towards the 
N-terminus of the amino acid sequence, which is highly conserved amongst JEV strains and 
related flaviviruses, and has a direct influence upon particle release and virus pathogenicity in 





1.1.5.3 E protein 
The E protein (~500 amino acids; predicted MW ~53 kDa) is the major envelope glycoprotein 
and the dominant immunogenic antigen on the surface of JEV virions, and is integral for the 
attachment, membrane fusion and entry of the virus into permissive cells (Chambers et al, 
1990; Abraham et al, 2011). In the mature virion structure, there are 180 individual copies of E 
which are orientated as head-to-tail, anti-parallel homodimers and lay flat against, rather than 
protruding from, the lipid bilayer and nucleocapsid, creating a relatively smooth and spikeless 
virus surface compared to other families of viruses, such as Orthomyxoviridae and 
Coronaviridae (Mukhopadhyay et al, 2005). Each homodimer is itself arranged in sets of three 
parallel dimers, thus forming an icosahedral pattern of 30 E protein rafts across the virion 
surface. It appears inconclusive as to whether flaviviruses conform to T=3 or pseudo T=3 
icosahedral symmetry (Caspar and Klug, 1962; Mukhopadhyay et al, 2005).  Each JEV E 
monomer consists of three distinct domains: domain III is an immunoglobulin-like domain that 
creates slight protrusions from the smooth virion surface and is responsible for JEV binding to 
cellular receptors, as well as for initiating virus fusion and entry into susceptible cells; domain II 
is involved in maintaining E monomer homodimerisation ①W this domain is comprised of two 
①‘ĨŝŶŐĞƌ-ůŝŬĞ①?ƐƚƌƵĐƚƵƌĞƐĂŶĚĂůƐŽĐŽŶƚĂŝŶƐĂ①?①?-amino acid fusion loop at its distal end, which is 
hydrophobic and highly conserved amongst JEV strains; these two domain structures are 
connected by domain I, which possesses a beta-barrel in its centre to facilitate its role as a 
domain II-III hinge (Wu et al, 2003; Pierson and Diamond, 2012). Notably, compared to other 
species of flaviviruses such as DENV and YFV, the domain II central dimerisation region 
between constituent monomers within the mature JEV E homodimer possesses a notably short 
dimer interface. Furthermore, multiple conserved histidine residues in the E protein structure 
appear to act as important quarternary points of load-bearing contact between monomers in 
the homodimer complex (Luca et al, 2012).  
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1.1.5.4 Non-structural proteins 
The JEV RNA genome expresses seven non-structural proteins: NS1, NS2A, NS2B, NS3, NS4A, 
NS4B and NS5. The ~48kDa NS1 protein in flaviviruses is immunogenic and is capable of 
stimulating a host protective antibody response. Its function is involved with virus replication, 
as well as regulation and evasion of the innate immune response directed against the virus 
(Fan and Mason, 1990; Muylaert et al, 1996; Lindenbach and Rice, 1997; Chung et al, 2006a; 
Chung et al, 2006b)①?/ŶĂĚĚŝƚŝŽŶ①?E^①?①?①?ĂůĂƌŐĞƌ①?①?ŬĂE^①?-related protein, is also often 
detected in JEV-infected cells. This protein variant is reported to be brought about via 
ribosomal frameshifting, and plays a role in viral neuroinvasiveness (Chambers et al, 1990; 
Melian et al, 2010). NS2A is a viral membrane-associated, hydrophobic protein with a diverse 
array of functions: it possesses enzymatic activity to cleave the expressed polyprotein at the 
NS1-NS2A junction, interferes with the host antiviral response by inhibiting the interferon (IFN) 
signalling pathway, and also contributes to the functioning of the life cycle at several other 
stages - RNA replication and the viral replicase complex, as well as viral assembly and egress 
from the host cell (Falgout and Markoff, 1995; Kümmerer and Rice, 2002; Liu et al, 2006; Leung 
et al, 2008). NS2B and NS3 remain associated to one another as a heterodimer which anchors 
itself into the endoplasmic reticulum membrane, where it acts as a crucial factor to the NS2B-
NS3 serine protease, which cleaves the expressed JEV polyprotein at several points between 
non-structural proteins (Lindenbach and Rice, 2003; Abraham et al, 2011). The NS3 protein 
also plays a role in viral replication and assembly dues to its enzymatic activity as a RNA 
helicase, serine protease and NTPase (Bollati et al, 2009; Assenberg et al, 2009; Pastorino et al, 
2010). NS4A is another relatively small hydrophobic protein, which possesses a similar role to 
the NS2A protein, as it is an IFN antagonist. Furthermore, cleavage of the NS4A-4B complex 
may also mediate host cell cytoplasmic membrane biogenesis, which facilitates efficient RNA 
replication and intracellular trafficking of viral components (Roosendaal et al, 2006; Lin et al, 
2008). The JEV NS5 protein is the largest of all the proteins expressed from the JEV genome, 
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with a variety of functions. The protein displays methyltransferase and RNA-dependent RNA 
polymerase (RdRp) at its N-terminal and C-terminal regions, respectively (Kim et al, 2007; 
Davidson, 2009). It also inhibits the JAK-STAT signalling cascade, via inhibiting a 
phosphorylation step of the pathway, which compromises the antiviral efficiency of IFN (Lin et 
al, 2006).   
 
  
Figure 6. Japanese encephalitis virus virion and genome structure. A schematic of the mature JEV 
virion is shown, including the orientation and organisation of E protein dimers at the external virus 
surface, as well as a virion cross-section, with annotations of the membrane and capsid proteins, 
and the genomic RNA.The JEV genome ŝƐĂůƐŽƐŚŽǁŶ①?ďŽƚŚĂƐĂƉŽůǇƉƌŽƚĞŝŶǁŝƚŚ①?①?ĂŶĚ①?①?ƚĞƌŵŝŶŝ①?
and with a breakdown of each component gene, alongisde the corresponding enzyme that cleaves 
each junction of the polyprotein during virus assembly  (adapted from Viralzone, 2011). 
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1.1.6 Virus life cycle 
1.1.6.1 Attachment, entry and cellular receptors 
Entry into living host cells is a vital initiatory step of any viral infection, and the process of 
entering living cells contributes towards what defines a pathogenic microbe as a virus. Like 
with virtually all viruses, the JEV infection life cycle begins with entry and penetration of host 
ĐĞůůƐ①?ŝŶƐƚŝŐĂƚĞĚǁŚĞŶĚŽŵĂŝŶ///ŽĨƚŚĞǀŝƌƵƐ①?ƉƌŽƚĞŝŶĞŶŐĂŐĞƐƌĞĐĞƉƚŽƌƐŽŶƚŚĞŚŽƐƚĐĞůů
surface. Despite significant advancements in recent decades of knowledge concerning the 
structure and organisation of JEV virions, our comprehension of the molecular interactions 
ƚŚĂƚŽĐĐƵƌǁŚĞŶƚŚĞǀŝƌƵƐ①?ƉƌŽƚĞŝŶďŝŶĚƐƚŽƌĞĐĞƉƚŽƌƐĂƚƚŚĞĐĞůůŵĞŵďƌĂŶĞŝƐĂƚĂŵƵĐŚŵŽƌĞ
rudimentary level than that of flavivirus virion structure. However, current understanding of 
the JEV infectious entry model suggests that at least two distinct cell surface molecules may be 
actively involved - attachment factors that help to stabilise individual virions and concentrate 
them at the plasma membrane, so that primary receptors can be physically bound by viral 
envelope glycoproteins to initiate entry and infection. Several protein families have been 
reported in relevant, recent literature as being involved in JEV attachment and entry into host 
cells (Table 1), and some of the best-characterised of these putative cellular receptors are 
detailed below: 
 1.1.6.1.1 Glycosaminoglycans (GAGs) and heparan sulfate 
Perhaps the best-established set of molecules demonstrated to interact with the JEV envelope 
glycoprotein during entry and infection are glycosaminoglycans, otherwise known as GAGs, 
which are long, unbranched polysaccharides containing sulphate groups, bound and anchored 
to the plasma membrane by core proteins themselves embedded in the cell surface. These 
protein-polysaccharide complexes are called proteoglycans (Zhang, 2010). GAGs are the initial 
point of contact for the JEV E protein with the plasma membrane during virus infection and 
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host cell penetration, and these large linear structures act as an important attachment factor, 
by stabilising individual virions and facilitating virus adhesion to the cell surface, in order to 
bring about binding of the JEV envelope protein to primary cellular receptors (Lee et al, 2006). 
Positively charged amino acid residues on the JEV E protein are able to exploit and interact 
with the negatively charged sulphate groups of the GAG (Chen et al, 1997; Perera-Lecoin et al, 
2014). Furthermore, GAGs and proteoglycans are ubiquitous molecules found on the 
extracellular surfaces of all tissues, meaning that JEV can easily utilise them as docking stations 
for viral adhesion onto a wide variety of cell types (Zhang, 2010). Several other flaviviruses, 
such as DENV, YFV, WNV and TBEV, also exploit GAG interactions to anchor onto the external 
face of the cellular plasma membrane, prior to viral entry and host cell fusion (Chen et al, 
1997; Hilgard and Stockert, 2000; Su et al, 2001; Germi et al, 2002; Kroschewski et al, 2003; 
Okamoto et al, 2012).  
 1.1.6.1.2 CLEC5A 
CLEC5A is a member of the C-type lectin receptor (CLRs) family, which are specialised 
receptors that possess the ability to recognise carbohydrate profiles on invading pathogens, 
including viruses aiming to infect host cells, and subsequently play an important role in 
activating and initiating host cell immune responses against such pathogens. CLRs in general, 
and more specifically CLEC5A, are commonly expressed at high levels on myeloid cells, such as 
monocytes, macrophages and dendritic cells ①W these cell types fall under the tropism of many 
flaviviruses, and the presence of CLEC5A receptors may be accountable for JEV infection in 
such myeloid cells. Following carbohydrate motif recognition, CLRs also act as internalisation 
receptors that target pathogens to acidified intracellular endosomes for enzymatic 
degradation and disposal from the cell (McGreal et al, 2005). Despite the interaction of CLEC5A 
with JEV virions being demonstrated, as well as with DENV, it has not yet been confirmed 
whether the receptor interacts with glycans on the envelope glycoprotein of JEV. However, the 
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literature postulates that CLEC5A functions neither as a primary receptor nor an attachment 
factor. Rather, due to its lack of a cytoplasmic tail with internalisation motifs, which are 
observed on other members of the CLR family exploited for flavivirus infection, such as DC-
SIGN and L-SIGN, a positively charged amino acid residue on the transmembrane domain of 
CLEC5A reacts with the DNAX-activating protein 12kDa, otherwise known as DAP12 (Watson et 
al, 2011). DAP12 is an immunoreceptor tyrosine-based activation motif (ITAM)- bearing 
adapter molecule, which instigates the activation of intracellular signalling pathways (Bakker et 
al, 1999; Colonna, 2003). When binding of CLEC5A by JEV E occurs, the DAP12 molecules 
present in macrophages and microglia become phosphorylated, thus triggering signal 
transductions that stimulate the release of proinflammatory cytokines, which cause various 
pathologies, such as inflammation, vascular leakage and cell death, and serve to significantly 
increase JEV disease severity (Chen et al, 2008; Wu et al, 2013). Neutralising antibodies raised 
against CLEC5A efficiently inhibit these inflammatory pathologies by preventing JEV E binding 
and subsequent DAP12 activation and signal transduction (Chen et al, 2012). Therefore, these 
findings indicate that CLEC5A plays a vital part in JEV infection, particularly with regards to the 
pathogenesis of the viral disease and its progression to severe encephalitis.  
 1.1.6.1.3 High affinity laminin receptor 
A recent study, designed by Thongtan et al in 2012, aimed to elucidate molecules that were 
actively associated with the entry and infection of JEV into microglial cells, an integral neuronal 
cell type distributed throughout the brain and spinal cord tissues. Following a virus overlay 
protein binding assay (VOPBA) using the pan-specific anti-flaviviral monoclonal antibody 
HB112 (Henchal et al, 1982), to assess which proteins expressed on the microglial cell surface 
bind the JEV envelope glycoprotein, and liquid chromatography-mass spectrometry analysis 
(LC-MS/MS), in order to physically separate then gauge the elemental compositions and 
masses of the candidate JEV-binding proteins, the 37/67 kDa high affinity laminin receptor was 
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repeatedly and consistently identified in the spectroscopic analyses. Subsequent antibody-
mediated inhibition experiments displayed that anti-laminin antibodies significantly 
neutralised JEV infection and entry into mouse microglial BV-2 cells (Thongtan et al, 2012). 
Therefore, it is postulated that the high affinity laminin receptor is a promising potential 
cellular receptor for JEV, specifically for microglial entry. However, this study also emphasises 
the palpable complexity of the interactions between JEV virions and target cellular receptors ①W 
the engagement of different receptors, and indeed co-receptors, across the range of cell 
tropism of the virus is highly likely, and as more knowledge is acquired of JEV cell entry 
processes, this may be an ongoing obstacle for novel antiviral development.  
The 67kDa high affinity laminin receptor is believed to mediate many of the cellular 
interactions of the major basal membrane component laminin, which is ubiquitous across 
many mammalian tissue types, and plays a pivotal role in cellular morphology, adhesion and 
differentiation, amongst other functions (Castronovo et al, 1991, Ardini et al, 1998). 
Interestingly, this receptor has also been demonstrated to definitively act as a cellular receptor 
for the Sindbis virus in several cell types ①W importantly, Sindbis virus is a member of the 
Alphavirus genus, a group of viruses that display very similar cell entry and fusion mechanisms 
as flaviviruses (Wang et al, 1992; Morizono et al, 2010). This similarity between these two virus 
genera may be a factor into their mutual exploitation of the high affinity laminin receptor to 
penetrate cell membranes.  
 1.1.6.1.4 Heat shock protein 70 (HSP70) 
Another protein that is implicated alongside the laminin receptor in Thongtan et al①?Ɛ①?①?①?①?
study to discover microglial cell surface JEV-binding molecules is the heat shock protein 70 
(HSP70). The heat shock family of proteins are upregulated in response to a variety of 
conditions of cellular stress, such as extreme heat or cold, hypoxia, toxin exposure, starvation 
and water deprivation. These proteins also act as important intracellular chaperones to ensure 
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the correct folding and conformation of newly translated proteins takes place, as well as to 
prevent unwanted protein aggregation following their expression (Whitley et al, 1999). In fact, 
this finding has been independently corroborated in a number of other recent studies, where 
HSP70 appears to have putative cellular receptor qualities in several other cell types.  
 
Using similar methodologies as observed in other studies aiming to identify proteins with 
flavivirus-binding characteristics, the HSP70 protein has been flagged as a potential JEV cellular 
receptor in neuroblastoma cells (Das et al, 2009). More specifically, using the mouse-derived 
cell line Neuro2a, a VOPBA was conducted to isolate membrane-located proteins that were 
interacting with the JEV E glycoprotein, yielding an approximately 70kDa protein as a 
candidate, which was then subjected to matrix-assisted laser desorption/ionization-time of 
flight (commonly abbreviated to MALDI-TOF) mass spectrometry and subsequent MASCOT 
protein identification software, used to analyse and compare the peptide mass fingerprint of 
the said protein against established protein databases. The experimental protein showed 
palpable homology with HSP70, and receptor function and characteristics were confirmed by a 
range of downstream tests, including infection inhibition and plaque reduction assays using 
anti-HSP70 polyclonal antibodies, as well as presenting the knockdown of JEV infection in a 
plaque assay utilising the compound quercetin, a potent HSP70 antagonist (Das et al, 2009).  
Since then, it has also been indicated that the human hepatoma cell line Huh7 is permissible to 
JEV infection due to HSP70 presence, in association with lipid rafts at the plasma membrane 
(Zhu et al, 2012). Firstly, polyclonal antibody treatment of HSP70 at varying concentrations 
revealed a specific, dose-dependent decrease of JEV infection into Huh7 cells, and this finding 
was corroborated by small interfering RNA treatment of the HSP70 receptor, bringing about its 
depletion throughout the hepatoma cells and in turn, markedly reducing cellular entry of the 
virus. Binding and co-immunoprecipitation assays were then used to confirm a tangible 
interaction between the JEV glycoprotein and HSP70, before a series of experiments utilising 
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the cyclic oligosaccharide methyl-ɴ-cyclodextrin (MɴCD) were conducted, which selectively 
disrupts membrane cholesterol, an important component of membraneous lipid rafts 
(Ilangumaran and Hoessli, 1998). It was deduced that cholesterol breakdown at the plasma 
membrane adversely affected JEV entry and infection, and biochemical fractionation of JEV-
infected Huh7 cells following MɴCD treatment revealed that HSP70 migrates to other areas of 
the plasma membrane in the absence of intact lipid raft domains, although interestingly this 
ĚŽĞƐŶŽƚĂĨĨĞĐƚůĞǀĞůƐŽĨ:sĐĞůůďŝŶĚŝŶŐ①?dŚĞƐĞĨŝŶĚŝŶŐƐůĞĚƚŚĞĂƵƚŚŽƌƐƚŽĞůƵĚĞƚŽ,^W①?①?①?Ɛ
role as a putative JEV cellular receptor, and conclude that viral entry is facilitated by lipid raft 
interaction, possibly by clustering and co-localising of JEV virions and HSP70 molecules around 
membrane cholesterol domains (Zhu et al, 2012).  
Furthermore, it appears that the very similar heat shock cognate protein 70 (HSC70), which 
shares a very high percentage homology with HSP70, may act as a cellular receptor for JEV on 
the Aedes albopictus mosquito cell line C6/36, as determined by co-immunoprecipitation and 
mass spectrometry (White, 1987; Ren et al, 2007). Interestingly, this study also speculates on 
the potential of these heat shock proteins to not only anchor JEV virions to the host cell 
plasma membrane, but also to fulfil the role of chaperone and facilitate conformational 
changes of the envelope glycoprotein during virus fusion, in keeping with a primary function of 
heat shock proteins (Boonsanay and Smith, 2007; Ren et al, 2007).    
Finally, one of the earliest studies to focus on cell membrane proteins that interact with JEV 
concluded that a ~74kDa protein specifically present on the plasma membrane of Vero cells 
binds the JEV envelope glycoprotein, and that JEV monoclonal antibody inhibition significantly 
prevents cell-virus binding. This study does not speculate or attempt to confirm the identity of 
this 74kDa protein, but the molecular weight alone begs the question that the protein singled 
out here could possibly be HSP70 (Kimura et al, 1994).    
Collectively, these studies provide a convincing body of evidence with which to confidently 
suggest that heat shock protein 70 could act as a putative cellular receptor for Japanese 
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encephalitis virus. However, it is worth considering that, if HSP70 were confirmed to be a 
primary cellular receptor for JEV, developing treatments which would directly antagonise 
function of the receptor and bring about a knockdown of JEV infection may detrimentally 
ĂĨĨĞĐƚƚŚĞƉƌŽƚĞŝŶ①?ƐŝŶƚƌĂĐĞůůƵůĂƌĐŚĂƉĞƌŽŶĞĨƵŶĐƚŝŽŶƐ①? 
  1.1.6.1.5 Vimentin 
Perhaps the most recent addition to the list of putative JEV cellular receptors, or proteins 
which engage the flavivirus at the cell surface, is vimentin ①W a type III intermediate filament 
protein expressed in mesenchymal cells. First presented in 2011, the interaction of vimentin 
with the JEV envelope glycoprotein in neuroblastoma cells was characterised using a virus-
protein binding pull-down assay, which yielded a 57kDa protein which was found to interact 
with virulent and attenuated variants of the NT109 strain of JEV. Following 
immunoprecipitation, mass spectrometry and BLAST bioinformatics analyses, the detected 
protein was identified as vimentin. This result was subsequently verified by antibody 
neutralisation and vimentin expression knockdown experiments, and JEV binding of vimentin 
was also exploited to perform mutation analyses on the virus envelope glycoprotein, in order 
to elucidate an amino acid residue which is integral in vimentin binding (Liang et al, 2011).  
/ŶƚŚĞƐĂŵĞǇĞĂƌ①?ƚŚĞĐĂƐĞĨŽƌǀŝŵĞŶƚŝŶ①?ƐƌŽůĞĂƐĂƉƵƚĂƚŝǀĞ:sĐĞůůƵůĂƌƌĞĐĞƉƚŽƌǁas 
strengthened, as another article outlining the interactions of the JEV E protein with vimentin at 
the membrane of PS porcine kidney cells was published (Das et al, 2011). Using conventional 
methodology of a VOPBA, followed by MALDI-TOF mass spectrometry, an approximately 
60kDa protein candidate was revealed to be vimentin, which was then further investigated by 
the utilisation of anti-vimentin monoclonal antibodies, and also with a co-immunoprecipitation 
assay, which confirmed the co-localisation and tangible interaction of the viral and cellular 
proteins (Das et al, 2011).   
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 1.1.6.1.6 Integrin ɲVɴ3  
In a study detailing the interaction of West Nile virus with the integrin ɲVɴ3 with regards to 
mediation of Vero cell entry of WNV, it was also discovered that, when comparing the 
neutralisation potencies of an anti- integrin ɲVɴ3 antibody against other flaviviruses, entry of 
JEV into the Vero cells was also significantly inhibited, albeit to a lesser extent than WNV. This 
prevention of cellular entry indicates that JEV may exploit the integrin ɲVɴ3 protein on plasma 
membranes to augment its infection efficiency into certain cell types (Chu and Ng, 2004).  
Integrins are an important family of proteins involved in the attachment and bridging of the 
cell cytoskeleton to the extracellular matrix, thus acting as the scaffolding for cell-cell 
interactions (Alberts et al, 2002). This set of cell adhesion molecules are in fact extensively 
implicated as cellular receptors for a range of viruses, including foot-and-mouth disease virus 
(FMDV) and the hantaviruses NY-1 and Sin Nombre virus (Ren et al, 2007). The fact that 
integrins are repeatedly presented in the literature as putative cellular receptors for 
evolutionarily distinct viruses implies the feasibility of integrin ɲVɴ3 playing a similar role for 
JEV, alongside other flaviviruses.  
 1.1.6.1.7 Nucleolin 
Nucleolin is a multi-functional phoshoprotein derived from and localised abundantly within the 
nucleolus of the cell, although it has also been detected in various other organelles of 
eukaryotic cells, such as the cytoplasm and at the plasma membrane. Expression levels of 
nucleolin correlate strongly with the rate of functional activity of the nucleolus, and this 
protein regulates a range of important nucleolar roles, such as: ribosomal RNA (rRNA) 
synthesis and expression; biogenesis, maturation and folding of ribosomes; manipulation of 
chromatin structure; cytokinesis; and the synthesis and nucleocytoplasmic trafficking of 
nascent pre-RNA molecules (Tajrishi et al, 2011). In addition, interactions between viral 
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proteins and nucleolin, as well as the whole nucleolus, have been widely reported in the 
literature (Masiuk, 2008). 
In microglial cells, nucleolin was identified via VOPBA and LC-MS/MS spectroscopic analysis as 
a protein which interacts with JEV at the cell surface, and could be a potential cellular receptor 
for the flavivirus. This finding was made by Thongtan et al and was discovered alongside the 
aforementioned high affinity laminin receptor. However, unlike the laminin receptor, upon 
incubation of microglial cells with an anti-nucleolin monoclonal antibody, it was found that JEV 
infection was not significantly neutralised, indicating nucleolin probably does not possess the 
role of cellular receptor for the flavivirus into microglial cells (Thongtan et al, 2012).  
Despite this study concluding that nucleolin does not mediate Japanese encephalitis virus 
infection, it is certainly feasible to suggest that it could engage the envelope glycoprotein of 
JEV at the plasma membrane in some way, since it is well-recognised that nucleolin associates 
with and is exploited by a wide variety of both RNA and DNA viruses (Hiscox, 2002; Salvetti and 
Greco, 2014). Firstly, the protein acts as a cellular receptor for human parainfluenza virus type 
3 (HPIV-3; Bose et al, 2004) and human respiratory syncytial virus (RSV; Tayyari et al, 2011), 
and also appears to contribute towards the entry of human immunodeficiency virus (HIV) into 
both CD4(+) and CD4(-) cells, as determined by the use of nucleolin-specific ligands at the cell 
membrane, such as midkine, pleiotrophin and lactoferrin, which resulted in competitive 
inhibition of HIV infection (Callebaut et al, 2001; Said et al, 2002; Legrand et al, 2004; Said et 
al, 2005; Hovanessian, 2006; Masiuk, 2008). Furthermore, nucleolin appears to be integral for 
the success of several other viruses throughout their life cycles ①W for instance, the replication 
and capsid assembly of adeno-associated virus type 2 (AAV-2) is greatly facilitated by nucleolin 
co-localisation and binding (Qiu and Brown, 1999), and the phosphoprotein is also involved in 
the life cycle of herpes simplex virus type 1 (HSV-1), including nucleolin recruitment during 
HSV-1 replication to augment replicative activity, and also by interacting with the C-terminal of 
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the HSV-1 UC11 protein, to enable one-way directional trafficking of the herpesvirus from the 
nucleus to the cytoplasm during virus assembly (Callé et al 2008; Greco et al, 2011).  
However, interestingly, nucleolar proteins such as nucleolin have also been reported to 
possess an active involvement in the life cycle and proliferation of a number of Flaviviridae 
family members, including HCV, DENV, WNV and, most importantly, JEV. Often, these 
interactions usually occur with the flaviviral capsid protein and revolve around the 
upregulation of virus replication (Salvetti and Greco, 2014). Indeed, in the case of JEV, select 
amino acid residues in the C protein appear to have a bearing on nucleolar and nuclear 
localisation and detection of the virus, which in turn has a beneficial impact on virus 
propagation, as determined by mutation analyses resulting in impairment and knockdown of 
JEV production (Mori et al, 2005). Also, a similar nucleolar phosphoprotein to nucleolin, named 
B23, translocates from the nucleoli to the cytoplasm upon JEV infection, subsequently co-
localising and binding to the capsid protein, once again with implications for the efficiency of 
viral replication (Tsuda et al, 2006).  
To conclude, the breadth of interaction between nucleolin and various viral proteins begs the 
question, despite a lack of validation in the literature, of whether this nucleolar 
phosphoprotein may contribute in some way to the cell entry, infection and replication of 
Japanese encephalitis virus.  
 
Another consideration regarding the search for putative JEV cellular receptors is that, due to 
the broad host cell range of the flavivirus, a highly conserved receptor may be required to 
enable the virus to effectively enter many permissible cell types. Therefore, it may be possible 
that a non-protein-based cellular receptor is involved in cell entry, such as sialic acid residues 
in influenza cell entry mechanisms, which are ubiquitously found at the plasma membranes of 





















BHK-21 ①W baby 
hamster kidney 
fibroblasts 
Initial point of cellular 
contact with virus ①W 
attachment factor that 
stabilises virion at 
plasma membrane 
 





C-type lectin ①W roles 
include cell-cell adhesion, 
pathogen immune 
responses, apoptosis and 



























surface receptor ①W 
binds laminin with 
high affinity 
 
BV-2 ①W mouse 
microglia 
Putative cellular 
receptor ①W plays a 
role in facilitating 







Heat shock protein ①W 
upregulated in response 
to cellular stress, 
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Huh7 ①W human 
hepatoma 
Putative cellular 
receptor ①W important 
for attachment and 
entry of JEV into host 
cells 
Kimura et al, 
1994; Ren et 
al, 2007; Das 
et al, 2009; 
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N18 ①W mouse 
neuroblastoma 
HTB-11 ①W human 
neuroblastoma 
PS ①W porcine 
kidney 
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receptor ①W critical 
for facilitating cell 
entry and infection 
of JEV 
 
Liang et al, 
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bridging of cell 
cytoskeleton and 
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act as scaffolding for cell-
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convincingly as WNV 
 





①W regulates rRNA synthesis 






BV-2 ①W mouse 
microglia 
Engages JEV envelope 
glycoprotein at the 
plasma membrane in 
some way, but no 






Table 1. Summary of the host cell surface molecules that are reported to interact with 
Japanese encephalitis virions and facilitate the entry and infection of the flavivirus into host 
cells. Surface molecules and their functions, as well as target cell lines, mechanisms of 
interactions and references are listed. 
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1.1.6.2 Fusion, expression, assembly and egress 
Following cellular receptor engagement, JEV undergoes a process known as clathrin-mediated 
endocytosis (CME) in order to penetrate the host cell plasma membrane. Receptor binding at 
the cell surface activates the highly conserved adapter protein 2 (AP2), located proximally to 
the cytoplasmic side of the plasma membrane, to recruit clathrin proteins to the area, which 
assemble around the activated binding site and create a clathrin-coated pit (Pearse, 1976). 
Membrane invaginations begin to form at the internalisation site ①W clathrin acts to stabilise and 
strengthen the curvature of the plasma membrane, as it gradually expands to create a coated 
vesicle rather than a pit. A further protein named dynamin congregates at the attached base of 
the vesicle, and is responsible for its scission and release from the cell membrane. The clathrin 
molecules subsequently uncoat and are recycled, permitting the vesicle to migrate and 
incorporate into early endosomes (McMahon and Boucrot, 2011).  
Upon exposure to the acidic environment of this prelysosomal endocytic cellular 
compartment, domain II of the JEV E glycoprotein swings outwards from the domain I-II hinge 
region and re-orientates itself towards the host endosomal membrane. This induces a 
rearrangement of the E proteins into a lateral positioning, enabling the fusion peptide at the 
apex of domain II to insert itself into the host cell. In turn, an irreversible trimerisation of the 
JEV E glycoprotein takes place. Once this trimerisation has occurred, domain III bends back 
upon itself, and in so doing draws the viral and endosomal membranes into close proximity 
with each other, so that hemifusion can take place (Figure 7; Mukhopadhyay et al, 2005; 
Kaufmann and Rossmann, 2011).   
After the virus has undergone fusion, the nucleocapsid is released into the cytoplasm of the 
host cell. A dissociation between the structural capsid protein and its encapsulated viral RNA 
occurs, in turn releasing the genetic material into the cytosol. From here, replication and 
translation of the JEV RNA genome is able to take place, expressing the JEV polypeptide as one 
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complete, intact protein molecule, encoded from a single open reading frame (Lindenbach and 
Rice, 2003). The polyprotein then undergoes a variety of co- and post-translational enzymatic 
modifications by a combination of proteases and signal peptidases derived not only from the 
host cell, but also from the non-structural regions of the expressed JEV genome itself, including 
the NS2B-NS3 serine protease complex, the NS2 autoprotease and the NS4A protease co-
factor. These enzymes collectively cleave the JEV polyprotein at several points, to yield ten 
individual viral proteins (Murray et al, 2008; Daly and Solomon, 2010). Significant proliferation 
and upregulation of membranous perinuclear organelles, such as the rough endoplasmic 
reticulum (RER) and the Golgi apparatus, is also observed in early JEV-infected cells, and these 
ƐƵďĐĞůůƵůĂƌƐƚƌƵĐƚƵƌĞƐŵĂǇŚŽƵƐĞ①‘ǀŝƌƵƐĨĂĐƚŽƌŝĞƐ①?ƚŽŵĂǆŝŵ ƐĞƚŚĞƌĂƚĞŽĨZEƐǇŶƚŚĞƐŝƐ①?
translation and subsequent progeny virion assembly (Hase et al, 1990).  
In the first instance, immature JEV virions are assembled and bud from the lumen of the ER. 
The immature JEV virion includes both the E and the full prM proteins, and possesses a 
somewhat larger structure (600Å external diameter) than its mature counterparts, with 60 
irregular, trimeric E protein spikes protruding from the virus surface. This conformation 
exposes the prM proteins, which sit at the apical tip of each E trimer and are consequentially 
cleaved by furin-like proteases in the acidic trans-Golgi network (TGN), releasing the precursor 
section from the remainder of the M  protein (Kaufmann and Rossmann, 2011). This cleavage 
disrupts the E protein spike trimer, enabling the rearrangement of the envelope into the flat, 
spikeless and smooth icosahedral pattern characteristic of the mature JEV virion 
(Mukhopadhyay et al, 2005).  
Subviral particle (SVP) production is routinely observed and is a hallmark trait in JEV infection, 
as well as with many other flaviviruses. SVPs share the same smooth exterior as mature JEV 
virions, but have an average diameter of 315Å, and are comprised solely of a lipid membrane 
and the E and M proteins. Like with the complete virus, JEV SVPs are also assembled at the 
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endoplasmic reticulum, and following expression and budding, they are subject to the same 
modifications in the trans-Golgi network. However, they are subsequently non-infectious, 
since they lack a nucleocapsid. Both mature JEV virions and subviral particles egress from the 
host cell via exocytosis (Mukhopadhyay et al, 2005).  
Figure 7. Schematic of the proposed Class II mechanism of fusion between the viral and endosomal 
membranes necessary for JEV entry into and infection of target cells. A) The dimeric JEV E protein is 
lying flat on the virus surface, with the fusion peptide (shown in green) buried into the dimer. B) Upon 
receptor binding and internalisation into the host cell endosome, low pH conditions induce an 
outward swinging action of domain II (in yellow), most likely at the domain I-II hinge region (domain I 
in red). C) Lateral rearrangement of the E proteins takes place, enabling fusion peptide insertion into 
the outer leaflet of the host cell membrane and subsequent E protein trimerization. D) Folding of 
domain III (in blue) of the E protein back onto itself results in drawing the viral and host cell 
membranes into close proximity with one another. E) Following the continuing movement of domain 
III towards domain II, hemifusion occurs between the two membranes. F) An E protein trimer forms, 
where the transmembrane domain and fusion peptide are near each other (adapted from 
Mukhopadhyay et al, 2005).  
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1.1.7 Immunity and pathogenesis 
1.1.7.1 Humoral immunity 
The humoral, antibody-mediated immune response against JEV is well-documented in the 
literature and known to play a central role in protection against the virus. Upon primary 
infection with JEV, an IgM antibody response is raised in the patient, usually within 7 days of 
initial infection, and correlates well with a positive disease prognosis if observed within this 
timeframe. Maximum serum IgM levels are usually reached about 9 days post-infection 
onwards (Solomon et al, 2000). Presence of IgM at raised levels in both the sera and 
cerebrospinal fluid (CSF) is often seen in symptomatic, encephalitic patients; however, an IgM 
response is not usually discernible in the CSF of asymptomatic patients but only in serum 
samples, further suggesting that viral infiltration of the CNS is concomitant with the 
development of characteristic JEV symptoms. Isolation of the virus in patient samples has only 
been achieved when a potent IgM response is absent, as antibody-mediated neutralisation has 
not curbed the levels of viraemia, and this is associated with patient fatality. Immunoglobulin 
class switching subsequently takes place in convalescent patients, and by 30 days post-
infection, the majority of antibodies present in positive serum of CSF samples are class IgG 
(Abraham et al, 2011).   
Indeed, virus neutralising antibodies (VNAbs) of either class IgM or IgG, which bind to antigenic 
epitopes on viral proteins and inhibit their entry into host cells, are primarily elicited against 
the E glycoprotein of JEV and alone are able to confer strong levels of protective immunity 
from the virus (Kimura-Kuroda and Yasui, 1988; Zhang et al, 1989; Pan et al, 2001). Antibody 
responses have also been observed against a variety of non-structural JEV proteins, but these 
almost invariably offer negligible to no protection from the virus (Lin et al, 2008). VNAbs work 
to inhibit the replication and spread of JEV infection, in turn mediating the damaging 
cytopathic and encephalitic effects of the virus.  
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In some instances, flaviviruses are able to exploit the adaptive immune system to their own 
advantage, with a process known as antibody-dependent enhancement (ADE) of infection. IgM 
or IgG antibodies bind specifically to viral proteins with their Fab fragments. This engagement 
ŝƐŝŶƚĞŶĚĞĚƚŽŶĞƵƚƌĂůŝƐĞƚŚĞǀŝƌƵƐ①?,ŽǁĞǀĞƌ①?&ĐɶƌĞĐĞƉƚŽƌƐƉƌĞƐĞŶƚŽŶŝŵŵƵŶĞĐĞůůƐ①?ƐƵĐŚĂƐ
lymphocytes, macrophages and neutrophils, also bind the antibody-virus complex by the 
ĂŶƚŝďŽĚǇ①?Ɛ&ĐĨƌĂŐŵĞŶƚ①?ǁŚich should stimulate the immune cells to initiate phagocytosis or 
cell-mediated cytotoxicity to destroy the virus, but instead brings the virus particles into close 
proximity with the surface of the immune cells, leaving them susceptible to infiltration and 
infection by the flavivirus. Internalisation of the virus can also be brought about by antibody-
mediated activation of the classical complement cascade, and consequential binding to the 
C1q receptor on target cell surfaces. The phenomenon of ADE has been observed for DENV 
and YFV, as well as for JEV (Gould and Buckley, 1989; Kliks et al, 1989). 
1.1.7.2 Cell-mediated immunity 
Despite being an area of ongoing research and development, our knowledge of cell-mediated 
immunity against Japanese encephalitis virus is more rudimentary than that of its humoral 
counterpart. Early studies showed that thymus-deprived mice displayed an impaired anti-JEV 
antibody response, suggesting a significant role for T cell immune responses in the activation 
of corresponding B cell immunity against JEV (Mori et al, 1970). Furthermore, a certain species 
of monkey that normally exhibits resistance to JEV became susceptible to the virus when T cell 
function was suppressed (Nathanson and Cole, 1970). It appears inconclusive whether both 
CD4+ and CD8+ T-cell responses are both required for protection against JEV ①W some studies 
report that both immune populations are necessary, and that depletion of either class results 
in the loss of functional protective capacity in murine subjects (Murali-Krishna et al, 1996); 
however, other studies conflict with these findings, postulating that CD4+ knockout mice, 
immunized with an envelope DNA vaccine, experienced an abrogation of immune protection 
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upon JEV challenge, while this phenomenon was not witnessed in counterpart CD8+ knockout 
mice, concluding that only CD4+ T-cells were required to contribute to functional immunity 
against JEV (Pan et al, 2001). Indeed, the activation of CD8+ T-cell responses has also been 
shown to potentially contribute to the pathogenicity of related flaviviruses, such as DENV, as 
well as MVEV, where a lack of the expression of perforin and Fas/FasL conferred host 
protection against the virus (Licon Luna et al, 2002; An et al, 2004).  
Since then, both CD4+ and CD8+ T-cell responses against JEV have been identified in peripheral 
blood mononuclear cell (PBMC) samples, collected from vaccinated patients who had received 
ĂƉƵƌŝĨŝĞĚ:sǀĂĐĐŝŶĞ①?ŝŶĂĐƚŝǀĂƚĞĚǁŝƚŚĨŽƌŵĂůŝŶĂŶĚĚŝƌĞĐƚĞĚĂŐĂŝŶƐƚƚŚĞǀŝƌƵƐ①?ƐƚƌƵĐƚƵƌĂů
proteins. Interestingly, vaccine recipients displayed T-cell responses of both subsets, primarily 
targeting structural proteins, whereas in contrast, patients infected naturally by JEV presented 
with CD4+/CD8+ T-cell responses against the capsid and non-structural proteins (Konishi et al, 
1995).  
Indeed, the viral non-structural proteins act as important immunogens in the initiation of T-cell 
responses, with NS3 eliciting the strongest cell-mediated response. Amino acid residues 193-
324 on the JEV NS3 protein act as a dominant epitope for the binding of CD4+ and CD8+ T-
cells, and subsequent IFN-ɶƉƌŽĚƵĐƚŝŽŶƐƚŝŵƵůĂƚĞĚďǇE^①?-binding suggests that an active, pro-
inflammatory Th1 response against this non-structural protein may contribute as a crucial 
aspect of immune control against JEV (Kumar et al, 2004a; Kumar et al, 2004b).  
A more recent study was the first to conduct a full-breadth analysis of the human T cell 
response to JEV by systematically mapping JEV epitopes, using a full-length, synthetic peptide 
library. The study concluded that T-cell responses in healthy, JEV-exposed donors are primarily 
CD8+, and predominantly targeted against the NS3, NS4 and NS5 proteins of the virus, 
whereas recovered JE patients mostly mount JEV-specific CD4+ T-cell responses. Additionally, 
these responses, in particular the CD8+ responses observed in healthy donors, reveal an 
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extensive level of  cross-reactivity with other flaviviruses, such as DENV and ZIKV. Overall, a 
high-quality, polyfunctional CD4+ T-cell response was associated most strongly with complete 
recovery from JE infection (Turtle et al, 2016).  
1.1.8 Vaccines 
JEV is a vaccine-preventable disease and a variety of vaccines of different derivations have 
been developed. The first to be licensed was a mouse brain-derived, killed-inactivated vaccine 
based on the prototype Nakayama strain of JEV. This was commercially distributed under the 
name JE-VAX. Although highly efficacious and immunogenic, JE-VAX possessed a number of 
drawbacks, including high cost, varying levels of side-effects and the necessity to administer 
multiple primary doses plus vaccine boosters (Yun and Lee, 2014). More recently, inactivated, 
Vero cell culture-derived vaccines have become more commonplace and are based upon 
either SA-14-14-2 or Beijing-1 strains of JEV (WHO, 2014b). These vaccines are licensed under 
several different names, such as ENCEVAC, based on Beijing-1, and IXIARO, which is adjuvanted 
with an aluminium hydroxide compound and based on SA-14-14-2. These JEV vaccines are 
advantageous as they are generally considered to be safer than JE-VAX. Also, cell culture-
derived vaccines are more amenable for large-scale production than those derived from 
mouse brain (Yun and Lee, 2014). A recombinant, live-attenuated chimeric vaccine produced 
by introducing the structural prM and E genes from JEV SA-14-14-2 into the YFV 17D vaccine 
strain has also recently been licensed under the name ChimeriVax, and is commercially 
available in some countries, such as Australia and Thailand (Monath et al, 2002). Experimental 
vaccine technologies currently in the pipeline include: the production of virus-like particles 
displaying particularly immunogenic peptide portions of the E protein of JEV; the use of 
recombinant vaccinia or canarypox viruses as viral vectors to deliver the genes of JEV antigens 
to produce in vivo protective immunity; and intramuscular immunization with plasmid DNA 




To date, there are no fully licensed antivirals available for treatment of patients infected by 
JEV. Treatment is purely supportive and involves symptom relief and stabilization of patients 
with severe encephalitis. However, a number of promising candidates for JEV antiviral 
therapies have been developed in recent years including minocycline, a tetracycline derivative 
antibiotic which has also been shown to be protective in cases of flaviviral infection, by 
alleviating a number of JEV pathologies, such as neuronal apoptosis, microglial activation, 
caspase activity and release of proinflammatory cytokines (Dutta et al, 2010); glucosidase 
inhibitors situated at the endoplasmic reticulum (ER) that restrict N-linked glycosylation and 
hinder the production of a number of ER-budding viruses; and rosmarinic acid, which is a 
phenolic compound found in the Labiatae family of herbs, which also reduces neuronal 
apoptosis and cytokine accumulation (Saxena et al, 2014). However, all these potential 
antivirals would have to undergo a rigorous clinical trial system before commercial utilisation.  
1.1.10 Diagnosis and serology 
As there are several causes of acute encephalitic syndrome, laboratory confirmation of JEV 
infection is essential for diagnosis. This could be achieved via direct virus isolation or reverse 
transcription polymerase chain reaction (RT-PCR) of viral RNA ①W however, due to the transient 
and moderate viral load in symptomatic patients, this can be problematic. Therefore, diagnosis 
is often retrospectively ascertained by determining antibody levels in patient serum or CSF 
samples (Solomon et al, 2000).  
A variety of serological assays that quantify antibody titres raised against viral proteins (in the 
case of JEV, the majority of antibodies target the E glycoprotein) have been developed for the 




1.1.10.1 Detection of JEV IgM antibodies  
Following infection of JEV, the first step of acquired immune response is the production of IgM 
antibodies against viral antigens, which are usually present at a detectable level at 6 to 14 days 
post-infection (Maeda and Maeda, 2013). However, this antibody class can persist in 
convalescent stage patients for up to 4 months post-infection (Roehrig et al, 2003; Prince and 
Matud, 2011). The serological assay primarily used to detect this immunoglobulin class in 
potentially-infected subjects is the MAC-ELISA (Martin et al, 2000; WHO, 2003). For this assay, 
the viral antigens to calibrate the IgM antibody level in patient serum samples can be acquired 
from various sources, such as infected tissue culture cells, virus-infected mouse brains, and 
recombinant virus antigens. The specificity and sensitivity of the MAC-ELISA varies depending 
on the source of the antigen used, and in some cases when changing the target antigen, the 
specificity can rise while the sensitivity falls and vice versa. Moreover, the relatively low 
specificity of this assay makes it difficult to distinguish between similar clinical virus infections. 
For example, JEV and DENV co-circulate in many regions of India, and WNV has also been 
shown to be responsible for a proportion of encephalitis cases in India, leading to cross-
reactivity issues and low specificity when using the MAC-ELISA (Khan et al, 2011). In an 
attempt to overcome this, two commercially available and commonly-used MAC-ELISA kits, the 
Panbio® Japanese encephalitis①WDengue IgM Combo ELISA (Alere, Australia) and the Venture 
Technologies Dengue①WJEV modified antigen capture ELISA (Universiti Sains Malaysia, 
Malaysia), function by simultaneously testing for antibodies to JEV and DENV, with the highest 
antibody response being indicative of the virus causing the infection (Lewthwaite et al, 2010). 
Another obstacle when utilising this assay is that cerebrospinal fluid (CSF) is the ideal sample 
to use, in order to diagnose a flavivirus infection with viral encephalopathy as opposed to an 
incidental peripheral infection, but CSF can be difficult to extract with only limited volumes in 
children, who are commonly infected with JEV and other encephalitis flaviviruses due to their 
undeveloped immunity through vaccination or long-term exposure (Anuradha et al, 2011). 
72 
 
1.1.10.2 Detection of JEV IgG antibodies 
If IgG class antibodies elicited against JEV E protein, or other viral antigens, are present in a 
ƉĂƚŝĞŶƚ①?ƐƐĞƌƵŵƐĂŵƉůĞ①?ƚŚŝƐŝƐŝŶĚŝĐĂƚŝǀĞŽĨĂůŽŶŐ-term infection (Kuno, 2003). In order to 
detect antibodies of this class, either an IgG-ELISA or an indirect fluorescent antibody (IFA) test 
is commonly used (Malan et al, 2003; Foral et al, 2007). A good advantage for the use of these 
assays is their simplicity, leading to them being commonly used for identifying JEV and other 
flaviviral infections. However, their low levels of specificity, in a similar vein to the MAC-ELISA, 
mean that it is difficult to make a specific and definitive diagnosis using these assays alone, and 
a confirmatory plaque reduction neutralisation test (PRNT) is often required in addition 
(Maeda and Maeda, 2013).  
1.1.10.3 Haemagglutination inhibition (HI) 
Haemagglutination inhibition (HI) assays have been consistently used for flavivirus 
serodiagnosis for many years, as well as for several other viruses from different taxonomic 
families, including influenza, rabies, and members of the Alphavirus and Bunyavirus genera 
(Nagarkatti and Nagarkatti, 1980). The assay works by measuring the total antibody response, 
including IgM and IgG class antibodies, raised against JEV via inhibition of virus-mediated 
erythrocyte agglutination. It is a cheap assay to perform as it does not require any specialised 
equipment, instrumentation or expensive antibodies, and a main advantage of this test is that 
it is not species-specific, meaning that serum samples extracted from a variety of species 
commonly infected by JEV can be employed in this assay and retrospectively diagnosed. 
Disadvantages of the HI assay include the results often displaying high levels of cross-reactivity 
between flaviviral infections, as well as the measurement of binding and not necessarily 
neutralising antibodies, and quality control problems regarding the species from which the 
erythrocytes are sourced for the assay (Cha et al, 2014).  
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1.1.10.4 Plaque reduction neutralisation test (PRNT)  
dŚĞƉůĂƋƵĞƌĞĚƵĐƚŝŽŶŶĞƵƚƌĂůŝƐĂƚŝŽŶƚĞƐƚ①?WZEd①)ŝƐŐĞŶĞƌĂůůǇƌĞŐĂƌĚĞĚĂƐƚŚĞ①‘ŐŽůĚƐƚĂŶĚĂƌĚ①?
serological assay due to its high level of specificity, enabling it to distinguish not only between 
different flavivirus infections, but also between immunoglobulin classes (Johnson et al, 2009; 
Maeda and Maeda, 2013). This assay is performed by serially diluting patient samples, such as 
serum or alternatively cerebrospinal fluid (CSF), and mixing with a constant amount of virus. 
Following an incubation step of a sufficient duration to allow any antibodies in the patient 
sample to bind to antigens on the virus surface, the mixture is added to a confluent monolayer 
of cells permissive to infection by the virus being tested for.  After a second incubation step to 
account for virus attachment and entry into the target cells, the assay medium is aspirated and 
replaced with a semisolid overlay medium such as agarose or carboxymethylcellulose (CMC), 
so that once set, progeny viruses released from infected cells are prevented from spreading to 
and infecting non-adjacent cells in the same well (Calisher et al, 1989). This technique results 
in the formation of plaques or lesions in the cell monolayer caused by virus-induced cytopathic 
effect (CPE) ①W these plaques are then used to indirectly quantify virus infection in the assay and 
are commonly given the unit of plaque forming units per ml (PFU/ml). The antibody 
concentration which confers a reduction of plaque formation at a given percentage (usually 
50% or 90%), compared to a positive virus control sample known to be free of antibodies, 
enables the calculation of a PRNT50 or PRNT90 neutralising antibody titre (as reviewed in 
Mather et al, 2013). If neutralising antibodies are being detected against a virus that does not 
cause discernible CPE in target cells, an altered PRNT known as the focus forming assay can be 
employed, which uses immunostaining with fluorophore- or enzyme-conjugated secondary 
antibodies. The localised clusters of infected cells can then be counted using fluorescent 
microscopy and measured as focus forming units per ml (FFU/ml) (Payne et al, 2006). Flow 
cytometry is an alternative, less conventional assay readout approach for viruses that neither 
cause CPE nor form plaques measurable using the focus forming assay (Kraus et al, 2007).  
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 The ability of the PRNT to distinguish between antibodies against different virus species, as 
well as to determine type-specific antibodies due to its high specificity, is by far the most 
significant advantage of this assay. However, it also possesses some drawbacks, including the 
requirement for wild-type infectious virus, necessitating the use of expensive, high-
containment tissue culture facilities and extensive personnel training, Also, the assay is 
laborious and can take up to 7-10 days for definitive plaques to develop, which restricts 
throughput. Finally, unlike some of the aforementioned serological assays, the PRNT requires a 
readily culturable cell line which is permissive to infection by the given virus (Maeda and 




1.2 Surrogate virus particles for flavivirus serology 
Considerable research focus has been invested in developing novel antigenic reagents for 
serological assays that enable sensitive and specific quantification of neutralizing antibodies 
raised against flaviviruses, as well as other viral families, whilst addressing persistent dilemmas 
of high biosafety containment and prohibitive expense associated with traditional methods. 
These surrogate viruses employed in innovative serological assays are primarily based on the 
genetic manipulation of the viral genome, especially concerning the genes that encode the 
structural viral proteins, in order to attenuate pathogenicity but maintain a virus particle with 
serological value.  
1.2.1 Genetically modified and recombinant viruses  
Recent advances in technology facilitating the production of recombinant DNA have allowed 
for the manipulation of flaviviral genomes, to enhance the development and evaluation of 
novel vaccines, as well as to perform serosurveillance and track the spread of emerging viruses 
of the Flaviviridae family. A chimeric virion, in which the pre-membrane and envelope protein 
genes of WNV were inserted into the corresponding region of the yellow fever vaccine virus 
17D strain genome, was engineered and characterised as a live attenuated vaccine candidate 
(Arroyo et al, 2001). However, this viral chimera was also subsequently utilised as a BSL-2 
reagent in PRNT studies, to retrospectively establish the infection profiles of species involved 
in the 1999 outbreak of WNV in north-eastern USA. A 96% concordance between results 
obtained by native WNV and the WNV-YFV chimera was observed when evaluating panels of 
equine and avian sera sampled from the outbreak, with high levels of sensitivity and specificity 
and comparable virus neutralizing antibody titres recorded (Komar et al, 2009). Genetic 
modifications of the genomes of emerging viruses, such as flaviviruses, could have important 
ramifications not only for vaccine research and development, but also for use as serological 
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tools for the quantification of neutralising antibodies, whilst circumventing requirements for 
high biosafety levels.  
1.2.2 Reporter virus particles 
One form of low pathogenic, surrogate virus particle which has been constructed and applied 
widely across the area of flavivirus biology is the reporter virus particle (RVP). For Japanese 
encephalitis virus, a rapid production method to yield JEV RVPs has been established (Suzuki et 
al, 2014). This methodology initially revolves around the assembly of a sub-genomic replicon 
(SGR) of viral RNA, possessing all of the necessary viral non-structural genes, but omitting the 
C, prM and E genes. This SGR can then be transiently co-transfected into producer cells 
alongside a DNA expression plasmid bearing the corresponding JEV structural genes, ultimately 
creating by trans-complementation pseudo-infectious virions that encapsidate the SGR. These 
RVPs are only capable of one round of infection into target cells, since the replicon packaged 
into the virus particles does not contain the structural viral genes (Suzuki et al, 2014). In other 
studies, RVPs, also known as single-round infectious particles (SRIPs) and pseudo-infectious 
particles (PIPs), have been produced with reporter genes, such as enhanced green fluorescent 
protein (eGFP) or renilla luciferase (R. luc) incorporated into the JEV replicon system, usually as 
a direct substitute to the structural genes, enabling an easier method with which to validate 
successful SGR packaging, RVP formation and transduction, and for clarity in downstream 
applications (Li et al①?①?①?①?①?①)①?dŚĞƌĞƉŽƌƚĞƌŐĞŶĞĐĂŶĂůƐŽďĞĂƉƉĞŶĚĞĚƚŽƚŚĞ①?①?ƵŶƚƌĂŶƐůĂƚĞĚ
region of the replicon, although this is less frequently seen. Once generated, JEV reporter virus 
particles have been used to facilitate the characterisation of novel genotype V strains of the 
virus, and as vaccine candidates, due to their immunogenicity (Huang et al, 2012; Ishikawa et 
al, 2015). Since replicons are easily manipulated by molecular cloning, it is also possible to 
incorporate the genes of heterologous antigenic epitopes into the SGR, creating RVPs able to 
confer dual immune protection in immunized mice upon lethal challenge (Huang et al, 2015).  
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In addition to JEV, a variety of other flaviviruses have been modified and used to create RVPs 
for subsequent usage in serological assays. Kunjin virus (KUNV) was among the first flaviviruses 
for which trans-packaging technology was developed for RVP production, and encapsidation 
was originally achieved following sequential electroporations of the KUNV SGR, followed by a 
second, recombinant replicon of Semliki Forest virus (SFV) carrying the KUNV structural protein 
genes. Expression and assembly of the KUNV RVPs was verified by Northern blotting and 
immunofluorescence, and anti-KUN E monoclonal antibodies were able to potently neutralize 
the virus-like particles (Khromykh et al, 1998). This discovery has been refined and advanced 
somewhat with the generation of a tetracycline-inducible packaging cell line, which 
constitutively expresses a Kunjin structural gene cassette, meaning that encapsidation and RVP 
production can be accomplished solely by transfection of the relevant replicon RNA (Harvey et 
al①?①?①?①?①?①)①?DŽƌĞƌĞĐĞŶƚůǇ①?tEs①?ƚŚĞƚĂǆŽŶŽŵŝĐ①‘ƉĂƌĞŶƚ①?ǀŝƌƵƐŽĨ<hEV, has also successfully 
been incorporated into the replicon system, with luciferase- and GFP-expressing SGRs created 
for encapsidation, and a packaging cell line also being developed for ease of RVP production 
(Pierson et al, 2006; Fernández et al, 2014). In this case, the WNV RVPs were utilised in 
downstream assays to assess the neutralizing efficiency of the monoclonal antibody 7H2 
(Pierson et al, 2006). However, these virus-like particles could be used for other subsequent 
applications, such as comparative serology. DENV RVPs have been generated in several 
studies, using the genomes of different subtypes of the virus, as well as introducing a number 
of reporter genes into the replicon platform (Lai et al, 2008; Zou et al, 2011; Mattia et al 2011). 
Among these, a panel of GFP-expressing RVPs mimicking all four of the DENV serotypes were 
developed and employed to quantify neutralising antibody levels in human serum samples. 
Results correlated strongly with those obtained by the conventional PRNT and were serotype-
specific, overcoming a persistent problem with DENV serology (Mattia et al, 2011). Other 
flavivirus RVPs to be successfully produced include TBEV and YFV (Gehrke et al, 2003; Jones et 
al, 2005).  
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Reporter virus particles are a promising solution to the ongoing problems of handling native, 
wild-type virus, such as high biosafety containment requirements and the associated costs for 
this infrastructure, as well as being easy to manipulate for mutagenesis and serosurveillance 
studies. Furthermore, using RVPs, assays are robust and reproducible and issues of low-
throughput inherent with PRNT-based studies are resolved.   
1.2.3 Virus-like particles produced in insect cells 
A series of studies conducted by Yamaji et al. in recent years have detailed multiple techniques 
for the production of JEV virus-like particles using insect cell expression systems (Yamaji and 
Konishi, 2016). This technology harnesses the characteristic of flavivirus capsid and envelope 
proteins to self-assemble when expressed into particulate structures which closely resemble 
authentic virus particles. However, VLPs are replication-deficient and non-infectious, since no 
incorporation of viral RNA takes place upon particle formation (Noad and Roy, 2003).  
Using the established baculovirus-insect cell expression system, JEV VLPs have successfully 
been generated. First, a recombinant Bombyx mori baculovirus is constructed bearing the prM 
signal sequence and the genes encoding the JEV prM and E proteins. Baculoviral infection of 
lepidopteran insect cell lines, such as Sf9 or High Five cells, results in high levels of VLP 
secretion, as determined by Western blotting and ELISA of the JEV E protein, as well as 
sucrose-density gradient sedimentation analysis to verify the particulate formation of the E 
antigen molecules. Utilisation of Sf9 cells enables a 10-fold increase in expression of the gene 
of interest, when compared to corresponding mammalian expression cell lines, such as CHO 
(Yamaji et al, 2012). A primary advantage of the baculovirus-insect cell system is the ease with 
which genes can be incorporated into the baculovirus genome for expression, allowing for the 
manufacture of many antigenic proteins in VLP form in a short space of time.  
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However, a similar yet distinct alternative to the baculovirus platform is that of stably 
transformed lepidopteran insect cells. In this method, the structural protein genes of JEV are 
cloned into a plasmid expression vector, importantly under the control of the Bombyx mori 
polyhedrin promoter, which is responsible for the high expression of antigen observed in both 
systems. A blasticidin resistance gene is also included, so that transformed High Five cells can 
be selected for, to achieve a stable lepidopteran insect cell line. When constitutively 
expressed, higher amounts of expressed E protein were observed, in comparison to the 
baculovirus infection technique (Yamaji et al, 2013; Yamaji and Konishi, 2013). The stably 
transformed insect cells are more suitable for the production of complex secreted proteins in 
VLP form, since the machinery necessary for protein synthesis, processing and assembly is not 
damaged by baculovirus infection.  
Insect cell expression systems offer a novel approach for the rapid, large-scale manufacture of 
VLPs, which can subsequently be used to induce neutralizing antibodies as vaccine candidates, 




1.3 Pseudotype viruses  
1.3.1 Overview and functions 
Pseudotype viruses (PVs) are increasingly being used in serological assays for the diagnosis of 
viral infection or vaccine seroconversion (Table 2). A pseudotype is a chimeric virion that 
comprises the structural and enzymatic core of one virus and the heterologous envelope 
glycoprotein(s) of another, which mimics the entry mechanisms of wild-type viruses and can 
be safely employed in neutralisation assays. Retroviruses are often employed as the core for 
this technology, with lentiviruses and gammaretroviruses such as HIV and murine leukemia 
virus (MLV) providing an ideal pseudotype backbone. Rhabdoviruses, such as vesicular 
stomatitis virus (VSV), and other retroviruses, such as equine infectious anemia virus (EIAV), 
are also increasingly used as pseudotype cores. Their RNA genomes are manipulated to encode 
a quantifiable marker gene, which is packaged by retroviral core proteins (Mather et al, 2013). 
Transduction of the target cells by the pseudotype is dependent on the ability of the envelope 
protein to engage receptors on the cell surface. If entry is successful, the RNA genome is 
transferred from virus to cell, resulting in reporter gene reverse transcription, genome 
integration and expression. Levels of marker protein expressed in infected cells can 
subsequently be measured, which produces a quantitative readout synonymous with the 
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Flaviviridae Flavivirus ①W JEV 






Bartosch et al, 
2003; Lee et al, 
2009 
Filoviridae Filovirus - Ebola, 
Marburg 
HIV Luciferase Chan et al, 2000 
Bunyaviridae Hantavirus - Hantaan, 
Seoul  






Ogino et al, 2003; 
Ma et al, 1999 
Paramyxoviridae Henipavirus ①W Nipah, 
Morbillivirus ①W 








Frecha et al, 2008; 
Kaku et al, 2009; 
Tamin et al, 2009; 
Humbert et al, 
2012; Logan et al; 
2016a, 2016b 
Togaviridae Alphavirus - Ross 
River virus, 
Chikungunya virus 
MLV Luciferase Salvador et al, 
2009; Sharkey et al, 
2001 
Retroviridae Lentivirus - HIV MLV ɴ-galactosidase Kim et al, 2001 
Table 2. Establishment of the pseudotype platform across several families of emergent RNA 
viruses (adapted from Mather et al, 2013). Along with the conventional retroviral vector 
system, vesicular stomatitis virus (VSV) core pseudotyping is also commonly utilised. Reporter 
gene flexibility within the plasmid co-transfection method for pseudotype production enables 
cost customisation of the pseudoparticles, maximising the scope for laboratories with varying 





PVs are created by simultaneous introduction of the envelope gene, retroviral gag ?pol genes 
(responsible for the manufacture and enzymatic processing of the core structural proteins and 
insertion of the reporter gene into the host chromosome) and the chosen reporter gene into 
producer cells such as HEK293T cells, using a multi-plasmid co-transfection system (Figure 8). 
After transcription and translation of the imported genes by the relevant cellular machinery, 
an RNA dimer of the reporter gene is packaged into the core; these processes are driven by an 
upstream promoter and a packaging sigŶĂů①?Ɏ①?ƌĞƐƉĞĐƚŝǀĞůǇ①?dŚĞƐĂŵĞƉĂĐŬĂŐŝŶŐƐŝŐŶĂůŝƐ
omitted from the gag ?pol construct to prevent replication competence and nullify the 
potential risk of pathogenic virus proliferation. PV capsids are subsequently induced by further 
signals in order to transit to the plasma membrane of the producer cell before they bud 
extracellularly. The virus envelope bearing the heterologous glycoprotein is usually formed 
from the plasma membrane. This process results in a virus-rich supernatant of culture 
medium, which can be harvested and titrated on the target cell. The reporter gene is flanked 
by long tandem repeats (LTRs); these facilitate integration into the target cell genome. 
Integration is catalysed by the lentiviral polymerase/integrase, which is packaged as part of the 
pseudotype virion. The titre of the PV is calculated as a function of reporter gene expression 
(Mather et al, 2013; Temperton et al, 2015). 
Alongside serology, pseudotype viruses have been utilised for a variety of other functions 
(Temperton et al, 2015). These include the identification of virus cellular receptor targets and 
the elucidation of specific viral entry processes (Wang et al, 2004; Simmons et al, 2004); the 
study of innate antiviral processes mediated by post-entry cellular restriction factors, such as 
dZ/D①?ɲĂŶĚWK①?ĂĞĂŶĚ:ƵŶŐ①?①?①?①?①?①)①?ƚŚĞƐĐƌĞĞŶŝŶŐŽĨ ŽǀĞůĂŶƚŝǀŝƌĂůĐŽŵƉŽƵŶĚƐƚŽ
inhibit viral entry and egress mechanisms (Su et al, 2008; Basu et al, 2014); the delivery of 
therapeutic genes for clinical treatment purposes (Bischof and Cornetta, 2010); and the 
83 
 
Figure 8. Three-plasmid co-transfection method for pseudotype virus production. (A) 
Conventional plasmid DNA expression vectors bearing (i) the HIV gag ?pol gene, (ii) the 
envelope glycoprotein from the virus of interest and (iii) a reporter gene (e.g., luciferase) are 
generated. (B) ůůƚŚƌĞĞƉůĂƐŵŝĚƐĂƌĞƚƌĂŶƐĨĞĐƚĞĚŝŶƚŽ①‘ƉƌŽĚƵĐĞƌ①?ĐĞůůƐ①?Ğ①?Ő①?①?,<①?①?①?dĐĞůůƐ①)①?
(C) PV supernatants are harvested and titrated onto permissible target cell lines, to obtain a 
relative transduction titer. (D) PVs can be subsequently employed as surrogate viruses in 
pseudotype neutralization assays to quantify VNAb responses. (iv) In the absence of VNAbs, 
the envelope protein of the virus of interest enables entry of the PV into the target cell and 
the reporter gene is integrated and expressed. (v) Binding of the envelope protein by specific 
antibodies in the sample blocks entry of the PV into the target cell, thus preventing 
expression of the reporter gene. The antibody titre can be expressed as the highest dilution 
of sample that inhibits expression by 50 or 90% (figure sourced from Mather et al, 2013).  
incorporation of pseudotypes as immunogenic antigen in vaccine preparations (Szécsi et al, 






Using pseudotype viruses as serological reagents addresses a number of recurrent 
disadvantages present in the employment of traditional serological assays. PVs are able to be 
utilised in neutralisation assays in low bio-containment laboratories, bypassing the need for 
native, pathogenic virus which dramatically widens the scope of laboratories able to effectively 
diagnose suspected cases of viral infection (Mather et al, 2013).  
The flexibility of reporter genes that can be incorporated into the co-transfection stage of 
pseudoparticle production is another major advantage of the viral pseudotyping approach (as 
reviewed in Mather et al, 2013). The most frequently used reporter genes are GFP, firefly 
luciferase and renilla luciferase. >ƵĐŝĨĞƌĂƐĞĐĂŶďĞƌĞŐĂƌĚĞĚĂƐƚŚĞ①‘ŐŽůĚƐƚĂŶĚĂƌĚ①?ƌĞƉŽƌƚĞƌ
ŐĞŶĞĨŽƌƚŚĞƉƐĞƵĚŽƚǇƉĞƉůĂƚĨŽƌŵ①?ǁŝƚŚƌĞƐƉĞĐƚƚŽƚŚĞĂƐƐĂǇ①?ƐƌĞĂĚŽƵƚƉƌĞƉĂƌĂƚŝŽŶƚŝŵĞĂŶĚ
quantitative data analysis, although the cost of luciferase reagent kits and the necessity for 
specialist detection equipment may restrict its widespread application. Use of a GFP reporter 
does not necessitate additional reagents for reading neutralization titres, but nevertheless 
requires relatively expensive and time-consuming readout equipment, such as a fluorescent 
microscope. ůƚĞƌŶĂƚŝǀĞůǇ①?ɴ-galactosidase substrates can be used to quantify pseudotype and 
VNAb titers by the introduction of the lacZ gene as a reporter (Wright et al, 2009). The readout 
can be obtained in a cost-effective fashion, either by counting cells under a light microscope 
after incubation with 5-bromo-4-chloro-3-indolyl-ɴ-d-galactopyranoside (X-gal) or by the 
evaluation of a colorimetric substrate ①W either O-nitrophenyl-ɴ-d-lactopyranoside (ONPG) or 
chlorophenol red-ɴ-d-galactopyranoside (CPRG) ①W using an ELISA plate reader or by eye (Figure 
9).  
In order to maximise the utility of the pseudotype assay system, multiplexing of PVNAs has 
been demonstrated which permits simultaneous quantification of VNAb responses against 
several PVs, each harbouring a different reporter gene, in the same assay, sparing valuable 
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reagents such as serum samples (Wright et al, 2010; Molesti et al, 2014). For example, Wright 
et al. have explored the potential of multiplexing the pseudotype virus system as a means for 
simultaneously screening of VNAb responses to more than one virus in diagnostic and 
serosurveillance studies (Wright et al, 2010). Renilla or firefly luciferase reporter genes were 
incorporated into pseudotyped particles bearing the envelope proteins for Lagos bat virus 
(LBV) and Mokola virus (MOKV), respectively. LBV and MOKV are phylogroup 2 lyssaviruses 
that are clinically indistinguishable. A dual PNA was performed in which renilla and firefly 
luciferase expression was quantified. Results from the duplex assay correlated well with those 
from PNAs using the individual pseudotypes, and overall seroprevalence of the two 
lyssaviruses within an Eidolon helvum bat reservoir was in accordance with previous studies 
(Hayman et al, 2008; Kuzmin et al, 2008). The ability to multiplex the pseudotype platform 
enables resource-poor laboratories to detect VNAbs for several viruses at once, reducing the 
necessary reagent and sample volumes. The system could be further multiplexed by use of 
fluorescent markers such as GFP and RFP for additional pseudotype viruses. Ultimately, 
serological assays could be carried out for whole families of emerging viruses, such as 
henipaviruses, coronaviruses and hantaviruses that have already been adapted to the 




Figure 9. Choice of reporter gene readouts for the measurement of target cell 
transduction by pseudotype viruses.  Images of serial dilutions from neutralisation 
assays are shown, with heightened levels of pseudotype transduction as serum 
sample concentration decreases.  The expense and accuracy levels of the readout 
systems increase as you descend through the rows of the figure from X-gal to 










The aim of this project is to attempt the production of functional JEV pseudotype viruses, 
which act as safe, replication-defective surrogates for wild-type, infectious JEV in downstream 
virus neutralisation assays. Such PVNAs could be used to quantify the VNAb response raised 
against the JEV antigenic surface glycoproteins, following vaccination or natural infection. This 
report details a variety of approaches taken to try and induce successful JEVpp generation, as 
well as addressing several considerations to increase the amenability of the pseudotype virus 





General materials and methods 
2.1 Molecular biology 
2.1.1 Plasmids 
Commerically synthesized genes were received as cloned inserts into the pUC57 plasmid 
(Genscript®, cat. n° SD1176). pUC57 (2710bp) is a high-copy pUC19 derivative plasmid, 
ŽƌŝŐŝŶĂůůǇŝƐŽůĂƚĞĚĨƌŽŵƚŚĞ,①?ɲƐƚƌĂŝŶŽĨE.coli, and is commonly used as a cloning vector 
(Yanisch-Perron et al, 1985). This plasmid possesses a bla gene to confer ampicillin resistance 
and a lacZ gene, within which the multiple cloning site (MCS) resides, for blue/white selection 
during cloning. Also, an origin of replication derived from the pMB1 plasmid is present to 
enable plasmid amplification in bacterial cells, as well as a CAP protein binding site and a lac 
repressor binding site, which are vital alongside the lacZ gene to complete the lac operon 
mechanism for blue/white screening (Figure 10).  
During the cloning of the JEV prME envelope glycoprotein genes, pCAGGS was used as a 
destination vector, and was also used for downstream pseudotype production attempts ①W this 
is a high-copy, ampicillin-resistant pUC13-based plasmid, which permits robust, efficient 
mammalian cell expression of a desired gene insert in a various of eukaryotic cell lines, due to 
the inclusion of a CAG promoter, consisting of a CMV immediate-early (CMV IE) enhancer, 
folloǁĞĚďǇƚŚĞĐŚŝĐŬĞŶɴ-actin promoter. Downstream of the promoter lies the ƌĂďďŝƚɴ-
globin ŐĞŶĞ①?①?ĨůĂŶŬŝŶŐƐĞƋƵĞŶĐĞ①?ǁŚŝĐŚĐŽŶƚĂŝŶƐĂƐƉůŝĐĞĂĐĐĞƉƚŽƌƐŝƚĞĂŶĚĂƉŽůǇĂĚĞŶǇůĂƚŝŽŶ
signal. Furthermore, an SV40 origin of replication for prokaryotic expression and a neomycin 
resistance gene for selection of positively-transfected eukaryotic cells are included in this 




Figure 10. Plasmid map of pUC57. Arrows pointing in an anticlockwise direction 
indicate that the genetic element is located on the antisense strand of the plasmid 
DNA. Grey arrows on the plasmid map display the locations of the bla ampicillin 
resistance gene and the pMB1 origin of replication. The blue and grey arrow is 
representative of the lacZ gene location, with the green segment on this arrow 
denoting the bounds of the multiple cloning site, of which the sequence is displayed in 
more detail below the plasmid map. This sequence shows each restriction enzyme 
cleavage site within this region, as well as the annealing sites of the M13 sequence 




Figure 11. Plasmid map of pCAGGS. The yellow, purple and brown segments present 
on the plasmid map display the locations of the cytomegalovirus immediate-early 
ĞŶŚĂŶĐĞƌ①?ƚŚĞƌĂďďŝƚɴ-ŐůŽďŝŶ①?①?ĨůĂŶŬŝŶŐƐĞƋƵĞŶĐĞĂŶĚƚŚĞSV40 origin of replication 
respectively. The green and sky blue arrows pointing in a clockwise direction indicate 
ƚŚĞƐŝƚĞƐŽĨƚŚĞĐŚŝĐŬĞŶɴ-actin promoter and the neomycin resistance gene, which are 
located on the sense strand. The antisense, anticlockwise-pointing red arrow denotes 
the bla ampicillin resistance gene. The small orange segment is the multiple cloning 
site, with common restriction enzymes featured in a list alongside it. Plasmid map 
design was carried out using SimVector 4.6 software (PremierBiosoft®, CA, USA).  
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2.1.2 Liquid and solid bacterial media 
To produce stock solutions of antibiotics used in the preparation of bacterial media, either 
ampicillin sodium salt (Fisher Scientific, cat. n° BP1760) or kanamycin sulphate (Fisher 
Scientific, cat. n° BP906) were dissolved in UltraPure①? DNAse/RNAse free distilled water 
('ŝďĐŽ①?①?/ŶǀŝƚƌŽŐĞŶ①?①?ĐĂƚ①?Ŷ①?①?①?①?①?①?-049), to a final stock concentration of 100mg/ml for 
ampicillin, and 10mg/ml for kanamycin. Ampicillin was diluted to a working concentration of 
100µg/ml in liquid bacterial media and 200 µg/ml in solid bacterial media, whereas kanamycin 
was used in a working solution at the concentration of 50µg/ml in both solid and liquid 
bacterial media.  
When preparing solid and liquid bacterial media, ready-to-dissolve Luria Bertani (LB) agar 
(Fisher Scientific, cat. n° BP1425 and Sigma-Aldrich, cat. n° L3147) and LB broth (Fisher 
Scientific, cat. n° BP1426) were respectively used. These powders were dissolved in double 
ĚŝƐƚŝůůĞĚǁĂƚĞƌĂƐƉĞƌƚŚĞŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐƌĞĐŽŵŵĞŶĚĂƚŝŽŶƐĂƚƚŚĞĨŽůůŽǁŝŶŐĐŽŶĐĞŶƚƌĂƚŝŽŶƐ①P
16g per 400ml for LB agar; 12.5g per 500ml for LB broth. The prepared solutions were then 
autoclaved, cooled and sealed before use.  
Super Optimal broth with catabolite expression, or SOC broth (SOC; Invitrogen①?, cat. n° 15544-
034), which contains 2% tryptone (w/v), 0.5% yeast extract (w/v), 10mM NaCl, 2.5mM KCl, 
10mM MgCl2, 10mM MgSO4 and 20mM glucose, was utilised during bacterial transformation 
as a recovery medium, thus increasing the efficiency of the process.  
2.1.3 Transformation of chemically competent E. coli cells 
In order to propagate plasmid stocks or amplify a cloned plasmid following ligation during 
molecular cloning, a conventional transformation protocol was followed, utilising Subcloning 




/ŶŝƚŝĂůůǇ①?Ă①?①?①?①?②?ůŽƌ①?①?②?ůĂůŝƋƵŽƚŽĨ,①?ɲǁĂƐƌĞŵŽǀĞĚĨƌŽŵ-80°C cold storage and thawed on 
ice, before adding 1-2.5µl (within a range of 0.5-10ng) of the desired plasmid DNA. The 
transformation mixture was then incubated on ice for 30 minutes, before a heat shock step at 
①?①?①?ĨŽƌ①?①?ƐĞĐŽŶĚƐĞŝƚŚĞƌŝŶĂǁĂƚĞƌďĂƚŚ①?:ŽƵĂŶ①?ĐĂƚ①?Ŷ①?①?① ①? ①?①?①?①?①)ŽƌĂŶĐĐƵůŽĐŬ①?ŝŐŝƚĂů
Dry Bath (Labnet International, cat. n° D1100-230 V) ①W the bacterial heat shock temporarily 
permeabilises the bacterial cell wall and allows entry of intact, circular plasmids. The aliquot 
was subsequently placed back on ice for 2 minutes to halt the heat shock process. Following 
this, 250µl of SOC medium was added prior to recovery incubation in a NĞǁƌƵŶƐǁŝĐŬ①?
Scientific C25KC Incubator Shaker (Eppendorf, Germany) for 1 hour at 37°C and 225rpm. This 
enables the transformed cells to express the relevant antibiotic resistance protein from its 
corresponding gene present in the recombinant plasmid, which is essential prior to antibiotic 
selection on Luria Bertani (LB)-agar (Sigma Aldrich, UK) plates ①W 50µl of each transformation 
mixture was plated before overnight incubation (Genlab, cat. n° INC/75) at 37°C.    
2.1.4 Plasmid DNA purification from bacterial culture 
To amplify and purify plasmid DNA required for transfection into eukaryotic cells, sequencing 
or analysis following cloning processes, the commercial QIAprep Spin Miniprep Kit (QIAGEN, 
ĐĂƚ①?Ŷ①?①?①?①?①?①?①?①?①?①?①?①?①)ǁĂƐĨŽůůŽǁĞĚĂƐƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐŝŶƐtructions (QIAGEN, 2012), which 
employs a modified alkaline lysis with sodium dodecyl sulphate (SDS) technique.  
Bacterial colonies transformed with a single copy of the desired plasmid were inoculated into 
5ml of antibiotic-containing LB broth, before being incubated overnight (12-16 hours) at 37°C 
and 225rpm in a shaking bacterial incubator. At this stage, 1ml of each bacterial culture was 
removed and supplemented with 80% (v/v) glycerol to make a 15% glycerol stock and frozen 
down at -80°C as a stock from which to further inoculate and propagate any required plasmid. 
The cultures were then pelleted for 3 minutes at 6800 x g using a table-top microcentrifuge 
(Thermo Fisher Scientific, cat. n° 10524723) before removal of the supernatant. The bacterial 
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cell pellet was resuspended in 250µl Buffer P1 containing 100µg/ml RNase A until a 
homogenous bacterial solution was achieved. The RNase A enzyme efficiently breaks down any 
RNA contamination in the solution, thus helping to create a purer end sample. 350µl of the 
alkaline Buffer P2 (containing sodium hydroxide and SDS) was then added to lyse the bacterial 
ĐĞůůǁĂůůƐĂŶĚƌĞůĞĂƐĞƚŚĞĐĞůůƐ①?ĐŽŶƚĞŶƚƐ①?ŝŶĐůƵĚŝŶŐƉůĂƐŵŝĚE①?ďĞĨŽƌĞĂĚĚŝŶŐ①?①?①?ƵůŽĨƚŚĞ
neutralisation Buffer N3, which is acidic and contains potassium acetate, to neutralise the 
alkaline pH of the sample and precipitate out any bacterial macromolecules, such as protein, 
lipids and chromosomal DNA, as well as SDS from the sample solution. The pH-neutralised and 
salt-balanced lysate was then cleared of all precipitate by centrifugation for 10 minutes at 
17000 x g, pelleting the unwanted contents so that the plasmid DNA-containing supernatant 
could be loaded onto a QIAprep Spin Column, which possesses a silica membrane that 
exclusively binds DNA. The loaded spin column was centrifuged for 1 minute at 17000 x g, 
before flow-through was discarded and two wash buffers were added successively: first, 500µl 
of Buffer PB, followed by 750µl of Buffer PE. These wash steps were both followed with further 
centrifugation steps at 17000 x g for 1 minute, and subsequent disposal of flow-through. To 
ensure the clearance of any ethanol residue from the membrane, a dry centrifugation step of 
the same duration and speed was performed. In order to elute the plasmid DNA, 50-100µl of 
nuclease-free water was added to the spin column, incubated for 1 minute to allow for the 
dissolving of the plasmid DNA into the water, before a final centrifugation step at 17000 x g for 
1 minute. The plasmid DNA-rich flow-through was retained in a 1.5ml microcentrifuge tube 
(Greiner Bio-One, cat. n° 616201), ready for downstream usage.  
2.1.5 Calculation of nucleic acid concentration 
To calculate the concentration and purity of plasmid DNA, as well as DNA fragments 




units were given as ng/µl and purity as an absorbance ratio of 260nm/280nm.  
2.1.6 Oligonucleotide primers for molecular biology and sequencing purposes 
Primers required for molecular biology or sequencing purposes were ordered from Eurofins 
MWG Operon at a 25nmol synthesis scale and were delivered in a lyophilised, desalted state 
(unless stated otherwise in the text). Prior to use, the primers were reconstituted in sterile, 
nuclease-free water to a final stock concentration of 100pmol/µl, before further dilution down 
to a 10pmol/µl working concentration.  
2.1.7 Sanger chain termination sequencing 
To verify the successful incorporation of desired genes into plasmid vectors via molecular 
cloning, recombinant plasmid DNA was sent to GATC Biotech AG for Sanger sequencing, using 
either the ^hWZDƌƵŶ①? or >/',dƌƵŶ①? sequencing systems, depending on the availability of 
sequencing barcodes and universal primers. For the SUPREMErun①? system, 20µl of plasmid at 
an 80ng/µl concentration and 20µl of the appropriate sequencing primer were posted in 
separate tubes to GATC Biotech AG. In some instances, primers were not required to be sent, 
as GATC Biotech AG could supply an in-house stock of universal primers with which to 
sequence the plasmid sample (Table 3).  For the >/',dƌƵŶ①? sequencing system, 5µl of 80ng/µl 






























































































2.1.8 Polymerase chain reactions 
In order to amplify genes for routine molecular biology purposes, polymerase chain reaction 
was used. Since desired prME genes were subcloned from recombinant plasmids following 
commercial gene synthesis, PCR was used primarily for analytical applications, as opposed to 
for cloning. Therefore, utilisation of a polymerase enzyme with high levels of amplification 
fidelity was unnecessary, and so the DreamTaq polymerase was chosen for use (Thermo Fisher 
Scientific, cat. n° K1081 or K1082), which is designed to consistently offer robust and reliable 
amplification.  
To perform amplification reactions, a 25µl reaction mixture was made up in 0.2µl thin-walled 
PCR tubes (VWR International Ltd, cat. n° 732-0548) on ice, by mixing 12.5µl DreamTaq Green 
PCR Master Mix with 1µM of both the forward and reverse primer required in the PCR 
reaction, as well as approximately 10ng of template plasmid DNA. Nuclease-free, sterile H2O 
was then added to achieve a final reaction volume of 25µl. Samples were subsequently 
Table 3. Characteristics of sequencing primers. The M13 and pCAGGS sequencing primer 
pairings are listed, along with the full sequences and lengths in nucleotides, as well as their 
percentage GC contents and the level of presence of secondary structures and primer 
dimers. Additionally, a brief description of the function of each primer is given.  
96 
 
vortexed and transferred to either the Mastercycler Ep Gradient (Eppendorf) or the 
Mastercycler Ep Gradient S (Eppendorf) thermal cycler, before being run on a PCR program 
appropriate to achieve substantial amplicon yields.  
2.1.9 Restriction endonuclease digestion of DNA 
Restriction endonuclease digestion reactions were performed for subcloning purposes in this 
study, in order to isolate prME gene inserts from original plasmid vectors, as well as to create 
the necessary compatible nucleotide overhangs at the ends of both expression vector and 
insert DNA fragments prior to ligation. Furthermore, restriction digest screening to identify 
successful production of recombinant plasmids was also carried out.  
For subcloning purposes, conventional restriction endonucleases (Thermo Fisher Scientific) 
were generally utilised. In each instance in this study, the two enzymes that were required 
achieved 100% mutual compatibility in the universal Tango buffer (Thermo Fisher Scientific, 
cat. n° BY5) at a 2X final concentration. Approximately 800-1000ng of plasmid DNA was mixed 
with 10U of each enzyme in restriction digest reaction mixtures, before addition of the Tango 
buffer and sterile, nuclease-free H2O to a final volume of 20µl. As these restriction 
endonucleases are suspended in a buffer that contains glycerol, it was important to consider 
that the overall percentage of glycerol in each reaction mixture was always 10% or less (as 
recommended by the manufacturers). Reactions were then incubated for 2 hours at 37°C in a 
waterbath, before use in downstream subcloning purification applications (see sections 2.1.13 
and 2.1.14).  
When restriction digestion was required for analytical purposes, FastDigest® enzymes (Thermo 
Fisher Scientific) were used to perform such reactions. Approximately 500ng of plasmid DNA 
was digested in a total volume of 20µl. When using FastDigest® enzymes, the universal 
FastDigest® Green Buffer (Thermo Fisher Scientific, cat. n° B72) was able to be used, alongside 
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10U of each enzyme required in the restriction digest. Final reaction volumes were reached by 
addition of the appropriate volume of nuclease-free, sterile H2O. Samples were subsequently 
transferred to a thermocycler, where they were incubated for 15 minutes at 37°C, followed by 
an enzyme denaturation step at 80°C for 5 minutes, before being analysed by agarose gel 
electrophoresis (see section 2.1.12).  
2.1.10 DNA ligation 
DNA ligation was used in this study to join open, digested expression vectors and JEV prME 
genes by their complementary restriction enzyme nucleotide overhangs, in the presence of 
1U/µl T4 DNA ligase (Thermo Fisher Scientific, cat. n° EL0011) and its corresponding buffer 
(Thermo Fisher Scientific, cat. n° B69).  
Prior to ligation, the concentration and purity of the vector and insert DNA fragments was 
ĞůƵĐŝĚĂƚĞĚƵƐŝŶŐƚŚĞEĂŶŽĚƌŽƉ①?①?①?①?①?^ƉĞĐƚƌŽƉŚŽƚŽŵĞƚĞƌ①?EĂŶŽƌŽƉ①?WƌŽĚƵĐƚƐ①?
ThermoFisher Scientific). These values guided the calculation of the molar ratio for the ligation 
reactions, which defines the number of copies of insert and vector DNA incorporated into each 
reaction sample, using the following formula:   
 
Ligations were set up at a 1:1 and 1:3 vector to insert molar ratio, in a volume of 10µl or 
otherwise, the lowest possible volume. A negative control reaction sample, containing only a 
vector fragment and no insert, was also made up to determine whether any undigested or re-
ligated vector was present.  The sample reactions were usually incubated overnight (~16 
hours), but in some instances over a weekend (~64 hours), at room temperature, allowing a 
sufficient duration for recombinant plasmids to be formed by ligation.  
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2.1.11 Colony polymerase chain reaction for screening of recombinant clones 
Colony PCR is a rapid, high-throughput method, which in this study enabled fast determination 
of successful recombinant plasmid DNA in candidate bacterial transformants, via amplification 
of the desired prME gene, following ligation and transformation. 
Each selected colony, alongside a positive (colony with vector plus insert) and negative (colony 
with empty vector) control, was touched lightly with a pipette tip before being streaked onto a 
designated section of a fresh ampicillin LB-agar gridplate, then into a corresponding tube 
containing 25µl nuclease-free water. The gridplate was left at 37°C to promote fresh growth of 
the E.coli cells, whilst the inoculum tubes were incubated for 10 minutes to allow bacterial 
equilibration in the water. The inoculated water samples were then transferred to a thermal 
cycler and heated to 94°C for 3 minutes to further lyse the the E.coli cells and release their 
contents, including copies of the desired recombinant plasmid, if present. 5µl of each of the 
heated inocula samples were mixed with 20µl of a Green DreamTaq master mix (Thermo 
Fisher Scientific, cat. n° K1081 or K1082) cocktail, containing 1µM each of the relevant forward 
and reverse primer, for each colony being sampled. Subsequently, the samples were run on a 
PCR program appropriate to achieve strong amplification of the plasmid gene insert.   
2.1.12 Gel electrophoresis of DNA 
Agarose gel electrophoresis was utilised for analytical purposes to identify the lengths (in 
nucleotide base pairs) of DNA fragments at several stages throughout the subcloning process, 
such as after restriction digestion of both insert and vector DNA, as well as post-colony PCR 
and digest screening. Since the lengths of the desired DNA fragments fall between the range of 
500bp and 10kb, a 1% (w/v) agarose (Fisher Scientific, cat. n° BP1356) gel dissolved in 0.5X tris-
acetate-ethylenediaminetetraacetic acid (EDTA) buffer (TAE; 50X stock solution, Alpha 
Laboratories, cat. n° EL0077; or Fisher Scientific, cat. n° BP1332) was used as the 
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electrophoretic matrix. To achieve fluorescence of DNA bands on the gel under ultraviolet 
light, either ethidium bromide (Sigma-Aldrich, cat. n° 46067) or Nancy-520 (Sigma-Aldrich, cat. 
n° 01494) intercalating dyes were added to the molten agarose mixture before pouring, to a 
final concentration of 0.1µg/ml or 0.5µg/ml, respectively.  
It was necessary for loading dye to be added prior to adding the samples onto the gel: for PCR 
products amplified using the Q5 polymerase, and restriction digest samples cut with 
conventional restriction endonucleases, 6X DNA loading dye (Thermo Fisher Scientific, cat. n° 
R0611) was added, diluted to a 1X working concentration; however, when PCR products were 
amplified using the DreamTaq polymerase or when FastDigest® reactions were performed, the 
samples were able to be loaded directly onto the gel, since the DreamTaq Green PCR master 
mix and the FastDigest® Green buffer already contain loading dyes. The GeneRuler 1kb DNA 
ladder (Thermo Fisher Scientific, cat. n° SM0311) was added to each gel ①W this molecular 
weight marker contains an amalgam of DNA fragments of known lengths, which migrate across 
ƚŚĞĞůĞĐƚƌŽƉŚŽƌĞƚŝĐŐĞůĂƚĚŝĨĨĞƌĞŶƚƐƉĞĞĚƐ①?ĐƌĞĂƚŝŶŐĂ①‘ƌƵůĞƌ①?ƚŚĂƚĐĂŶďĞƵƐĞĚƚŽĂƉƉƌŽǆŝŵĂƚĞůǇ
measure the lengths of experimental DNA sample fragments.  
When a preparative agarose gel needed to be made in order to subsequently excise and 
ĞǆƚƌĂĐƚĂEĨƌĂŐŵĞŶƚ①?hůƚƌĂWƵƌĞ①?ŐĂƌŽƐĞ①?/ŶǀŝƚƌŽŐĞŶ①?①?ĐĂƚ①?Ŷ①?①?①?①?①?-500) was used, as a 
direct substitution for the aforementioned agarose.  
All gels were run submerged in a 0.5X TAE electrophoretic running buffer, using a power 
supply (Consort, cat. n° EV231) and electrophoretic chambers (SCIE-PLAS, cat. n° SVG-SYS Vari-
gel MINI; or PEQLAB Biotechnologie GmbH, cat. n° 40-124 or 40-0911; or Sigma-Aldrich, cat. n° 
EP1101). Analytical gels were run at a voltage of 100-120V, whereas preparative gels were run 
at 40V to avoid over-heating and re-melting of the gel. Electrophoresis was halted when the 
loading dye front had migrated across the entire length of the gel.  
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For observation of gels prior to excision of a DNA band, a trans-illuminator was used (UVItec, 
cat. n° BXT-26.MX). However, for gels where only images and downstream analysis was 
required, a G:Box Chemi XT Chemi XT Imaging System (Syngene), along with GeneSnap 
software (Syngene), was utilised. 
2.1.13 Polymerase chain reaction and restriction digest purification of DNA fragments 
When PCR and restriction digest reaction samples required purification before subsequent 
subcloning stages, the QIAquick PCR purification kit (QIAGEN, cat. n° 28104) was used, 
ĨŽůůŽǁŝŶŐŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐŝŶƐƚƌƵĐƚŝŽŶƐ①?ZĞĐŽŵŵĞŶĚĞĚŬŝƚƉƌŽƚ ĐŽůƐǁĞƌĞĨŽůůŽǁĞĚ①PďƌŝĞĨůǇ①?
Buffer PB was added to the experimental sample at a volume 5 times that of the sample 
volume, before addition of 10µl of 3M sodium acetate at a pH of 5.0. This enables reaction 
mixture acidification, acting against buffer PB, as the optimal pH for DNA binding is 7.5. The 
sample was then placed in a QIAquick column and centrifuged at 17000 x g for 1 minute. At 
this stage, DNA adsorption to the silica membrane should occur. Flow-through was discarded 
and 750µl of Buffer PE, which contains ethanol, was added in order to remove any presence of 
contaminating salts, with another centrifugation step of the same speed and duration. Ethanol 
residue was then removed from the membrane by a subsequent 2 minute centrifugation, 
before DNA elution was carried out by adding 30µl of sterile, nuclease-free H2O at 70°C, 
incubating at room temperature for 1 minute, then transferring the silica membrane to a fresh 
1.5ml microcentrifuge tube and performing a final centrifugation step at 17000 x g for 1 
minute.    
2.1.14 Agarose gel extraction of DNA fragments 
In order to purify fragments of DNA following preparative agarose gel electrophoresis and 
scalpel excision of the DNA band of interest, agarose gel extraction was carried out, using 
either the QIAquick Gel Extraction Kit (QIAGEN, cat. n° 28704) or the MinElute Gel Extraction 
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Kit (QIAGEN, cat. n° 28604). The protocol recommended by the manufacturers was followed: 
briefly, 3 volumes of buffer QG was added to the sample, corresponding to 1 weight of gel 
slice. This buffer enables dissolving of the agarose present in the experimental sample when 
incubated at 50°C for 10 minutes with frequent vortexing. The pH of the sample was then 
adjusted by adding 10µl of pH 5.0 3M sodium acetate, followed by one sample volume of 
isopropanol (Fisher Scientific, cat. n° P/7500/17). The sample was subsequently loaded onto 
either a QIAquick or a MinElute spin column by a 1 minute centrifugation at 17000 x g. 
Centrifugation-based wash steps with Buffers QG and PE were then performed to ensure 
complete removal of agarose and salt traces, followed by a dry centrifugation of the column at 
17000 x g for 2 minutes to remove ethanol residue. To elute, 30µl of of sterile, nuclease-free 
H2O at 70°C was added to the spin column being used, before a final incubation for 1 minute at 
room temperature and a 1-minute centrifugation at the same speed, into a clean 1.5ml 
microcentrifuge tube. Use of sterile water instead of an elution buffer ensures there is no 
possibility of EDTA presence in DNA samples, which can hinder downstream applications.  
2.1.15 Site-directed mutagenesis of DNA using Q5 polymerase 
When it was necessary to alter the nucleotide sequence of a prME envelope glycoprotein 
gene, site-directed mutagenesis was carried out. In all instances, the Q5 site-directed 
mutagenesis kit (New England Biolabs, MA, USA; Cat. No. #E0554) was utilised, due to the high 
fidelity of the polymerase and its ability and versatility to incorporate large insertion mutations 
into existing plasmid constructs. The mutagenesis system works by whole-plasmid PCR 
amplification elongating from mutagenic primers ①W designed using the EĂƐĞŚĂŶŐĞƌ①? 
program ①W ďĞĨŽƌĞĚŝƌĞĐƚƚƌĞĂƚŵĞŶƚǁŝƚŚĂ①‘<>①?ĞŶǌǇŵĞŵŝǆǁŚŝĐŚĐŽŶƚĂŝŶƐĂŬŝŶĂƐĞĂŶĚůŝŐĂƐĞ
ƚŽ①?①?ƉŚŽƐƉŚŽƌǇůĂƚĞĂŶĚĐŝƌĐƵůĂƌŝƐĞƚŚĞWZƉƌŽĚƵĐƚ①?ĂƐǁĞůůĂƐƚŚĞDpnI restriction enzyme 





into the reverse primer.  
Reaction sample mixtures to perform Q5 site-directed mutagenesis are compiled by mixing 
12.5µl of the 2X Q5 Hot-Start High Fidelity PCR Master Mix with the forward and reverse 
mutagenic primers to a final concentration of 0.5µM each, and also a mass of template 
plasmid DNA equivalent to 1-25ng. Addition of sterile, nuclease-free H2O takes place to 
achieve a final reaction volume of 25µl. Samples are then subjected to the following 30-cycle 
PCR program: an initial 30 second denaturation step at 98°C, followed by 30 cycles of a 10 
second denaturation step at 98°C, a 30 second annealing stage at a temperature dictated by 
the properties of the mutagenic primers, and then an elongation step of 72°C for 30 
seconds/kb of plasmid length. A final extension stage of 2 minutes at 72°C is added to the end 
of the PCR program.  
1µl of each amplified sample is carried forward to the KLD stage of the mutagenesis 
methodology. Reaction mixtures are compiled by assembling the following reagents: 1µl of 
PCR product, 5µl of the 2X KLD Reaction Buffer, 1µl of the 10X KLD Enzyme Mix and 3µl of 
sterile, nuclease-free H2O to reach a total reaction volume of 10µl. Samples are mixed well and 
incubated at room temperature for at least 5 minutes, before downstream transformation, 
colony PCR and sequence verification can take place, to assess correct mutagenic alteration of 
the template sequence.  
In all instances, mutagenesis was carried out on pUC57 recombinant plasmids harbouring a 
prME gene, due to the relatively short length of the pUC57 plasmid. As the Q5 mutagenesis 
system employs amplification of the whole plasmid to incorporate mutations, amplifying a 




2.2 Cell culture 
All cell culture maintence and procedures were carried out in a MSC-ĚǀĂŶƚĂŐĞ①?ůĂƐƐ//
Biological Safety Cabinet (Thermo Fisher Scientific, cat. n° 51028226). Cultures were incubated 
ŝŶĂ,ĞƌĂĐĞůů①?①?①?①?ŝŚƵŵŝĚŝĨŝĞĚK①?/ŶĐƵďĂƚŽƌ①?dŚĞƌŵŽ&ŝƐŚĞƌ^ĐŝĞŶƚŝĨŝĐ①)Ăƚ①?①?①?ĂŶĚ①?% CO2.  
2.2.1 Maintenance and characteristics of cell lines 
Human embryonic kidney 293T clone 17 cells (HEK293T/17; Pear et al, 1993) were used for 
transfections to attempt production of JEV pseudotype viruses, as well as to determine 
expression and intracellular localisation of the prME proteins. Also, HEK293T/17 cells were 
used as a potential target cell line in JEV transduction experiments, along with baby hamster 
kidney 21 cells (BHK-21; Stoker and Macpherson, 1964), Crandell-Rees feline kidney cells (CrFK; 
Crandell et al, 1973) and Vero cells (Yasumura and Kawakita, 1993), as they are generally 
considered to be permissive to JEV infection and are commonly used in studies involving 
cellular entry of JEV.  
TELCeB6 and TECeB15 are packaging cell lines modified from TE671 cells (ATCC HTB-139) to 
express MLV gag-pol and produce replication-defective MLV gammaretrovirus cores, which 
can subsequently be pseudotyped with a heterologous envelope glycoprotein. In addition, 
TELCeB6 cells express the vector MFG-nlslacZ ǁŚŝĐŚŝŶĐŽƌƉŽƌĂƚĞƐƚŚĞɴ-galactosidase reporter 
into the MLV cores. Despite this, different reporter genes can be incorporated into these 
cores, providing the correct packaging signals are active. These packaging cells were used for 
transfections to attempt production of JEV-pseudotyped MLV, using a slightly different 
technique to conventional multi-plasmid co-transfection.  
In all instances, cell lines were cultured ŝŶƵůďĞĐĐŽ①?ƐDŽĚŝĨŝĞĚĂŐůĞ Medium (DMEM) with 
ŚŝŐŚŐůƵĐŽƐĞĂŶĚ'ůƵƚĂDy①? ①?'ŝďĐŽ①?①?/ŶǀŝƚƌŽŐĞŶ①?①?ĐĂƚ①?Ŷ①?31966-021),  or an equivalent 
DMEM medium (Sigma-Aldrich, cat. n° D6429, or PAN-Biotech, cat. n° P04-04510), 
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supplemented with 15% (v/v) European Union approved origin heat-inactivated Fetal Bovine 
^ĞƌƵŵ①?&^①?'ŝďĐŽ①?①?/ŶǀŝƚƌŽŐĞŶ①?①?ĐĂƚ①?Ŷ①?①?①?①?①?①?-064, or PAN-Biotech, cat. n° P30-8500) and 1% 
(v/v) 10000 U penicillin/10mg/ml streptomycin (Sigma-Aldrich, cat. n° P4333). 
All cell cultures were grown in T75 culture flasks (Thermo Fisher Scientific, cat. n° 156499), 
expect for HEK293T/17 cells, which were maintained in 10cm sterile Nunclon® surface cell 
culture dishes (Thermo Fisher Scientific, cat. n° 150350).  
When subculturing was necessary, old medium was aspirated from the cell monolayer, before 
rinsing with 2ml of 0.05% (w/v) Trypsin-0.53mM EDTA solution (Sigma-Aldrich, cat. n° T3924, 
or PAN-Biotech, cat. n° P10-040100), then incubation with 2ml of fresh trypsin-EDTA solution 
at 37°C and 5% CO2, until complete detachment of the cells from the culture vessel took place. 
This trypsinisation reaction was quenched by the addition of 6ml 15% FBS-DMEM medium, in 
which the cells were thoroughly resuspended, and a fraction of this cell suspension was 
seeded into a fresh 15% FBS-DMEM containing culture vessel, at an appropriate dilution to 
achieve a designated subculturing ratio (these ranged from 1:4 to 1:12 for different cell lines).   
2.2.2 Freezing and thawing of cell lines 
Upon reaching 80% confluency, cell lines were frozen down to create stock aliquots, from 
which subsequent cultures of the cell line can be propagated. Cell monolayers were detached 
from the culture vessel by the aforementioned trypsinisation process, then centrifuged at 1000 
x g for 5 min to pellet the contents of the cell suspension. The old medium supernatant was 
discarded before addition of 5ml of fresh freezing DMEM medium, which includes 10% (v/v) 
dimethyl sulfoxide (DMSO; VWR International Ltd, BDH Prolabo GPR RECTAPUR®, cat. n° 
282164K). Three cryovials of cell solutions to be frozen are then produced and placed in a Mr. 
&ƌŽƐƚǇ①?&ƌĞĞǌŝŶŐŽŶƚĂŝŶĞƌ①?dŚĞƌŵŽ&ŝƐŚĞƌ^ĐŝĞŶƚŝĨŝĐ①?ĐĂƚ①?Ŷ①?5100-0001), inside a -80°C 
freezer. This freezing container acts as an isopropanol bath for the cryovials of cells, enabling 
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their temperature to reduce down to -80°C at a rate of 1°C/minute, and thus ensuring their 
continued viability. Frozen cell aliquots were then stored long-term inside a cryobox (Thermo 
Fisher Scientific, cat. n° 1417563).  
In order to thaw frozen aliquots of cell lines to begin a new culture, cryovials were added to a 
37°C waterbath to thaw the contents as quickly as possible. The frozen cells were then 
transferred to a 15 ml tubes (Greiner Bio-One, cat. n° 188271) containing 7 ml of the 
appropriate culture medium, before centrifugation at 1000 x g for 5 minutes and removal of 
the supernatant to ensure there are no traces of cytotoxic DMSO carried forward to the 
established culture. Cell pellets were then resuspended in 5-10ml of fresh 15% FBS-DMEM 
medium and transferred to the appropriate culture vessel, before placing in the humidified 
incubator at 37°C and 5% CO2 to permit cell adhesion and monolayer formation before 
subculturing and culture maintenance begins.  
2.3 Pseudotype production 
2.3.1 Plasmids used for pseudotype production 
The following core and reporter gene plasmid constructs were used in pseudotype virus 
production attempts, alongside recombinant pCAGGS-prME plasmids subcloned in earlier 
methodology in this study (see Section 2.1.1): 
p8.91, which was originally named pCMV-②?Z①?①?①?①?①?ƵĨĨĞƌĞǇet al, 1997), is the primary HIV core 
plasmid used in this study. It was kindly provided by Dr Nigel Temperton (Universities of 
Greenwich and Kent, Medway, UK). This plasmid is a second generation lentiviral packaging 
plasmid construct which expresses the HIV gag-pol genes, driven by a human CMV promoter. 
The HIV-1 accessory genes vif, vpr, vpu and nef have been deleted from this construct. The 




Plasmids encoding the MLV gag-pol genes used in one technique to attempt MLV-JEV 
pseudotype generation were pCMVi and pHCMV-MLVgagpol. These plasmids were a kind gift 
from Dr Alexander Tarr, via Dr Barnabas King, University of Nottingham. 
pCSFLW, which was also kindly provided by Dr Nigel Temperton, is a self-inactivating lentiviral 
vector, which possesses a Ɏ packaging signal, as well as an internal promoter derived from the 
U3 segment of the long terminal sequence of the spleen focus forming virus (SFFV); a 
Woodchuck hepatitis virus post-transcriptional regulatory element (WPRE) which enhances the 
expression levels of the reporter gene; and the the central polypurine tract cis-active sequence 
(cPPT). The pCSFLW plasmid was modified from the similar pCSGW plasmid (originally known 
as Ɖ,Z①?^/E-cPPT-SE; Demaison et al, 1992). However, the pCSGW plasmid contains an eGFP 
reporter gene system, instead of a corresponding firefly luciferase one. In this study, pCSFLW 
and pCSGW were used as reporter gene plasmids for incorporation into the pseudotyping 
system, to attempt to produce HIV-JEV pseudotypes with firefly luciferase and GFP readouts, 
respectively. Gammaretroviral reporter genes used in this study for attempted generation of 
MLV-JEV pseudotype viruses were pMLVluc for luciferase (provided by Dr Nigel Temperton), 
and pCNCG (provided by Dr Nigel Temperton) and phCMV-MLVgfp (also kindly received from 
Dr Alexander Tarr, University of Nottingham) for GFP.  
2.3.2 Protocol for pseudotype production 
Multi-plasmid co-transfections were used for all pseudotype production attempts in this study. 
24 hours prior to transfection, approximately 8x105 HEK293T/17 producer cells (except for the 
MLV packaging cell line experiments, in which case either TELCeB6 or TECeB15 cells were used 




On the day of transfection, a DNA mix containing a selected gag-pol, reporter gene and prME 
construct was set up at either a 1:1.5:1 (with masses of 500µg, 750µg and 500µg) or 1:1.5:3 
(core:reporter:envelope) ratio, and topped up with sterile, nuclease-free H2O to a volume of 
15µl. In a separate tube, 18µl of either the FuGENE® 6 (Promega, cat. n° E2692) or the 
polyethylenimine/PEI (Sigma Aldrich, cat. n° 408727) transfection reagent was directly diluted 
in 200µl  OptiMEM® I reduced serum medium ('ŝďĐŽ①?①?/ŶǀŝƚƌŽŐĞŶ①?①?ĐĂƚ①?Ŷ①?①?①?985-047), 
ensuring no contact was made with the inside walls of the microcentrifuge tube, as this can 
hinder the efficiency of transfection. After 5 minutes of incubation at room temperature, the 
DNA mix was added to the transfection reagent mix, and incubated for 15 more minutes, to 
allow for formation of complexes between the DNA and transfection reagent. The mixture was 
then added drop-wise to a well of the 6-well tissue culture plate, containing an 80% confluent 
monolayer of the required producer cell line. The transfection plate was then placed back into 
the incubator at 37°C and 5% CO2.  
At 24 hours post-transfection, the media was replaced for 1.5ml of fresh 15% FBS-DMEM. 
Pseudotype supernatants were harvested at 48 hours after transfection by removal of the cell 
culture medium using a 5ml syringe, and by passing through a 0.45µm mixed cellulose ester 
membrane filter (Merck Millipore, cat. n° SLHA033SB), before storing at -80°C until required 
for use in titration assays.  
2.3.3 Titration assay for pseudotype viruses 
For all titration assays, a starting volume of 100µl of each viral pseudotype candidate 
supernatant was 1:2 serially diluted across a white 96-well tissue culture plate (Nunc 
Microwell, Thermo Scientific, UK) before addition of 1x104 desired target cells and incubation 
in a humidified tissue culture incubator. In all instances where a luciferase reporter gene was 
incorporated into pseudotype particles, titration assay plates were incubated for 48 hours, 
prior to measuring relative luminescent units per ml (RLU/ml), using the Bright-'ůŽ①?ĂƐƐĂǇ
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system (Promega, cat. n° E2650) andGloMax Multi detection system luminometer (Promega, 
cat. n° E7031 and E7041) to quantify luciferase reporter expression. Pseudotype transduction 
titres were calculated by converting RLU readout values at a range of assay dilutions into 
RLU/ml, before determining the arithmetic mean and standard deviation (SD). When GFP 
reporters were packaged into pseudotype viruses, the titration assay was incubated for 72 
hours prior to optical determination of transduction by visualising cells under a fluorescent 
microscope.   
2.3.4 Pseudotype virus neutralisation assay 
When assessing the ability of serum samples to neutralise and inhibit the infectivity and 
transduction of functional pseudotype viruses into permissible target cell lines, the pseudotype 
virus neutralisation assay (PVNA) assay.  
To perform the PVNA, 2-fold serial dilutions of the experimental serum samples are performed 
across the 96-well assay plate, starting with 5µl of neat serum in a 100µl mixing volume. In the 
last serial dilution, 50µl of the mixing volume is discarded. The assay plate was then 
centrifuged for 1 minute at 500 x g, using an ELMI CM-6MT Centrifuge and rotor 6M04, before 
addition to each experimental well of 50µl the relevant pseudotype virus supernatant, 
adjusted to contain exactly 1x106 RLU. A viral input control (containing no serum) and a cell 
only control (containing no virus or serum) were also included on the assay plate, which was 
centrifuged again for 1 minute at 500 x g, before placing in the humidified incubator for 1 
hour. This allotted time frame enables binding of any neutralizing antibodies in the antiserum 
sample to antigenic epitopes exposed on the pseudotype virus surface or envelope 
glycoprotein.  Finally, the last addition to the assay plate is 1x104 cells of the target cell line 
being employed in the experiment, in a volume of 50µl, before a final centrifugation step of 
the same speed and duration, before incubation at 37°C and 5% CO2.  
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48 hours later, the knockdown of firefly luciferase expression was quantified by addition of 
50µl of Bright-'ůŽ①?ƐŽůƵƚŝŽŶ ĂŶĚ①?ĂĨƚĞƌ①?ŵŝŶƵƚĞƐ①?ŝŶĐƵďĂƚŝŽŶĂƚƌŽŽŵƚĞŵƉĞƌĂƚƵƌĞ①?ƌĞĂĚŝŶŐ
the plate using the GloMax luminometer.  
Analysis of resultant assay data was performed using Microsoft® Excel 2011 and GraphPad 
Prism® version 6 (GraphPad Software). To measure serum sample neutralization potency, RLU 
values, as originally determined from the titration assay, were normalised and presented as a 
percentage neutralisation value. Normalisation was achieved by defining 0% and 100% 
neutralisation as the arithmetic mean of the viral input and cell only controls, respectively. 
Percentage neutralisation was calculated by working out the percentage reduction of 
luminescence, and in turn of subsequent pseudotype entry inhibition into target cells, 
between these two neutralisation bounds. Half maximal and 90% inhibitory concentrations 
could then be deduced, expressed as assay serum dilution factors, by using a non-linear 
regression analysis system (log [inhibitor] vs normalised response ①W variable slope).  
2.4 Validation of protein expression 
2.4.1 Immunocytochemistry/immunofluorescence 
In order to identify the intracellular localisation of any expressed prME protein, indirect 
immunofluorescent staining was employed.  In advance, poly-D-lysine (PDL) coated coverslips 
(Vitrocam, UK) were placed into wells of a 6-well plate and UV sterilised in a tissue culture 
cabinet for 30 minutes. 8x105 HEK293T/17 cells were then seeded into the 6-well tissue culture 
plates and placed in a humidified incubator for 24 hours to reach ~70-80% confluence, 
including on the coverslip. Cells were transfected with 1µg of either pCAGGS-15SPprME or a 
pI.18 plasmid encoding the haemmaglutinin (HA) envelope glycoprotein of 
A/equine/Sussex/89 H3N8 influenza, using PEI, and incubated for a further 48 hours ①W a 
sufficient duration for expression of the glycoproteins to occur. (The HA of this equine 
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influenza isolate was used as a positive control, as it is able to create successful HIV 
pseudotypes, and the primary polyclonal sera used for immunostaining was extracted  after 
vaccination with both JEV and equine influenza vaccines. This means that the same primary 
and secondary antibodies could be used for experimental samples and positive controls). 
Following the transfection and incubation, culture medium was aspirated and the cell 
monolayers were washed in a 3 x 5 minute schedule with 1ml PBS (Sigma Aldrich, UK). To fix 
and permeabilise the transfected cells, 1ml of 100% methanol was added to each well and the 
plate incubated on ice for 10 minutes. A 1:200 dilution (in PBS) of neat serum from an equine 
vaccinated against JEV (and H3 influenza) was used as the primary antibody sample, and a 
FITC-conjugated, rabbit anti-horse IgG (H+L) secondary antibody (Sigma Aldrich, UK) was 
utilised at a 1:1000 dilution (in PBS). NucBlue Live Fixed Cell Nuclear Stain (Life Technologies, 
UK) was also added to the secondary antibody stock at a 1 drop/3ml concentration. Sample 
wells were thoroughly washed with PBS (in the same schedule as previously) after the fixing, 
permeabilisation and both antibody incubation stages of the immunofluorescent staining 
protocol. Coverslips were mobilised from sample wells and mounted onto microscope slides 
using Mowiol 4-88 anti-fade coverslip mounting medium (Sigma Aldrich, UK). Once mounted 
and set, the coverslips were scrutinised using a fluorescent microscope, selecting blue (DAPI) 
and green (FITC) filters for nuclear stain and expressed prME antigen visualisation, 
respectively.  
2.4.2 SDS-PAGE and Western blotting 
Examination of prME protein expression was achieved in this study using SDS-PAGE and 
Western blotting. Similar to the immunofluorescence experiments, 8x105 HEK293T/17 cells 
were seeded into 6-well plates and incubated for 24 hours to reach ~70-80% confluence, 
including on the coverslip. Cells were transfected with 0.5µg or 1.5µg of either pCAGGS-
15SPprME or pCAGGS -24SPprME, using PEI, and incubated for a further 48 hours. Following 
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removal of DMEM and addition of 1ml lysis buffer (20mM Tris Base, 137mM NaCl, 0.2% Triton 
X-100 plus protease inhibitors), cell monolayers were detached via scraping, transferred to a 
1.5ml Eppendorf tube and incubated on ice for 20 minutes. Cell lysates were then centrifuged 
at 14,000 rpm and 4°C for 10 minutes and the peptide-rich supernatant was retained. Protein 
samples, including a sample of an IXIARO® inactivated vaccine (Valneva) as a positive control, 
were mixed with 4x Laemmli sample loading buffer (BioRad, CA, USA) then heated for 5 
minutes at 95°C to denature all peptides, before loading onto a 12% polyacrylamide resolving 
gel. The gel was completely submerged in 1x SDS-PAGE running buffer (50mM Tris Base, 0.38M 
Glycine, 0.1% SDS (w/v)) and ran at 200V for 60 minutes, in order to separate cellular peptides 
by their molecular weight in kDa. Protein transfer onto a PVDF membrane (Immobilon P, 
Micropore, UK) was achieved by submersion in a transfer buffer (25mM Tris Base, 192mM 
Glycine, 20% methanol) and application of a 30V electrical voltage for 2 hours. Both the 
protein electrophoretic and transfer stages were carried out using the Mini-PROTEAN 
Electrophoresis System (BioRad, CA, USA). Next, membranes were blocked in a 3% Marvel 
dried skimmed milk solution prepared in TBS-T (25mM Tris Base, 137mM NaCl, pH 7.5 plus 
0.05% Tween20) for 1 hour at room temperature to prevent antibody binding of non-specific 
epitopes. Mouse JEV ab81193 (Abcam, UK) monoclonal antibody was used as a primary 
antibody to blot for domain III of the JEV E glycoprotein, produced a band of ~38kDa on 
downstream blot images. Mouse anti-ɴ-actin monoclonal antibody (Licor, NE, USA) was also 
ƵƐĞĚĨŽƌƉƌŝŵĂƌǇĂŶƚŝďŽĚǇďŝŶĚŝŶŐƚŽɴ-actin, serving as an internal control to determine 
blotting success. As both primary antibodies were murine-raised, one secondary antibody was 
utilised in this study: IRDye 800CW-conjugated, polyclonal goat anti-mouse IgG (H+L) (Licor, 
NE, USA). All antibodies were 1:1000 diluted in TBS-T + 1% Marvel solution before membranes 
were added and incubated on a rocking platform for 1 hour at room temperature. Membrane 
wash steps at a 3 x 5 minute schedule in TBS-T were undertaken between each of the blocking 
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and antibody binding stages of the protocol. Blotted membranes were visualised using the 










Manipulating transfection and assay parameters to attempt  
production of functional retroviral pseudotypes  
bearing JEV envelope glycoproteins 
 
3.1 Introduction 
As previously mentioned (see Section 1.3.3), the pseudotype virus platform offers a variety of 
benefits for utilisation in virus biology and serology experimentation, such as the opportunity 
to bypass high biosafety containment requirements, the flexibility of reporter gene packaging 
dependent upon laboratory financial constraints, multiplex pseudotype assays to reduce the 
cost-per assay burden, and the ability to swiftly incorporate different virus envelope protein 
genes into the co-transfection pool for the production of pseudotype particles for 
serosurveillance, mutagenesis, antigenic drift and other studies (Mather et al, 2013). 
Consequently, highly pathogenic members of several families of emergent RNA viruses have 
been pseudotyped, including Orthomyxoviridae, Rhabdoviridae, Coronaviridae, Filoviridae and 
Bunyaviridae (for a full breakdown, see Table 2). Likewise, pseudotyping technology has also 
been applied to various members of the Flaviviridae family, to facilitate clinical research 
without the necessity to handle native, pathogenic virus.  
Hepatitis C virus (HCV), a member of the Hepacivirus genus of Flaviviridae, is an infection of 
high clinical importance, as it infects several hundred million people worldwide, and is a 
common causative agent of chronic liver disease and hepato-cellular carcinoma. Historically, 
the study of HCV is hampered by the lack of an efficient cell culture system, capable of 
supporting virus replication in vitro (Bartosch et al, 2003a). To address this issue, HCV 
pseudotypes have been developed where the E1-E2 glycoproteins are displayed on both 
lentiviral and murine retroviral cores, with packaged GFP and luciferase reporter genes for 
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reliable and rapid determination of infectivity (Bartosch et al, 2003a; Hsu et al, 2003). 
Subsequently, these pseudotype particles have been employed in an array of downstream 
applications, such as determining neutralization epitopes on the HCV envelope glycoproteins, 
understanding the extent of genetic quasispecies variation in patients suffering from chronic 
liver disease, and elucidating the pH-dependent entry mechanisms of the virus, mediated by 
E1-E2 complexes (Bartosch et al, 2003a; Hsu et al, 2003; Bartosch et al, 2003b; Tarr et al, 2007; 
Dreux and Cosset, 2009; Bartosch and Cosset, 2009). More recently, the infectivity phenotype 
of many HCV pseudotypes isolated from chronically-ill patients was improved by 
comprehensive optimisation of many parameters of the viral pseudotype entry assay. In some 
instances, isolates which previously proved refractory to pseudotyping were incorporated into 
the chimeric pseudotype particles much more efficiently following assay optimisation 
(Urbanowicz et al, 2016). 
Within the Flavivirus genus, DENV pseudotypes for all four serotypes have also been created, 
consisting of the structural and enzymatic core of HIV harbouring a luciferase reporter gene, 
and displaying the heterologous prME glycoproteins of DENV. Interestingly, in order to achieve 
successful interaction between the HIV core and DENV envelope components, which is crucial 
in the generation of functional pseudotype particles, a chimeric glycoprotein was constructed, 
where the transmembrane domain of the DENV E protein was replaced with the cytoplasmic 
and transmembrane domains of the VSV-G protein. High infectivity titres into target cells were 
recorded, which could be effectively inhibited by lysosomotrophic agents and mutations to 
crucial amino acids located in the fusion loop of the DENV E protein, indicating a pH-
dependent, fusogenic mechanism of entry (Hu et al, 2007).  
Using different production approaches, pseudotype particles displaying the prM-E 
glycoproteins of Japanese encephalitis virus have also been generated. For instance, the 
TELCeB6 packaging cell line, which constitutively expresses the MLV gag-pol genes to encode 
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the viral nucleocapsid, can be employed as producer cells to create MLV-JEV pseudotypes, 
when transfected via ƚŚĞĐĂůĐŝƵŵƉŚŽƐƉŚĂƚĞŵĞƚŚŽĚǁŝƚŚ:sƉƌDĂŶĚɴ-galactosidase 
expression vectors. Resultant JEV pseudotypes could efficiently transduce permissible target 
cells, and were potently neutralized by positive JEV antisera, with results correlating closely 
with those obtained by PRNT (Lee et al, 2009; Lee et al, 2014).  
The VSV pseudotype platform, which is a common alternative to retroviral pseudotyping, has 
also successfully yielded functional chimeric virus particles possessing heterologous JEV 
envelope glycoproteins. VSV-JEV pseudotypes were generated initially by construction and 
production of a recombinant VSV lacking the G protein and possessing in its place a luciferase 
reporter gene (VSV-G/Luc-*G), followed by infection of VSV-G/Luc-*G into HEK293T cells or 
Huh7 cells transiently expressing the foreign JEV prME proteins. The pseudotype viruses 
produced were subsequently used to elucidate the inhibitory effects of cholesterol and the 
enhancing effects of ceramide on the infectivity, entry and proliferation of JEV (Tani et al, 
2010; Tani et al, 2012). JEV pseudotypes with VSV cores were also used to develop more 
understanding of the involvement of cyclophilin B in viral replication (Kambara et al, 2011).  
Additionally, utilisation of a recombinant TRIP lentiviral vector bearing the codon-optimised 
structural prME proteins was able to create viable JEV virus-like particles with a lentiviral core, 
which were immunogenic and able to seroconvert immunized piglets and BALB/c mice (de 
Wispelaere et al, 2015). However, from current relevant literature, it appears that no lentiviral 
or gammaretroviral pseudotype viruses displaying JEV envelope glycoproteins have 
successfully been produced using the conventional 3-plasmid co-transfection system.  
Therefore, the aim of this chapter is to explore and manipulate various cloning, transfection 
and assay parameters, in an attempt to generate JEV retroviral pseudotypes of a functionally 
high infectivity titre, so that they can be utilised in downstream serological applications.  
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3.2 Materials and Methods 
3.2.1 Molecular biology 
3.2.1.1 Genes 
The JEV isolate used to attempt pseudotyping in this chapter was the Beijing-1 strain (Genbank 
accession number L48961). The adjacent prM and E genes from Beijing-1 were custom 
synthesised by Genscript, NJ, USA and cloned within the pUC57 plasmid. The synthesised prME 
gene was designed to include the restriction sites for EcoRI and BglII ĂƚƚŚĞ①?①?ƚĞƌŵŝŶƵƐ①?ĂŶĚ
the sites for XhoI and NotI ƌĞƐƚƌŝĐƚŝŽŶĞŶǌǇŵĞƐĂƚƚŚĞ①?①?ƚĞƌŵŝŶƵƐ①?ĚĚŝƚŝŽŶĂůůǇ①?ƚŚĞƐĞƋƵĞŶĐĞ
encoding the last 15 residues from the C-terminus signal peptide of the JEV C gene 
(immediately upstream of the prM gene in the JEV genome) was also included in the 
synthesised gene construct.  
3.2.1.2 Restriction digests 
Restriction digests were performed during the subcloning process to isolate the prME gene 
from its original pUC57 vector, as well as to enable ligation of the pCAGGS expression vector 
and the prME insert, and for digest screening to identify successful pCAGGS-prME recombinant 
plasmids. Either conventional or FastDigest®EcoRI and XhoI restriction enzymes with 
corresponding buffers, were used.  More information on restriction digest reaction conditions 
can be found in Section 2.1.9.  
3.2.1.3 Gel electrophoresis 
Agarose gel electrophoresis was utilised in this chapter throughout the subcloning process, 
such as following restriction enzyme digests of prME and pCAGGS DNA, as well as after colony 
PCR and digest screening processes. In all cases, 1% agarose gels were used for DNA 
separation, prepared in 0.5x (TAE) buffer containing ethidium bromide (Sigma Aldrich, UK) at a 
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1:100,000 working dilution. 0.5x TAE was also used as an electrophoretic running buffer. More 
information regarding the loading dyes and DNA ladders used, as well as the electrophoretic 
voltages and visualisation techniques, can be found in Section 2.1.12. 
3.2.1.4 PCR purifications and gel extractions 
PCR purification was used to clean up and purifying the endonuclease-digested pCAGGS 
expression vector, before it could be used for ligation. The QIAquick PCR purification kit was 
used for this purpose, according to manufacturers①?ŝŶƐƚƌƵĐƚŝŽŶƐ①?ĂŶĚŵŽƌĞŝŶĨŽƌŵĂƚŝŽŶŝƐŐŝǀĞŶ
in Section 2.1.13. 
Following the digestion of the original pUC57-prME plasmid to release the prME gene, the 
sample was run on an Ultrapure agarose gel to separate out the vector (~2.7kb) and insert 
(~2.1kb) DNA fragments. The prME gene fragment could then be excised from the gel with a 
scalpel, aided by a benchtop UV transilluminator, before weighing the gel slice. To isolate the 
insert DNA and remove remnants of the TAE-agarose gel, the sample was processed through 
ƚŚĞDŝŶůƵƚĞ'ĞůǆƚƌĂĐƚŝŽŶ<ŝƚ①?YŝĂŐĞŶ①?EĞƚŚĞƌůĂŶĚƐ①)ĨŽůůŽǁŝŶŐŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐŝŶƐƚƌƵĐƚŝŽŶƐ 
(see Section 2.1.14).  
3.2.1.5 Ligations 
pCAGGS and prME DNA fragments were joined together by their complimentary restriction 
enzyme nucleotide overhangs by ligation. This process was catalysed by1U/µl T4 DNA ligase 
(Thermo Scientific, UK) and its corresponding buffer.  
Prior to ligations, the concentration (in ng/µl) and purity (as a A[260/280] ratio) of digested 
and appropriately purified pCAGGS vector and prME insert DNA samples was quantified using 
the Nanodrop 2000 (Thermo Scientific, UK). This information was used to perform molar ratio 
calculations, before ligations with a 1:1 and 1:3 vector:insert molar ratio, as well as a vector 
only negative control sample, were set up and incubated overnight at room temperature, 
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allowing a sufficient duration for recombinant pCAGGS-prME plasmids to be potentially ligated 
(for more details, see section 2.1.10).  
3.2.1.6 Transformations  
Subsequent to ligation, 2.5µl of the ligation samples (1:1, 1:3 and vector only) were each 
ƚƌĂŶƐĨŽƌŵĞĚŝŶƚŽĂƐĞƉĂƌĂƚĞ①?①?②?ůĂůŝƋƵŽƚŽĨ^ƵďĐůŽŶŝŶŐĨĨŝĐŝĞŶĐǇ,①?ɲŽŵƉĞƚĞŶƚE.coli cells 
(Life Technologies, UK). A detailed bacterial transformation protocol can be found in Section 
2.1.3. Antibiotic selection could then take place on Luria Bertani (LB)-agar (Sigma Aldrich, UK) 
plates containing 100µg/ml ampicillin - 50µl of each transformation mixture was plated before 
overnight incubation at 37°C.  
The resulting numbers of transformant colonies on each plate were assessed to determine the 
success of the subcloning procedure. The negative control plate (transformation of ligation 
mixture lacking the insert DNA fragment) acted as a background, as every colony on this plate 
will have most likely been formed by transformation of a completely uncut or partially-
digested and self-ligated pCAGGS plasmid vector.  
A proportion of the colonies present on the vector:insert plates were taken forward to be 
screened by colony PCR and in some instances, digest screening. If the number of vector only 
colonies was high compared to those on the insert plates, then the digested pCAGGS vector 
underwent alkaline phosphatase treatment (Thermo Scientific Fast AP, UK) following 
ŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐŝŶƐƚƌƵĐƚŝŽŶƐ①?ǁŚŝĐŚ①?①?ĚĞƉŚŽƐƉŚŽƌǇůĂƚĞƐƚŚĞĐƵƚǀĞĐƚŽƌƐĞƋƵĞŶĐĞ①? minimising 
the potential for vector self-circularisation during digestion.  
3.2.1.7 Colony PCR 
Colony PCR was used as a screening process to assess whether transformant colonies from the 
1:1 and 1:3 vector:insert molar ratio ligations harboured a recombinant pCAGGS-prME 
plasmid. This general protocol is outlined in Section 2.1.11. The forward and reverse primers 
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used to recognise the prME gene termini were as follows: (JEVprMEFwd primer: 
GAGAATTCAGATCTCATGTGGCTCGC; JEVprMERev primer: 
ATTGGTAGCTAAGAACACGACGACACCTCC). PCR samples were then run on a 30x thermal cycle 
with a 30-second denaturation step at 94°C, a 30-second annealing step at 50°C and a 2-
minute extension step at 72°C, before running on a 1% agarose gel to determine positive or 
negative plasmid clones. The colony PCR positive control amplified the original pUC57-prME 
plasmid, whereas the negative control was an identical PCR master mix but containing no 
template DNA.   
3.2.1.8 Overnight cultures 
Positive pCAGGS-prME clones, as determined by colony PCR, were further propagated by 
growth in overnight starter cultures. These 5ml cultures of LB growth medium (Sigma Aldrich, 
UK) contained 50µg/ml ampicillin ①W to select for recombinant plasmid-containing E.coli ①W and 
were inoculated by one of the positive colonies each, grown from the colony PCR LB-agar 
gridplates. The cultures were incubated overnight (12-16 hours) at 37°C and 225rpm in a 
shaking bacterial incubator.   
3.2.1.9 Plasmid purification 
ůůƉůĂƐŵŝĚƐƚŽĐŬƐŐƌŽǁŶƵƉŝŶ,①?ɲE.coli overnight cultures were purified using the QIAprep 
^ƉŝŶWůĂƐŵŝĚDŝŶŝƉƌĞƉ<ŝƚ①?YŝĂŐĞŶ①?EĞƚŚĞƌůĂŶĚƐ①)①?ĂƐƉĞƌŵĂŶƵĨĂĐƚƵƌĞƌ①?ƐŝŶƐƚƌƵĐƚŝŽŶƐ (a more 
detailed breakdown of this protocol can be found in Section 2.1.4). In all instances, 4ml of 
bacterial culture was taken forward into the plasmid purification process, with the remaining 
1ml being supplemented with 15% glycerol and frozen down at -80°C as a stock from which to 





3.2.1.10 Site-directed mutagenesis 
In order to increase the length of the JEV C-terminal capsid signal sequence from 15 to 24 
residues, Q5 site-directed mutagenesis was employed. The general methodology of this 
mutagenesis platform, as well as reaction mixtures, volumes and PCR thermal cycling 
programs, can be found in Section 2.1.15.  
 The mutagenic primer design, as carried out by the NEBaseChanger program, and the strategy 
of mutagenesis employed to insert the extra 27 nucleotides of the JEV capsid signal sequence, 
ĂƌĞƐŚŽǁŶŝŶ&ŝŐƵƌĞ①?①?①?dŚĞŵƵƚĂŐĞŶŝĐƐĞƋƵĞŶĐĞŝƐƐƉůŝƚĂĐƌŽƐƐƚŚĞƚǁŽƉƌŝŵĞƌƐ①?ƐŽƚŚĂƚƚŚĞ①?①?
①?①?ŶƵĐůĞŽƚŝĚĞƐŽĨƚŚĞƐĞƋƵĞŶĐĞƚŽďĞŝŶƐĞƌƚĞĚŝƐŝŶĐůƵĚĞĚŽŶƚŚĞ①?①?ƚĞƌŵŝŶƵƐŽĨƚŚĞĨŽƌǁĂƌĚ
oligonucleotide primer, and the beginning 14 mutĂŐĞŶŝĐŶƵĐůĞŽƚŝĚĞƐĂƚƚŚĞ①?①?ƚĞƌŵŝŶƵƐŽĨƚŚĞ
sequence for insertion are found ĂƚƚŚĞ①?①?ĞŶĚŽĨƚŚĞĐŽŵƉůĞŵĞŶƚĂƌǇƌĞǀĞƌƐĞƉƌŝŵĞƌ①?ǁŚŝĐŚ
will amplify in an antisense orientation. This creates a 9 amino acid residue insertion, directly 
before the start of the :sƉƌDƐĞƋƵĞŶĐĞ①?ĂŶĚŝŵŵĞĚŝĂƚĞůǇĂĨƚĞƌƚŚĞ①?①?ŽǀĞƌŚĂŶŐ①?ƌĞƐƚƌŝĐƚŝŽŶ
ĞŶǌǇŵĞƐŝƚĞƐĂŶĚƐƚĂƌƚŝŶŐŵĞƚŚŝŽŶŝŶĞĐŽĚŽŶůŽĐĂƚĞĚĂƚƚŚĞ①?①?ƚĞƌŵŝŶƵƐŽĨƚŚĞŝŶƐĞƌƚŐĞŶĞŝŶ
the pUC57-prME plasmid construct.  
Following mutagenic PCR and KLD enzymatic treatment, then positive colony screening, 
purification and sequence verification of the extended, full signal peptide JEVprME, the gene 







pUC57 vector sequence  ①?①?ŽǀĞƌŚĂŶŐ①?ĐŽZ/ƐŝƚĞ①?Őů//ƐŝƚĞĂŶĚƐƚĂƌƚŝŶŐMet 
Start of JEV prM New sequence to be introduced 
Sequence being introduced (first 9 residues of JEV signal peptide): 
GGCAAGAGAAGATCAGCAGGCTCAATC 















Figure 12. Outline of Q5 mutagenic primer design to produce full JEV C-terminal 
capsid signal sequence upstream of prME gene. The Q5 site-directed mutagenesis kit 
ǁŽƌŬƐďǇĂŵƉůŝĨǇŝŶŐƚŚĞǁŚŽůĞƉh①?①?ƉůĂƐŵŝĚ①?ƚŚĞƐĞĐƚŝŽŶĚŝƌĞĐƚůǇƵƉƐƚƌĞĂŵŽĨƚŚĞ①?①?
prME terminus highlighted in light blue) using specific mutagenic primers (mutagenic 
primer sequence highlighted in orange). In this strategy, the desired additional stretch 
of nucleotides (in purple) would be introduced directly in front of the start of the JEV 
prM sequence (including the shorter 15-residue signal peptide; in yellow) and the 
restriction sites and starting methionine residue (in green. The desired construct 




3.2.2 Production of pseudotype viruses and pseudotype-based assays 
3.2.2.1 Multi-plasmid co-transfection to produce pseudotype viruses 
Three- and four-plasmid co-transfections were used repeatedly in this chapter for all attempts 
to produce pseudotype viruses displaying the prME glycoproteins of the JEV virus, such as for 
candidate HIV-JEV and MLV-JEV pseudotype supernatants with each combination of core and 
reporter plasmid construct, and also for the furin introduction and low glucose environment 
experiments.  
Candidate transfections were carried out as described in more detail in Section 2.3.2, expect 
for in the following instances: a pCAGGS-furin plasmid was included in the DNA mix during 
transfection for these experiments (as described in more detail in Section 3.3.4); the regular 
DMEM medium formulation was replaced with a low glucose formulation in the study 
investigating the effect of glucose on JEV PV transduction (as described in more detail in 
Section 3.3.5); the HEK293T/17 cell line was replaced with the TELCeB6 and TECeB15 cell lines 
as producer cells, and the inclusion of pCMVi or pHCMV-MLVgagpol in the DNA mix for 
transfection was not required, in the MLV packaging cell line approach to MLV-JEVpp 
production (as described in more detail in Section 3.3.6).  
3.2.2.2 Titration assays 
Pseudotype titration assays were used in this chapter to establish whether successful 
production of function of HIV- or MLV-JEV pseudotypes had taken place. As described in more 
detail in Section 2.3.3, 100µl of each viral pseudotype candidate supernatant was serially 
diluted before addition of 1x104 target cells: for these experiments, either HEK293T/17, BHK-
21, CrFK or Vero. Assay incubation durations, readout systems and data analysis methods are 




3.2.3 Validation of protein expression 
3.2.3.1 Immunofluorescence 
To enable further investigation of the intracellular localisation of expressed prME protein 
when pCAGGS-prME plasmids are transfected into PV producer cells, indirect 
immunofluorescent staining was utilised. HEK293T/17 cells grown on poly-D-lysine coated 
coverslips in 6-well tissue culture plates were transfected with pCAGGS-15SPprME, before 
being incubated for 48 hours then fixed with 100% methanol. A seropositive polyclonal equine 
serum was used as a primary antibody sample, followed by staining with the FITC-conjugated, 
rabbit anti-horse secondary antibody to enable fluorescent visualisation of any expressed 
prME, so that its location could be gauged. The protocol followed to perform this technique 
can be found in detail in Section 2.4.1.   
3.2.3.2 SDS-PAGE and Western blotting 
Further examination of the expression of the prME protein was achieved by use of SDS-PAGE 
and Western blotting. 70-80% confluent HEK293T/17 monolayers with pCAGGS-15SPprME or 
pCAGGS-①?①?^WƉƌD①?ďĞĨŽƌĞ①?①?ŚŽƵƌƐ①?ŝŶĐƵďĂƚŝŽŶ①?dŚĞĐĞůůƐǁĞƌĞƚŚ ŶůǇƐĞĚand lysates were 
harvested, prior to running on a 12% polyacrylamide gel. Cellular proteins separated by their 
molecular weights in kDa were then transferred to a PVDF membrane, before blocking, binding 
with monoclonal primary antibodies and IRDye 800CW-conjugated secondary antibodies 
before visualisation of resultant blot images. A more detailed version of the protocol followed 
for this experiment can be found in Section 2.4.2.  For this Western blot, a sample of an 





3.3.1 Subcloning of 15SPprME gene into pCAGGS expression vector 
To enable eukaryotic expression of the JEV 15SPprME gene, the coding region was subcloned 
from pUC57 into the pCAGGS expression vector. This expression plasmid was chosen for 
ƐƵďĐůŽŶŝŶŐƉƌŝŵĂƌŝůǇĚƵĞƚŽƚŚĞƉƌĞƐĞŶĐĞŽĨŝƚƐĐŚŝĐŬĞŶɴ-actin promoter ①W preliminary 
attempts to create plasmid stocks with existing prME constructs in pI.18 and phCMV 
expression vectors were repeatedly unsuccessful (data not shown). Simultaneously, the insert 
(pUC57-prME) and vector (pCAGGS) plasmids were digested by EcoRI and XhoI restriction 
enzymes, prior to alkaline phosphatase treatment and PCR purification of pCAGGS. As DNA 
fragments of two different sizes were produced in the pUC57-prME restriction digest, these 
had to be electrophoretically separated in order to gel extract and purify the prME gene 
(Figure 13A). After NanoDrop quantification of prME and pCAGGS to determine DNA 
concentration and purity, ligations were set up at a 1:1 and 1:3 (vector:insert) molar ratio, as 
well as a vector only (V/O) control. Following transformation and plating of ligation samples, 
one, ten and zero colonies were observed on the 1:1, 1:3 and V/O plates, respectively (Figure 
13B-D). Nine of the colonies on the 1:3 plate were screened using colony PCR, revealing 
colonies #2, #4, #6 and #9 as positive pCAGGS-prME clones (Figure 13E). These colonies were 
subsequently cultured and plasmid DNA purified, before undergoing digest screening, which 
reinforced successful subcloning of the prME gene (Figure 13F). Finally, pCAGGS-prME clone #2 
was sequence verified (GATC Biotech), confirming 100% identity with the official Genbank 






15SPprME = 2083bp 
pUC57 = 2710bp A 
C 
B 






Figure 13. Subcloning of 15SPprME into pCAGGS. A) Ultrapure agarose gel displaying ~2.1kb 
15SPprME to be extracted, following digestion from pUC57. B-D) Transformation plates of pCAGGS-
prME ligations at 1:1 (B) and 1:3 (C) molar ratios, and vector only (D) control. E) Agarose gel of 
colony PCR screen, confirming pCAGGS-prME clones #2, #4, #6 and #9 as positive. ~2.1kb band at far 
right of gel is original pUC57-prME positive control. F) Restriction digest screen (EcoRI/XhoI) of 
pCAGGS-prME plasmid DNA purified from previously determined positive clones. Far right lane on 
gel is empty pCAGGS negative control; penultimate right lane is pUC57-prME.  
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3.3.2 Site-directed insertion mutagenesis to create 24SPprME 
In order to ensure correct signal peptidase cleavage at the JEV C-prM junction, in order to 
direct the transit and modification of expressed prME protein through the ER-Golgi complex, 
the truncated 15-residue signal peptide upstream of the prM gene ①W originally included in the 
synthesised JEV prME ①W was extended to produce the full, 24-residue signal peptide, using the 
Q5 SDM kit (New England Biolabs, MA, USA). prME mutagenesis was carried out within the 
smaller pUC57 vector, as opposed to pCAGGS, in order to reduce the chance of introducing 
non-ƐƉĞĐŝĨŝĐŵƵƚĂƚŝŽŶƐŽƌƉŽůǇŵĞƌĂƐĞ①‘ƐůŝƉƉĂŐĞ①?ŝŶƚŚĞŝŶƐĞƌƚŽƌǀĞĐƚŽƌĚƵƌŝŶŐǁŚŽůĞƉůĂƐŵŝĚ
amplification. The mutagenesis thermal cycling program included 25 cycles: denaturation at 
98°C for 10 seconds, annealing at 70°C (Tannealing = highest primer Tmelting + 3°C) for 30 seconds, 
and elongation at 72°C for 2 minutes (10-20 seconds per kb of plasmid). After rapid ligation of 
the amplicon and template removal via KLD treatment, mutagenic plasmid DNA was 
ƚƌĂŶƐĨŽƌŵĞĚŝŶƚŽ,①?ɲE.coli cells, propagated by overnight culture and purified. Sanger 
sequencing (GATC Biotech) of nucleic acid derived from two separate transformant colonies 
confirmed that the 27 N-terminal nucleotides of the signal peptide were correctly inserted into 
the prME construct (Figure 14). 24SPprME was then subcloned from pUC57 into pCAGGS 







Figure 14. Multiple sequence alignment (Jalview, UK) of the 24SPprME construct (top row) 
and the JEV Beijing-1 prME Genbank database sequence (bottom row). Nucleotides 34-105 
(shaded in blue) encode the 24-residue C-terminal signal peptide of the JEV C gene. 
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3.3.3 Production of JEV pseudotype viruses with HIV and MLV cores 
Following successful construction and subcloning of 15SPprME and 24SPprME, the production 
of retroviral pseudotypes was attempted, using the multi-plasmid co-transfection system. A 
variety of candidate JEV pseudotype supernatants were harvested: for lentiviral pseudotypes, 
the HIV gag-pol was expressed from p8.91 or psPAX2 plasmids, whereas for gammaretroviral 
pseudotypes, the pCMVi plasmid encoded the MLV gag-pol genes. Furthermore, pCSFLW or 
pMLVluc luciferase plasmids, and 0.5µg or 1.5µg of either pCAGGS-15SPprME or pCAGGS-
24SPprME were transfected into HEK293T/17 producer cells during JEVpp production. The 
candidate HIV-JEVpp and MLV-JEVpp supernatant samples were titrated onto four target cell 
lines ①W HEK293T/17, BHK-21, CrFK and Vero ①W and incubated for 48 hours, before quantifying 
luciferase expression (in RLU/ml) as an indirect measurement of virus infection (Figures 15-16). 
All titration assays iŶĐůƵĚĞĚƚǁŽŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƐ①P②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶ①?②?EG), which is a 
PV bearing no viral envelope glycoprotein, and a non-transduced cell only control. In every 
instance, relative transduction titres of JEVpp experimental samples were not significantly 
ŚŝŐŚĞƌƚŚĂŶƚŚŽƐĞŽĨ②?EG, indicating that no significant pseudotype particles bearing the 
envelope glycoproteins of JEV were produced. Additionally, the same candidate panel of JEV 
pseudotypes harbouring a GFP gene, which is a less sensitive system than luciferase, were also 
produced, but no GFP reporter gene expression was observed either, when these JEVpp 




Figure 15. Infectivity of JEV-pseudotyped lentiviral vector candidates onto HEK293T/17, BHK-21, 
CrFK and Vero target cell lines. Pseudotype transduction titres are expressed as mean ±SD (data 
ƌĞƚƌŝĞǀĞĚŝŶƚƌŝƉůŝĐĂƚĞ①)ŽĨƌĞůĂƚŝǀĞůƵŵŝŶĞƐĐĞŶƚƵŶŝƚƐƉĞƌŵů①?Z>h①?ŵů①)①?②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶĂŶĚ
ƚĂƌŐĞƚĐĞůůŽŶůǇŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƐĂƌĞĂůƐŽƐŚŽǁŶ①?①‘①?①?^W①?ĂŶĚ①‘①?①?^W①?ĚĞŶŽƚĞƐƚŚĞůĞŶŐƚŚŝŶĂŵŝŶŽ
acid residues of the signaůƉĞƉƚŝĚĞƵƉƐƚƌĞĂŵŽĨƚŚĞƉƌDŐĞŶĞ①?①‘①?①?①?②?Ő①?ĂŶĚ①‘①?①?①?②?Ő①?ƌĞĨĞƌƐƚŽƚŚĞ
mass of pCAGGS-15SPprME or pCAGGS-24SPprME transfected during JEVpp production attempts. 
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Figure 16. Infectivity of JEV-pseudotyped gammaretroviral vector candidate supernatants onto 




mass of pCAGGS-15SPprME or pCAGGS-24SPprME transfected during JEVpp production attempts. 
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3.3.4 Introduction of furin to increase infectivity of JEV pseudotype viruses 
As furin induces maturation of nascent JEV virions in the Golgi apparatus via cleavage of the M 
protein precursor, JEVpp production was attempted in the presence of additional furin 
protease expressed from a pCAGGS-furin plasmid, with masses of 0.25µg, 0.5µg, 0.75µg and 
1µg added alongside p8.91/pCMVi (0.5µg), pCSFLW/pMLVluc (0.75µg) and pCAGGS-24SPprME 
(0.5µg) during transfection. Pseudotype virus supernatant was harvested before titration onto 
HEK293T/17, BHK-21, CrFK and Vero cell lines to gauge JEVpp infectivity, measured in RLU/ml. 
Production of JEV pseudoparticles appeared to be unsuccessful in all cases, regardless of the 
mass of furin protease transfected or whether an HIV or MLV core was employed (Figure 17). 
Relative transduction titres of JEVpp preparations with additional furin protease were at 
ĞƋƵŝǀĂůĞŶƚůĞǀĞůƐƚŽWsŚĂƌǀĞƐƚƐůĂĐŬŝŶŐƚŚĞĨƵƌŝŶƉůĂƐŵŝĚĂŶĚ②?EG negative controls for each of 
the target cell lines, implying no transduction mediated by JEV prME envelope glycoproteins 
took place.   
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Figure 17. The influence of plasmid-derived furin protease expression on production of JEV-
pseudotyped retroviruses. Candidate JEVpp preparations were titrated onto HEK293T/17, BHK-21, 
CrFK and Vero target cell lines. Pseudotype transduction titres are expressed as mean ±SD (data 
retrieved in triplicate) of relative lumŝŶĞƐĐĞŶƚƵŶŝƚƐƉĞƌŵů①?Z>h①?ŵů①)①?②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶĂŶĚ
target cell only negative controls are also shown. The x-ĂǆŝƐǀĂůƵĞƐŽĨ①‘①?①?①?①?②?Ő①?①?①‘①?①?①?②?Ő①?①?①‘①?①?①?①?②?Ő①?ĂŶĚ
①‘①?②?Ő①?ƌĞĨĞƌƚŽƚŚĞŵĂƐƐŽĨƉ''^-furin transfected during JEVpp production attempts. 
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3.3.5 Low glucose environment for generating JEV pseudotype viruses 
Previous literature has reported that glucose can disrupt the mechanism of action of the C-
type lectin DC-SIGNR, which acts as an attachment factor on permissive target cells for a 
number of flaviviruses. Virion engagement by the carbohydrate recognition domain (CRD) of 
DC-SIGNR stabilises prME glycoprotein binding to a given cellular receptor, thus facilitating 
flavivirus fusion and entry. The binding and competitive inhibition of monosaccharides, such as 
glucose and mannose, to the CRD domain of DC-SIGNR, perturbs virus attachment and 
negatively impacts upon the success of flavivirus infection (Obara et al, 2013). To investigate 
whether this phenomenon effects HIV- and MLV-JEV pseudotype transduction of target cells, 
transfections and titration assays to produce and quantify the infectivity of JEV pseudotype 
viruses were carried out in a low glucose (1g/L) DMEM culture medium formulation. 
Transduction titres (measured in RLU/ml) were compared between JEVpp preparations (using 
pCAGGS-24SPprME) in low and high glucose DMEM (4.5g/L ①W typical glucose concentration in 
DMEM culture medium), with no significant improvement of infectivity observed by lowering 
the glucose concentration in the culture medium (Figure 18). All pseudotype virus titres were 
ŽĨĐŽŵƉĂƌĂďůĞůĞǀĞůƐƚŽ②?EG negative controls, indicating negligible production of functional 
JEV pseudoparticles.   
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Figure 18. Comparison of JEV pseudotype virus preparations in low and high glucose DMEM culture 
medium. Candidate JEVpp samples (with HIV and MLV cores) were titrated onto HEK293T/17, BHK-21, 
CrFK and Vero target cell lines. Pseudotype transduction titres are expressed as mean ±SD (data 
ƌĞƚƌŝĞǀĞĚŝŶƚƌŝƉůŝĐĂƚĞ①)ŽĨƌĞůĂƚŝǀĞůƵŵŝŶĞƐĐĞŶƚƵŶŝƚƐƉĞƌŵů①?Z>h①?ŵů①)①?②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶĂŶĚ
ƚĂƌŐĞƚĐĞůůŽŶůǇŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƐĂƌĞĂůƐŽƐŚŽǁŶ①?①‘>ŽǁŐůƵĐŽƐĞ①?ĂŶĚ①‘ŚŝŐŚŐůƵĐŽƐĞ①?ĂƌĞĚĞĨŝŶĞĚĂƐ①?Ő①?>
and 4.5g/L glucose in DMEDĐƵůƚƵƌĞŵĞĚŝƵŵ①?ƌĞƐƉĞĐƚŝǀĞůǇ①?①‘①?①?①?②?Ő①?ĂŶĚ①‘①?①?①?②?Ő①?ƌĞĨĞƌƚŽƚŚĞŵĂƐƐŽĨ
pCAGGS-24SPprME introduced into mammalian producer cells to create JEVpp particles.  
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3.3.6 Utilisation of MLV packaging cell lines to attempt JEV pseudotype production 
Successful production of JEV-pseudotyped MLV virus particles has been reported previously, 
using the MLV gag-pol packaging cell line TELCeB6 as opposed to transfecting the necessary 
components for functional pseudoparticle generation (Lee et al, 2009; Lee et al, 2014). Both 
TELCeB6 and TECeB15 cell lines constitutively express replication-defective MLV pseudotyping 
cores, and thus can be exploited to produce pseudotype viruses by transient transfection of a 
heterologous envelope glycoprotein and a chosen reporter gene. In a bid to mimic the 
reported JEV pseudotype formation, both of these packaging cell lines were utilised as 
producer cells in lieu of HEK293T/17, and were each simultaneously transfected with pCNCG 
(GFP-encoding gammaretroviral vector plasmid) and either 1µg or 3µg of pCAGGS-15SPprME 
using Fugene 6 transfection reagent (Promega, UK). After harvesting of the candidate 
pseudotype supernatant from the packaging cell line monolayers and filtration to remove 
cellular debris, the JEVpp preparations were titrated onto HEK293T/17, BHK-21 and CrFK target 
cell lines. Retroviral pseudotypes bearing the VSV-G glycoprotein and harbouring a GFP 
reporter gene were used as a positive control in the titration assays, which were incubated for 
72 hours, before assessing levels of GFP expression under a fluorescent microscope. As can 
clearly be seen from Figure 19, no observable green fluorescence is present in any of the 
experimental sample wells, despite witnessing highly efficient transduction and GFP 
expression in the VSV-G positive control wells. This is a convincing indication that no successful 
JEVpp particles have been generated and in turn, no target cell transduction, reporter gene 




Figure 19. Utilisation of MLV packaging cell lines TECeB15 and TELCeB6 to attempt JEV pseudotype 
production. Representative green fluorescent images are displayed following titration assays with JEVpp 
samples generated in TECeB15 and TELCeB6. Bright field images of each cell line, as well as VSVpp positive 
control ĂŶĚ②?'ŶĞŐĂƚŝǀĞĐŽŶƚƌŽůŝŵĂŐĞƐĂƌĞĂůƐŽƐŚŽǁŶ①?①‘①?②?Ő①?ĂŶĚ①‘①?②?Ő①?ƌĞĨĞƌƚŽƚŚĞŵĂƐƐŽĨƉ''^-
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3.3.7 Immunofluorescence to determine prME intracellular localisation  
As the alteration of a number of methodological parameters was not successful in the 
generation of functional pseudotype viruses bearing the JEV prME glycoproteins, indirect 
immunofluorescent staining was undertaken to ascertain the subcellular distribution of any 
expressed prME antigen. HEK293T/17 cells were transfected with 1µg of either pCAGGS-
15SPprME or pI.18-Sussex89H3 and incubated for 48 hours. Following 
fixation/permeabilisation of transfected cells and antibody staining, sample coverslips were 
mounted onto glass slides and visualised under a fluorescent microscope. A selection of 
negative controls was employed: to gauge whether any non-specific primary antibody binding 
was taking place, untransfected HEK293T/17 cells were stained with equine polyclonal 1° Ab, 
rabbit-anti-ŚŽƌƐĞ①?Zɲ,①)-FITC 2° Ab and NucBlue nuclear stain (Figure 20E); in order to rule out 
non-specific secondary antibody binding, 293T cells transfected with either the prME (Figure 
20B) or HA (Figure 20D) ƉůĂƐŵŝĚƐǁĞƌĞƐƚĂŝŶĞĚŽŶůǇǁŝƚŚƚŚĞZɲ,-FITC 2° Ab (PBS in place of 1° 
Ab) and NucBlue nuclear stain. From here, samples with the full combination of antibodies 
could be reliably compared to negative controls to ascertain immunostaining mediated by 
binding to virus glycoprotein. As expected for the HA positive control (Figure 20C), the 
ƐƚƌŽŶŐĞƐƚŝŵŵƵŶŽƐƚĂŝŶŝŶŐĐĂŶďĞŽďƐĞƌǀĞĚĂƐŐƌĞĞŶ①‘ŚĂůŽƐ①?Ăƚ ƚŚĞĞĚŐĞƐŽĨŝŶĚŝǀŝĚƵĂůĐĞůůƐ①?
which is indicative of plasma membrane-localised HA expression, and suitably explains why 
successful pseudotyping with this heterologous envelope glycoprotein occurs. However, the 
immunofluorescence image for JEV prME expression (Figure 20A) appears to contain 
ƉĞƌŝŶƵĐůĞĂƌŐƌĞĞŶ①‘ƉĂƚĐŚĞƐ①?①?ǁŚŝĐŚĐŽƵůĚďĞĚƵĞƚŽŐůǇĐŽƉƌŽƚĞŝŶůŽĐĂůŝƐĂƚŝŽŶat the 
endoplasmic reticulum. This result suggests that moderate levels of prME expression may be 
taking place, but that this glycoprotein is retained intracellularly, and is not being incorporated 
into retroviral pseudoparticles ①W possibly due to contrasting native budding sites of flaviviruses 






Figure 20. Indirect immunofluorescent staining images to determine JEV prME intracellular 
localisation. A) HEK293T/17 cells transfected with pCAGGS-15SPprME and stained with equine 
ƉŽůǇĐůŽŶĂů①?①?ď①?Zɲ,-FITC 2° Ab and NucBlue nuclear stain. B) HEK293T/17 cells transfected with 
pCAGGS-①?①?^WƉƌDĂŶĚƐƚĂŝŶĞĚǁŝƚŚW^①?Zɲ,-FITC 2° Ab and NucBlue nuclear stain. C) HEK293T/17 
cells transfected with pI.18-,①?①?①?ĞƋƵŝŶĞ①?^ƵƐƐĞǆ①?①?①?ĂŶĚƐƚĂŝŶĞĚǁŝƚŚĞƋƵŝŶĞƉŽůǇĐůŽŶĂů①?①?ď①?Zɲ,-FITC 
2° Ab and NucBlue nuclear stain. D) HEK293T/17 cells transfected with pI.18-H3/A/equine/Sussex/89 
ĂŶĚƐƚĂŝŶĞĚǁŝƚŚW^①?Zɲ,-FITC 2° Ab and NucBlue nuclear stain. E) Untransfected HEK293T/17 cells 







3.3.8 Western blotting to validate prME expression 
Due to the persistent inability to produce retroviral pseudotype viruses displaying the prME 
envelope glycoproteins, SDS-PAGE and Western blotting was carried out to validate whether 
any prME expression is taking place when transfecting the pCAGGS-15SPprME and pCAGGS-
24SPprME constructs into HEK293T/17 cells. Either 0.5µg 0r 1.5µg of the 15SP or 24SP prME 
plasmids were transfected and incubated for 48 hours, prior to cell lysis, protein separation by 
SDS-PAGE, transfer onto a PVDF membrane, and blotting for desired antigens. As an internal 
ĐŽŶƚƌŽů①?ɴ- actin was also immunoblotted for, to determine whether the protocol was 
functioning ĐŽƌƌĞĐƚůǇ①?ůŽƚŝŵĂŐĞƐƚĂŬĞŶƵƐŝŶŐƚŚĞKĚǇƐƐĞǇ>ǆŵĂĐŚŝŶĞƌĞǀĞĂůĞĚƚŚĂƚɴ-actin 
was present in all samples, as expected, but band size and clarity varied, indicating a relatively 
functional but inconsistent procedure. For prME expression, the JEV monoclonal antibody 
81193 was utilised in Western blotting, which binds to domain III of the E protein and yields a 
~38kDa band. According to the blot image, no mAb81193 binding or prME expression were 
detected in any of the sample wells (Figure 21). Furthermore, JEV E protein was also not 
detected by the mAB81193 in the IXIARO positive control lane, suggesting a shortcoming in the 
protocol used to produce the Western blot, such as poor protein transfer to the PVDF 
membrane. It is possible that this result may be legitimate ①W however, this protocol was not 
completely refined and could require further optimisation before an actual lack of prME 
expression could be confidently concluded. Potential further protocol alterations include: 
standardisation of the mass of expressed prME added prior to SDS-PAGE peptide separation; 
the percentage of the polyacrylamide resolving gel used for SDS-PAGE; the method of protein 
transfer from gel to PVDF membrane; and the affinity of the primary antibody utilised for prME 


















































































Figure 21. Western blot images of ɴ-actin (~42kDa) and JEV prME (~38kDa) to validate protein 
expression in HEK293T/17 cells. A 12% polyacrylamide resolving gel was used to separate cell lysate 
peptides, prior to protein transfer and blotting for desired antigens. Spectra BR ladders with 
molecular weights (kDa) are also displayed at their approximate position on the PVDF membrane, 
ƐŝŶĐĞƚŚĞǇǁĞƌĞŶŽƚǀŝƐƵĂůŝƐĞĚďǇƚŚĞKĚǇƐƐĞǇ>ǆ①?>ŝĐŽƌ①?E①?h^①)ŵĂĐŚŝŶĞ①?①‘①?①?①?②?Ő①?ĂŶĚ①‘①?①?①?②?Ő①?ƌĞĨĞƌ
to the mass of pCAGGS-①?①?^WƉƌD①?①‘①?①?^W①?①)ŽƌƉ''^-①?①?^WƉƌD①?①‘①?①?^W①?①)ƚƌĂŶƐĨĞĐƚĞĚŝŶƚŽ




As can clearly be seen from the set of results displayed in this report, retroviral 
pseudoparticles displaying the prM and E envelope proteins of JEV have not been successfully 
generated, despite the exploration of several variable parameters that could have had an 
impact on pseudotype production. This is not attributed to the prME gene and its 
manipulations, which were carried out at the start of the project ①W the subcloning process of 
the custom-synthesised gene yielded positive results throughout, with gel electrophoresis 
images indicating successful digestion and liberation of the prME insert, and positive pCAGGS-
prME clones being identified from colony PCR and restriction digest screens. Furthermore, 
recombinant pCAGGS plasmids containing the 15SPprME or the extended 24SPprME genes 
were sequence verified, ensuring that unwanted mutations could not alter the structure of 
expressed prME and subsequently hinder pseudotype virus assembly.  
In downstream transfections to generate JEV pseudotype viruses (PVs), both HIV and MLV 
cores were utilised, as well as employing two distinct approaches to produce the PVs: the 
conventional multi-plasmid co-transfection method, and the use of MLV packaging cell lines 
that stably express the gag-pol core proteins for coating with heterologous viral envelopes. 
This enabled the comparison of two distinct retrovirus cores to interact with JEV prME proteins 
and assemble functional pseudoparticles. However, neither core was able to initiate PV 
production. Additionally, despite reports of TELCeB6 cells effectively acting as an MLV 
pseudotype backbone (Lee et al, 2009; Lee et al, 2014), results from this project conflict with 
those findings. Overall, it appears that the choice of core retrovirus employed was not a 
dependent factor on the success of pseudotyping JEV prME in this instance. However, the 




The carboxyl (COOH) terminus signal peptide of the C protein is located at the C-prM junction 
of the JEV genome, and directs the translocation of the prM protein through the secretory 
pathway in eukaryotic cells, once cleaved by signal peptidases (Stocks and Lobigs, 1998). In the 
relevant literature, signal peptide lengths of both 15 and 24 amino acid residues have been 
reported (Davis et al, 2001; Lin et al, 1998). Initially, the synthesised pUC57-prME construct for 
this study contained a 15-residue (or 45-nucleotide) signal peptide upstream of the prM gene. 
However, in order to maintain the correct signal peptidase cleavage and ensure the COOH C 
protein signal peptide spans the ER membrane properly, a prME gene construct with the full 
24 residue (or 72 nucleotide) signal peptide was produced. Despite this, transfections with 
either the 15SPprME or 24SPprME genes did not produce functional JEV pseudotype viruses, 
indicating that the length of signal peptide and subsequent efficiency of prM and E protein 
trafficking through the Golgi apparatus was not a causal factor for the lack of successful JEVpp 
production.  
A variety of target cell lines were also exploited to monitor transduction of any functional 
JEVpp and subsequent reporter gene expression: HEK293T/17, BHK-21, CrFK and Vero. Of 
these, BHK-21 and Vero are extensively used in virology to study entry and fusion mechanisms 
of JEV, and thus are generally acknowledged as being permissive to JEV infection (Ding et al, 
2011, Makino and Jenkin, 1975; Su et al, 2002; Nawa et al, 2003). CrFK cells have also been 
utilised as target cells for JEV entry (Lee et al, 2009; Cochran et al, 1991). As these permissible 
cell lines were not infected by putative JEVpp preparations at significantly higher levels than 
HEK293T/17 (which is not usually employed in JEV entry studies), or indeed at all, it can be 
confidently concluded that the inability to develop pseudotype-based assays for JEV is not 
attributed to the lack of a specific cellular receptor on target cell lines.  
Furin-like proteases are known to cleave the precursor segment from the JEV M protein during 
virus egress, inducing a conformational change at the virus envelope to create mature, 
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infectious virions (Davis et al, 2006; Mukhopadhyay et al, 2005). Reports of endogenous furin 
protease expression in HEK293T/17 cells vary between publications (Xu et al, 2002; Tay et al, 
2012; Tse et al, 2014), so an additional range of masses of furin plasmid were transfected into 
producer cells during JEVpp generation, in an attempt to stimulate this proteolytic reaction 
and create JEV pseudotype viruses with a structurally mature envelope. Regardless of plasmid 
mass, the heightened eukaryotic expression did not appear to play a critical role in JEVpp 
production, maturation and infectivity. However, to further investigate this phenomenon, 
plasmid-derived furin protease expression could be quantified by Western blot, and a cell type 
confirmed to endogenously express higher levels of furin protease, such as Huh7 (Tay et al, 
2012), could also be employed as JEVpp producer cells.  
The potential inhibitory impact of using high glucose DMEM culture medium to produce JEV 
pseudoparticles was also explored. Glucose and similar monosaccharides (from approximately 
②?①?ŵDĐŽŶĐĞŶƚƌĂƚŝŽŶ①)ĂƌĞƉƌŽǀĞŶƚŽĐŽŵƉĞƚŝƚŝǀĞůǇŝŶŚŝďŝƚƚŚĞĐĂƌďŽŚǇĚƌĂƚĞďŝŶĚŝŶŐĚŽŵĂŝŶŽĨ
DC-SIGN, which can act as a stabilising attachment factor on host cell plasma membranes, 
facilitating entry and infection for a number of flaviviruses (Obara et al, 2013). Despite 
hypothesising that this phenomenon may play a role in preventing JEVpp target cell 
transduction, the infectivity titres of JEV pseudotypes generated and titrated in low or high 
glucose DMEM were not significantly different, suggesting that glucose concentration is not a 
variable that can detrimentally influence JEVpp infection.  
A critical factor for success in general pseudotyping, and more specifically for JEV pseudotype 
viruses, is to validate that the necessary plasmid-borne envelope glycoproteins are being 
efficiently expressed within producer cells such as HEK293T/17. Due to the customisation of 
plasmids designed for optimal eukaryotic expression, it would be logical to hypothesise that 
recombinant protein production is taking place, driven by the efficient promoter region 
upstream of the cloned gene.  Furthermore, indirect immunofluorescent staining was used to 
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identify the intracellular localisation of expressed prME antigen, with results suggesting that 
there is identifiable expression of JEV envelope glycoproteins following transfection with the 
pCAGGS-xSPprME constructs, but that it is retained in perinuclear regions of the cell. This 
finding is consistent with the possibility of endoplasmic reticulum retention of prME, and 
failure of the HIV and MLV cores to recruit the JEV envelope during their egress. Despite this, 
the immunofluorescence images are extremely faint, the Western immunoblotting images 
clearly did not detect any expressed prME protein and it is evident from these results that no 
substantial JEV prME expression has taken place. A further consideration for future work 
related to this project would be to obtain a definitive verdict of the levels and locations of 
intracellular prME expression within producer cells, as this would offer valuable insight for 






Genetic modification of the Japanese encephalitis virus pre-membrane 
and envelope proteins to augment eukaryotic expression and stimulate 
pseudotyping with heterologous nucleocapsids 
4.1 Introduction 
Despite its many advantages, the pseudotype virus platform also poses some significant 
challenges. For instance, the majority of viruses that have to date been adapted into 
pseudotypes possess a single envelope glycoprotein, though the expression of two distinct 
envelope proteins may be a prerequisite for the successful generation of a PV, such as with the 
routinely-pseudotyped HCV. This can lead to a more complicated process for achieving 
functional PV production (Bartosch et al, 2003a; Mather et al, 2013). Furthermore, 
discrepancies can occur between the density of envelope glycoproteins displayed on the 
surface of a pseudoparticle and of a native, wild-type infectious virus (Kolokoltsov and Davey, 
2004). This can be problematic, since a reduction of glycoprotein density can result in the loss 
of quarternary epitopes created by the tight packing of envelope protein complexes 
(Kaufmann et al, 2010). Conversely, over-expression and excessive display of glycoproteins on 
the pseudotype surface can in fact mask important antibody epitopes that are accessible and 
immunologically recognised on the native virion surface (Nelson et al, 2008). Therefore, to 
avoid substantial serological implications, close scrutiny of assay data when conducting 
comparative serology is vital.  
However, a major challenge and perhaps the most relevant with regards to this study, is that 
critical processes in the assembly and maturation of the envelope proteins in the wild-type 
virus may be lost in the generation of a PV. In particular, retroviral pseudotyping lends itself 
more readily to the incorporation of heterologous envelope proteins from external-budding 
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viruses. This is because particle formation of retroviruses occurs at the plasma membrane, 
whereas for internal-budding viruses such as flaviviruses, it occurs at the endoplasmic 
reticulum. Although some internal-budding viruses can be successfully pseudotyped, such as 
SARS and HCV (Bartosch et al, 2003a; Hsu et al, 2003; Simmons et al, 2004; Temperton et al, 
2005; Fukushi et al, 2006), in many instances, this mismatch in the subcellular locations of 
virus maturation can inhibit the creation of functional PVs.  
One approach for counteracting this obstacle to successful pseudotyping is via the 
construction of a chimeric glycoprotein (cGP), which can encourage interaction between the 
nucleocapsid core and virus envelope protein during the production, assembly and egress of 
pseudoparticles. This technology has been successfully employed in the generation of PVs for 
each of the four DENV serotypes, where the transmembrane (TM) domain of the DENV E was 
replaced with the TM and cytoplasmic (CY) domains of the VSV-G glycoprotein (Hu et al, 2007). 
Importantly, the ectodomain of the native glycoprotein gene (i.e. DENV E) is not amended, so 
that when expressed, resultant PVs do not possess any structural alterations from an external 
perspective. The VSV envelope protein is an ideal template for cGP construction as it efficiently 
and reliably creates high-titre retroviral pseudotypes, which are frequently employed as 
positive controls in other viral pseudotyping studies, due to their wide host range and cell 
tropism (Cronin et al, 2005; Temperton et al, 2015). Also, the VSV-G TM and CY domains 
contain a membrane-targeting signal (Rose and Whitt, 2001), which enhanced the intracellular 
trafficking and plasma membrane expression of the DENV prME, thus enabling the generation 
of functional DENV PVs. This finding was confirmed by Western blot of producer cell lysates 
and viral supernatant (Hu et al, 2007).  Moreover, it has also been reported that an effective 
method for overcoming problems concerning the infectivity titre of RABV lentiviral 
pseudotypes is through the creation of a chimeric glycoprotein. In this case, the construct 
consisted of the external and TM domains of RABV fused to the CY domain of VSV-G, and 
146 
 
resulted in increased incorporation of envelope glycoproteins onto HIV-1 lentiviral cores, as 
well as increased in vitro infectivity into HEK293T cells (Carpentier et al, 2011).   
Another modification that can be made to the genes of virus envelope proteins in a bid to 
promote successful incorporation into pseudotype particles is the upstream inclusion of a 
Kozak consensus sequence. Originally in 1978, Kozak described a scanning model for the 
initiation of translation in eukaryotic cells. Along with elucidating the mechanism of how the 
①?①?^ƌŝďŽƐŽŵĂůƐƵďƵŶŝƚďŝŶĚƐƚŽƚŚĞ①?①?ĞŶĚŽĨĂŶŵZEĂŶĚƐĐĂŶƐĂůŽŶŐŝƚĨŽƌĂŶh'
(methionine) codon before initiating translation, it was also proposed that if a particular 
sequence of nucleotides is located directly upstream of the AUG codon, the efficiency of 
translation initiation can be enhanced, which in turn has the effect of significantly boosting 
protein expression levels (Kozak, 1978; Kozak, 1986; Kozak, 2002; Nagakawa et al, 2008).  
Efficient expression of the heterologous envelope glycoprotein is a crucial criterion in the 
generation of high-titre, functional pseudotype viruses ①W it has been presented in some 
pseudotyping studies concerning the internal-budding SARS and MERS coronaviruses that 
ĂƵŐŵĞŶƚĞĚ①‘ŽǀĞƌĞǆƉƌĞƐƐŝŽŶ①?ŽĨƚŚĞĞŶǀĞůŽƉĞƉƌŽƚĞŝŶŐĞŶ ĐĂŶƌĞƐƵůƚŝŶŐůǇĐŽƉƌŽƚĞŝŶ①‘ůĞĂŬĂŐĞ①?
to the plasma membrane and subsequent incorporation onto retroviral nucleocapsids as they 
bud from the cell (Simmons et al, 2004; Perera et al 2013; Temperton et al, 2015). This 
phenomenon could translate to other families of internal budding viruses, such as flaviviruses. 
The heightened protein expression conferred by the incorporation of a Kozak sequence into 
the envelope gene plasmid may increase the glycoprotein abundance at the plasma 
membrane, and in turn the likelihood of successful pseudotype virus formation.  
In this chapter, the construction of chimeric virus glycoproteins featuring the JEV E 
ectodomain, as well as the introduction of distinct Kozak consensus sequences upstream of the 
prME gene, will be investigated in order to promote the production of functional retroviral 
pseudotypes displaying the JEV envelope glycoproteins.  
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4.2 Materials and Methods 
4.2.1 Mutagenic primer design and synthesis 
The design of primers to be employed for both the construction of the JEV/VSV chimeric 
glycoproteins and the introduction of Kozak consensus sequences was conducted using the 
NEBaseChanger online program (http://nebasechanger.neb.com/; New England Biolabs, MA, 
USA). This tool is recommended by New England Biolabs for generation of primer sequences 
and calculation of an optimal thermal cycling program, when using the Q5 Site-Directed 
Mutagenesis Kit. All Kozak and chimeric glycoprotein primers were synthesised to order by 
Eurofins MWG Operon, Germany.   
4.2.2 Polymerase chain reaction 
Polymerase chain reaction is used as an integral part of the protocol for all site-directed 
mutagenesis carried out in this chapter. The Q5 Hot-Start High Fidelity DNA Polymerase is 
utilised in this kit, as part of a 2X concentrated Master Mix, which also contains a polymerase 
buffer, dNTPs and Mg2+ ions. Once mixed with the relevant plasmid template DNA and 
mutagenic primers, it is subjected to a thermal cycling program, causing exponential 
amplification of the template and incorporation of the required mutations into the subsequent 
amplicon material. The pUC57 plasmid was chosen as an initial starting template for all 
mutagenesis presented in this chapter, since it is a shorter construct than the pCAGGS 
expression vector used in subcloning, minimising the potential for polymerase replication 
slippage and nucleotide discrepancies to occur in the PCR product. Information pertaining to 
the generic materials used for performing PCR can be found in Chapter 2 of this thesis. Further 
details of the mutagenic PCR reaction mixture and thermocycling program are shown in Tables 




Q5 site-directed mutagenesis ①? PCR reaction mixture ①? total volume 25µl 
Component Volume (µl) 
2X Q5 PCR Master Mix 12.5µl 
Fwd primer (10µM) 1.25µl 
Rev primer (10µM) 1.25µl 
Template plasmid DNA (diluted to 1-25ng/µl) 1µl 





Q5 site-directed mutagenesis ①? standard thermal cycling program 
Cycle stage Temperature (°C) and duration (mins/secs) 




98°C for 10 seconds 
Annealing 50-72°C for 30 seconds 
Extension 72°C for 2 minutes 
Final extension 72°C for 2 minutes 





Table 4. Q5 site-directed mutagenesis PCR reaction mixture. Volumes are 
stated in µl for each component in the reaction mixture, to a total volume of 
25µl. The final concentration of the oligonucleotide primers in the mixture was 
0.5µM. 
Table 5. Standard thermal cycling program for Q5 site-directed mutagenesis 
kit. Each cycle stage is given, with corresponding temperature (in °C) and 
duration (in mins/secs). The optimal annealing temperature varies in each 
mutagenic amplification taking place and is calculated by the NEBaseChanger 
online tool, depending on the melting temperature (Tm) of the forward and/or 
reverse primers. Recommendations range from 50-72°C. 
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4.2.3 Kinase-ligase-DpnI (KLD) enzyme treatment 
Once exponential amplification is complete, the next stage of the Q5 Site-Directed 
Mutagenesis kit, used for all mutagenesis attempted in this chapter, is the KLD enzymatic 
reaction. The enzyme mix contains a blend of kinase, ligase and DpnI enzymes. This treatment 
harnesses the catalysing abilities of the three enzymes, to bring about phosphorylation and 
intramolecular ligation of the whole-plasmid PCR product, as well as DpnI digestion of 
methylated template DNA. Mutagenic amplicons produced during the production of JEV/VSV 
chimeric glycoproteins and the insertion of Kozak sequences into the JEV prME gene construct 
underwent KLD treatment, with incubation for 5 minutes at room temperature, before 





Q5 site-directed mutagenesis ①? KLD treatment reaction mixture ①? total volume 10µl 
Component Volume (µl) 
PCR product 1µl 
2X KLD buffer 5µl 
10X KLD enzyme mix 1µl 
Nuclease-free H2O 3µl 
Table 6. Q5 site-directed mutagenesis KLD reaction mixture. Volumes are 





Following KLD treatment, the whole-plasmid mutagenic amplicons should be successfully 
phosphorylated and circularised, as well as in a template-free solution, thanks to the presence 
of DpnI digesting unwanted, methylated DNA. Therefore, the intact mutant plasmids can be 
ƚƌĂŶƐĨŽƌŵĞĚŝŶƚŽ,①?ɲĐŽŵƉĞƚĞŶƚE.coli cells for propagation. In all instances, transformation 
was carried out as is described in Chapter 2 of this thesis, with the only difference being the 
plasmid DNA introduced into the competent E.coli cells was different from sample to sample. 
Potential transformants, harbouring Kozak- or chimeric glycoprotein-mutated plasmids, were 
streaked onto ampicillin-LB agar plates to promote growth of resistant colonies.  
4.2.5 Colony PCR 
If bacterial colonies grow and produce distinct, isolated colonies on their respective ampicillin-
LB agar plates, this indicates that transformation of the particular mutated pUC57-prME 
plasmid inƚŽ,①?ɲĐĞůůƐŚĂƐďĞĞŶƐƵĐĐĞƐƐĨƵů①?ĚƵĞƚŽƚŚĞĂŵƉŝĐŝůů ŶƌĞƐŝƐƚĂŶĐĞŐĞŶĞ①?ůŽĐĂƚĞĚŽŶ
the pUC57 vector backbone. In order to confirm specific uptake of the desired mutagenic 
plasmid, colony PCR was used, which amplifies a particular gene or stretch of nucleotides, 
enabling the screening of a plasmid with a desired insert to take place, without the prior need 
for further culturing and purification steps. All colony PCR in this chapter, for both Kozak and 
chimeric glycoprotein experiments, was performed using the M13 Fwd and Rev universal 
sequencing primers, which bind to the pUC57 plasmid in the arms of the vector, flanking the 
ŝŶƐĞƌƚŐĞŶĞĨŽƌĂŵƉůŝĨŝĐĂƚŝŽŶ①?&ƵƌƚŚĞƌŵŽƌĞ①?ƚŚĞ①‘:s①?①?^ZE①?ƚŚĞƌŵĂůĐǇĐůŝŶŐƉƌŽŐƌĂŵƵƐĞĚ
to carry out the colony PCR amplification is detailed in Table 7. A more detailed protocol, 
which includes information on the DreamTaq Green polymerase used, as well as positive and 





Colony PCR ①? ①‘:s①?①?^ZE①?ƚŚĞƌŵĂůĐǇĐůŝŶŐƉƌŽŐram 
Cycle stage Temperature (°C) and duration (mins/secs) 




94°C for 30 seconds 
Annealing 50°C for 30 seconds 
Extension 72°C for 2 minutes 30 seconds 
Final extension 72°C for 5 minutes 




4.2.6 Restriction enzyme digest screening 
To corroborate findings determined by colony PCR, especially in instances when successful 
transformation of particular Kozak or chimeric glycoprotein mutant pUC57-prME plasmids 
cannot be definitively confirmed, a further screening process of restriction enzyme digestion 
was utilised.  This reaction uses either conventional or FastDigest EcoRI and XhoI restriction 
enzymes, which cleave the recombinant pUC57-prME plasmids in the multiple cloning site 
(MCS) of the plasmid backbone, thus accurately removing and separating out an insert, if it is 
present. The length of the resulting vector and insert fragments can then be calculated via gel 
electrophoresis (see section 4.2.7) to assess whether the desired insert gene is possessed. 
Details of the endonuclease reactions, including incubation durations and temperatures, can 
be found in section 2.1.9. Representative conventional and FastDigest restriction digestion 
reactions are respectively shown in Tables 8 and 9.  
dĂďůĞ①?①?①‘:s①?①?^ZE①?ƚŚĞƌŵĂůĐǇĐůŝŶŐƉƌŽŐƌĂŵĨŽƌĐŽů ŶǇWZƐĐƌĞĞŶŝŶŐ①?
Each cycle stage is given, with corresponding temperature (in °C) and duration 
(in mins/secs). Once finished, the samples were stored in a refrigerated state 
in the thermocycler until removed completely.  
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Restriction enzyme digest screening ①? conventional REs ①?  
reaction mixtures ①? total volume 20µl 
 
Component 
Sample reaction volumes (µl)  
or masses (ng) 
༃ ༄ ༅ 
pUC57-prME  
plasmid DNA 
②L ~500ng ~500ng 
pUC57 Kozak/cGP-prME 
mutant plasmid DNA 
~500ng ②L ②L 
EcoRI 
enzyme 
1µl 1µl ②L 
XhoI 
enzyme 
1µl 1µl ②L 
10X stock Tango buffer 4µl 4µl 4µl 
Nuclease-free H2O Up to  
20µl 
Up to  
20µl 





4.2.7 Gel electrophoresis 
Restriction enzyme digest screening ①? FastDigest REs ①?  
reaction mixtures ①? total volume 20µl 
 
Component 
Sample reaction volumes (µl)  
or masses (ng) 
༃ ༄ ༅ 
pUC57-prME  
plasmid DNA 
②L ~500ng ~500ng 
pUC57 Kozak/cGP-prME 
mutant plasmid DNA 
~500ng ②L ②L 
FD EcoRI 
enzyme 
1µl 1µl ②L 
FD XhoI 
enzyme 
1µl 1µl ②L 
10X FD Green buffer 2µl 2µl 2µl 
Nuclease-free H2O Up to  
20µl 
Up to  
20µl 
Up to  
20µl 
Table 8. Conventional restriction enzyme digest screening reaction mixture. Each component of 
the reaction mixture is detailed, along with its volume (in µl) or mass (in ng) for each of the 
ĞǆƉĞƌŝŵĞŶƚĂůƐĂŵƉůĞƐ①PƌĞĂĐƚŝŽŶ༃ŝƐĚĞƐŝŐŶĞĚƚŽĐůĞĂǀĞĂ<ŽǌĂŬŽƌĐ'WŵƵƚĂŐĞŶĞƐŝƐƉůĂƐŵŝĚ①?
ǁŚĞƌĞĂƐ༄ŝƐƚŚĞƉŽƐŝƚŝǀĞĐŽŶƚƌŽůĐŽŶƚĂŝŶŝŶŐƚŚĞƐĞƋƵĞŶĐĞ-verified pUC57-prME plasmid, and 
༅ŝƐĂŶƵŶĐƵƚŶĞŐĂƚive control containing no conventional restriction endonucleases.  
Table 9. FastDigest restriction enzyme digest screening reaction mixture. Each component of 
the reaction mixture is detailed, along with its volume (in µl) or mass (in ng) for each of the 
ĞǆƉĞƌŝŵĞŶƚĂůƐĂŵƉůĞƐ①PƌĞĂĐƚŝŽŶ༃ŝƐĚĞƐŝŐŶĞĚƚŽĐůĞĂǀĞĂ<ŽǌĂŬŽƌĐ'WŵƵƚĂŐĞŶĞƐŝƐƉůĂƐŵŝĚ①?




4.2.7 Gel electrophoresis 
When the results of colony PCR or restriction enzyme digest screening reactions needed to be 
visualised, gel electrophoresis was employed. 10µl and 20µl, for colony PCR and restriction 
digest screening respectively, of each sample was loaded onto a 1% (w/v) agarose gel, with 
0.5X TAE used as the gel solvent and electrophoretic buffer. A 120V voltage was subsequently 
applied, until the gel dye front had migrated to the foot of the gel. Further information 
concerning the visualisation of the gel, as well as the details and volumes of the ladder used on 
all agarose gels as size standard for the measurement of experimental DNA bands, is located in 
Chapter 2.  
4.2.8 DNA sequencing  
As a final screening process to validate whether successful introduction of Kozak consensus 
sequences or construction of JEV/VSV chimeric glycoproteins had taken place, pUC57-prME 
plasmids that had been subjected to Q5 site-directed mutagenesis were sent to GATC Biotech, 
in order to undergo Sanger sequencing and accurately determine the insert nucleotide 
sequence. Either pCAGGS or universal M13 forward and reverse sequencing primers were 
utilised for sequencing purposes, depending on whether the plasmid vector was pUC57 or 
pCAGGS, respectively. More details, including sample preparation for the ^hWZDƌƵŶ①? and 
>/',dƌƵŶ①? sequencing systems, is present in Section 2.1.7.  
4.2.9 Transmembrane domain prediction 
A crucial aspect of logically designing a series of chimeric glycoprotein constructs is to 
accurately predict the location of transmembrane and cytoplasmic domains in both the native 




In order to elucidate the most likely positions of the two transmembrane domains towards the 
JEV E C-terminus, the amino acid sequence of the envelope glycoprotein was processed 
through a variety of online transmembrane topology prediction programmes (Table 10): 
x HMMTOP: This automatic server for transmembrane helices and protein topology 
utilizes a hidden Markov model (HMM) to study amino acid distributions within 
sample sequences, against a large database of known membrane-spanning, 
cytoplasmic and extracytoplasmic protein segments, to predict transmembrane 
topology (Tusnády and Simon, 1998; Tusnády and Simon, 2001).  
x TMHMM: This transmembrane topology predictor also uses a hidden Markov model 
and builds upon very similar HMM architecture to HMMTOP. TMHMM is able to 
perform specialised modelling of various membrane protein regions, and is particularly 
well suited to TM domain prediction because it incorporates several parameters, such 
as amino acid hydrophobicity, charge bias and helix length into one sophisticated 
estimation model (Sonnhammer et al, 1998; Krogh et al, 2001).  
x Phobius: The strength of this transmembrane topology predictor is that it is also a 
signal peptide predictor, and has the ability to discriminate between TM domains and 
SPs. This is particularly advantageous, as their hydrophobic characteristics can lead to 
incorrect cross-prediction between these two motifs (Käll et al, 2004).  
x TMPred: The TMPred program is able to make a prediction of the location and 
ŽƌŝĞŶƚĂƚŝŽŶŽĨĂƉƌŽƚĞŝŶ①?ƐŵĞŵbrane-spanning regions, using an algorithm which 
examines an array of established membranous protein segments extracted from the 
UniProt KB/Swiss-Prot database. A variety of biological parameters are taken into 
account in the algorithm, such as putative transmembrane sequences, amino acid 
hydrophobicity, flanking region sequences and protein taxonomy (Hofmann and 
Stoffel, 1993).  
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x Sosui: This prediction system offers a fast, accurate determination of protein topology, 
with the unique ability to distinguish membrane-bound and soluble proteins from 
amino acid sequences, as well as identifying transmembrane domains and elucidating 
secondary and tertiary protein structures (Hirokawa et al, 1998; Mitaku and Hirokawa, 
1999; Mitaku et al, 2002).  
Following the processing of the JEV E protein sequence through these online transmembrane 
topology prediction programs, a consensus was drawn based upon the results yielded from 
each program. From here, the cGP constructs could be compiled in amino acid form and 
subsequently reverse transcribed to yield nucleotide sequences.  








HMMTOP http://www.enzim.hu/hmmtop/html/document.html  Tusnády and Simon, 1998; 
Tusnády and Simon, 2001 
TMHMM http://www.cbs.dtu.dk/services/TMHMM/ 
 
Sonnhammer et al, 1998; 
Krogh et al, 2001 
Phobius http://phobius.sbc.su.se/ 
 




Hofmann and Stoffel, 1993 
Sosui http://harrier.nagahama-i-bio.ac.jp/sosui/ 
 
Hirokawa et al, 1998; 
Mitaku and Hirokawa, 






Utilisation of the transmembrane domain and the cytoplasmic tail of the VSV-G protein in 
relevant literature is relatively established and their nucleotide sequences have been 
presented in several publications, with slight sequence variation observed amongst the 
Table 10. Transmembrane topology prediction programs for the determination of JEV E 
TM domains. A full list of the transmembrane topology programs utilised to predict the 
TM domains of the JEV envelope glycoprotein are displayed, including the website URLs of 
the programs, and their references.   
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defined sequences (Cleverley and Lenard, 1998; Lagging et al, 1998; Buonocore et al, 2002; 
Köhl et al, 2004; Lei et al, 2010; Gravel et al, 2011). For this study, the amino acid residues that 
constitute the VSV-G TM domain and C-tail were defined by alignment and comparison of 
previous iterations of the protein regions, before an informed estimation was made, based 
upon the usual length, hydrophobicity and charge capping of the two glycoprotein motifs.  
Once a consensus was reached for the TMD and C-tail for VSV-G, these defined sequences 
could then be input into the amino acid sequences of the designed chimeric glycoprotein 
constructs.  
4.3 Results 
4.3.1 Design of JEV chimeric glycoprotein constructs using a VSV-G template 
In an attempt to induce an interaction between the JEV envelope glycoproteins and retroviral 
gag-pol cores in pseudotype production, the construction of several chimeric glycoproteins 
was attempted. These maintain the E ectodomain of JEV on the external, extraviral surface, 
but the transmembrane domains (TMDs) of JEV are altered by introduction of, or swapping 
with, the TMD and cytoplasmic tail (C-tail) of vesicular stomatitis virus G protein (VSV-G). A 
VSV-G template was chosen to be employed in the production of JEV chimeric glycoproteins, 
since this envelope glycoprotein pseudotypes retroviral cores with high efficiency and has 
been shown to enhance the capability of other virus envelopes producing functional HIV 
pseudotypes (Carpentier et al, 2012).  The following JEV prME/VSV-G chimeric glycoproteins 
(cGP) constructs were considered for design and utilisation in JEV pseudotyping experiments 
(see Figure 22 for schematics of all constructs): 
Chimeric glycoprotein #1: Replacing second JEV E TMD with the C-tail of VSV-G 
The simplest chimeric glycoprotein approach involves the substitution of the second JEV E 
TMD with the C-tail of VSV-G. The VSV-G C-tail is essential for its interaction with retroviral gag 
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and subsequent glycoprotein coating during pseudotype production, so has been included in 
this cGP to stimulate similar connections for JEV envelope glycoproteins. However, a main 
concern with this cGP construct is that pseudotype viruses have to successfully engage with 
target cells and induce entry via membrane fusion ①W for VSV-G, it has been confirmed that its 
TMD is vital for fusion with permissible target cell membranes (Cleverley and Lenard, 1998), 
whereas the unique hairpin motif between the two flavivirus TMDs is crucial for fusion and 
cellular entry for this family of viruses (Fritz et al, 2011). The absence of the complete TMD 
segment from either virus may prevent the success of this cGP construct. 
Chimeric glycoprotein #2: Replacing both of the JEV E TMDs with the TMD and C-tail of VSV-G 
JEV/VSV cGP #2 involves the replacement of both JEV TMDs with the VSV TMD and C-tail. 
Although this construct possesses the intact VSV transmembrane and cytoplasmic sections so 
should be fusion competent, the unique feature of flavivirus envelope proteins is that they 
contain a double TMD with a hairpin. It is possible that interactions between the ectodomain 
and transmembrane regions of JEV could be hindered by the removal of the distinctive JEV 
TMD segment. Furthermore, heterodimeric interactions between JEV prM and E proteins have 
been previously reported (Lin and Wu, 2005; Peng and Wu, 2014), and the absence of the E 
TMDs from this chimeric glycoprotein may prevent their intra-membrane contact with the prM 
transmembrane residues, possibly resulting in reduced prM-E heterodimerisation and 
inhibition of JEV structural conformational change and maturation.  
Chimeric glycoprotein #3: Appending the VSV-G TMD and C-tail onto the C-terminus of full 
length, wild-type JEV E 
The third cGP involves appending the VSV-G TMD and C-tail onto the C-terminus of the full-
length JEV E protein. This construct will result in the expression of three TMDs: the JEV E 
double TMD hairpin followed by the VSV-G TMD. The presence of the intact JEV 
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transmembrane segment should allow for interactions between E and prM, and subsequent 
virion envelope maturation; interaction with HIV or MLV gag proteins, and in turn pseudotype 
virus formation should occur, owing to the VSV-G TMD/C-tail. If successful PV production 
indeed takes place, the pseudoparticles should be fusion-competent with target cell 
ŵĞŵďƌĂŶĞƐ①?ŵĞĚŝĂƚĞĚďǇĞŝƚŚĞƌǀŝƌƵƐ①?ƚƌĂŶƐŵĞŵďƌĂŶĞĚŽŵĂŝŶƐ①?,ŽǁĞǀĞƌ①?ĂƉŽƚĞŶƚŝĂů
disadvantage of this construct is that the addition of an extra, heterologous transmembrane-
spanning domain may physically block and hinder intra-membrane prM-E interactions.  
Chimeric glycoprotein #4: Appending a duplicate first JEV E TMD and the VSV-G C-tail onto the 
C-terminus of wild-type, full length JEV E 
Chimeric glycoprotein construct #4 is similar to #3, but involves the duplication of the first JEV 
E TMD, in place of the VSV-G TMD, whilst retaining the VSV-G C-tail. This approach may create 
lower levels of interaction inhibition between the prM and E TMDs, as the extra domain 
embedded in the membrane is native to JEV. Nonetheless, the presence of this duplicated 
TMD may cause steric hindrance and subsequent envelope protein conformational distortion, 
as well as potentially inducing incorrect interactions with other prM and E TMDs.  
Chimeric glycoprotein #5: Inserting an anti-parallel tandem repeat of the VSV-G C-tail between 
the two JEV E TMDs 
JEV/VSV cGP #5 involves the insertion of an anti-parallel tandem repeat of the VSV-G 
cytoplasmic tail between the two JEV E TMDs. As the VSV-G C-tail is all that is required to 
interact with retroviral core proteins during pseudotype assembly, it is possible that the TMD 
is obsolete for chimeric glycoprotein construction, as fusion of pseudoparticles into target cells 
can be mediated by the full JEV E TMD segment. If this is the case, then construct #5 would not 
alter the transmembrane topology of the JEV envelope proteins. As the VSV-G C-tail is 
naturally monomeric, inclusion of a single C-tail would probably result in hairpin loop 
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formation and attachment of its C-terminus to the second JEV TMD, restricting its interaction 
with retroviral gag. Inclusion of two anti-parallel C-tails should enable them to sit adjacent to 
















1 2 1 
#5 
1 2 
Figure 22. A selection of schematics to represent the five JEV/VSV chimeric glycoprotein constructs. #1) Replacing second JEV E TMD with the C-
tail of VSV-G. #2) Replacing both of the JEV E TMDs with the TMD and C-tail of VSV-G. #3) Appending the VSV-G TMD and C-tail onto the C-
terminus of wild-type, full length JEV E. #4) Appending a duplicate first JEV E TMD and the VSV-G C-tail onto the C-terminus of wild-type, full 
length JEV E. #5) Inserting an anti-parallel tandem repeat of the VSV-G C-tail between the two JEV E TMDs. Cartoon depictions of the native VSV-G 
and JEV E proteins are also displayed.    
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4.3.2 Prediction and definition of JEV E TM domains and VSV-G TM domain and C-tail 
Once the designs for the potential VSV-JEV chimeric glycoproteins were finalised, it was then 
necessary to accurately define the amino acid regions of the JEV and VSV envelope 
glycoproteins that would constitute the transmembrane domains and, in the case of VSV, the 
cytoplasmic tail. Confident prediction of these segments would then enable amino acid 
sequence compilation of the chimeric constructs, and subsequent primer design for the site-
directed mutagenesis required to produce the cGPs.  
As previously mentioned, the transmembrane domain and cytoplasmic tail of the VSV-G 
protein have been detailed in several previous publications (Cleverley and Lenard, 1998; 
Lagging et al, 1998; Buonocore et al, 2002; Köhl et al, 2004; Lei et al, 2010; Gravel et al, 2011) 
and the exact definitions of their sequences vary to a certain degree, particularly concerning 
the length and N-terminal cut-off point of the transmembrane domain. Therefore, to identify 
the optimum sequences for each domain, the candidate amino acid sequences were aligned 
and comparative analysis was performed, which involved examining sequence length, 
ŚǇĚƌŽƉŚŽďŝĐŝƚǇĂŶĚƚŚĞƉƌĞƐĞŶĐĞŽĨĐŚĂƌŐĞĚĂŵŝŶŽĂĐŝĚƐ①?ǁŚŝĐŚƚĞŶĚƚŽĂĐƚĂƐ①‘ĐĂƉƉŝŶŐ①?
residues at either extremity of a TM domain (Figure 23). The analysis revealed that the C-tail 
sequence is consistently defined in every aligned sequence as the final 29 residues of the C-
terminus of the VSV-G protein, and so this exact sequence was used as the VSV-G cytoplasmic 
tail in this study, as shown in Figure 23. Following assessment of the candidate transmembrane 
domains extracted from previously published articles, sequence #6 was originally deemed to 
be the most suitable defined TMD sequence, as at 21 amino acids long, it conforms to the 
typical length of a membrane-spanning segment of a protein, and this stretch of residues also 
begins with a positively-charged lysine, which would be likely to act as a capping residue 




and the JEV E sequence, as well as to allow for any potential inaccuracies in the visual 
prediction of the TMD sequence itself. Therefore, the final defined VSV-G TMD sequence 
selected for this study is actually identical to the candidate sequence #5 listed in Figure 23 
(Buonocore et al, 2002).  
In order to distinguish the locations of the two transmembrane domains at the C-terminus of 
the JEV E protein, a variety of online resources were utilised, which are designed to assess the 
transmembrane topology of proteins and identify intramembranous areas of submitted amino 
acid sequences (full details given in section 4.2.9). The prME proteins of a representative strain 
from genotypes I to IV of JEV were inputted into each of the TMD topology programs, to check 
for any structural or topology-based variability of a genotype-specific nature. Once the results 
were given, the predicted transmembrane domains from each request were compared across 
the different JEV strains and TMD topology programs used. A high level of consistency was 
observed between all the predictions, with the locations of the two transmembrane domains 
unanimously defined as between residues 631-655 and 661-682, respectively (Figure 24). This 
finding appears accurate when assessed in the context of the structure of JEV and flavivirus E 
proteins in mature virions, as the two TM domains reside in close proximity to one another at 
the C-terminus of the E sequence (Mukhopadhyay et al, 2005). In addition to the two 
corroborated transmembrane domain predictions, the TMPred topology program also 
recognised a third stretch of amino acids (residues 599-620) as possessing the potential to be 
membrane-spanning (Figure 24). However, upon further inspection, this result was 
disregarded, as the sequence corresponds to the location of the second stem helix of JEV E, 
which lies flat against the JEV envelope and makes contact with the phospholipid bilayer in the 
final virion structure. These contacts with the lipid membrane of the virus, which are 
important in its function of preventing electrostatic repulsions throughout the E protein in its 
mature conformation, require a higher presence of hydrophobic amino acids in this sequence 
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(Mukhopadhyay et al, 2005). The subsequent hydrophobicity and length of this stem helix is 
most likely the cause of its inclusion in one of the predictions made by the TMPred program.   
Candidate VSV transmembrane domain and  
cytoplasmic tail sequences - references 
Candidate sequence number (#) Corresponding reference 
#1 Lei et al, 2010 
#2 Köhl et al, 2004 
#3 (C-tail only) Köhl et al, 2004 
#4 Lagging et al, 1998 
#5 Buonocore et al, 2002 
#6 Cleverley and Lenard, 1998 
#7 Gravel et al, 2011 
 
Candidate VSV TMD and C-tail sequences 
#1 GDTGLSKNPIELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [70] 
#2          IELVEGWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [61] 
#3                                          RVGIHLCIKLKHTKKRQIYTDIEMNRLGK [29] 
#4                                GLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [39] 
#5               GWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [56] 
#6                     KSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [50] 
#7                           FFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [44] 
 
Defined VSV TMD and C-tail sequences 
TMD: GWFSSWKSSIASFFFIIGLIIGLFLVL [27] 
C-tail: RVGIHLCIKLKHTKKRQIYTDIEMNRLGK [29] 
TMD & C-tail: 
GWFSSWKSSIASFFFIIGLIIGLFLVLRVGIHLCIKLKHTKKRQIYTDIEMNRLGK [56] 
  
Figure 23. Comparative analysis for the definition of the VSV-G transmembrane domain (TMD) and 
cytoplasmic tail (C-tail). Candidate amino acid sequences for the VSV-G TMD and C-tail were aligned 
before definition of the C-tail and prediction of the TMD were confirmed, based upon sequence length, 
ŚǇĚƌŽƉŚŽďŝĐŝƚǇĂŶĚƚŚĞƉƌĞƐĞŶĐĞŽĨĐŚĂƌŐĞĚ①‘ĐĂƉƉŝŶŐ①?ƌĞƐŝĚƵĞƐ①?dŚĞĨŝŶĂůŝƐĞĚĂŶĚĚĞĨŝŶĞĚĂŵŝŶŽĂĐŝĚ
sequences, as well as the corresponding references for each candidate sourced from previously published 





Defined JEV TMD sequences 
TMD1: GAFRTLFGGMSWITQGLMGALLLWMGVNAR [30] 




















































































Figure 24. Determination of the transmembrane domains (TMDs) located at the C-terminus of the JEV 
E protein. Five TMD topology programs were used ①W HMMTOP, TMHMM, Phobius, TMPred and Sosui ①W 
to predict the membrane-spanning sites of E for four virus strains from distinct JEV genotypes, before a 
general consensus was drawn. The amino acid sequences for both JEV E TMDs are also defined. JEV E 
TMDs 1 and 2 are coloured in green and blue, respectively. 
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Figure 25. Amino acid sequences of wild type JEV Beijing-1 prME and the five JEV/VSV chimeric glycoprotein 
constructs. The two JEV E transmembrane domains, as well as the VSV transmembrane domain and cytoplasmic 
tail, are highlighted in colour (in accordance with Figures 4.2 and 4.3). In construct #5, the two lysine residues 
shaded in grey indicate the middle of the VSV-G C-tail anti-parallel tandem repeat.  
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4.3.3 Mutagenic primer design for the construction of VSV/JEV chimeric glycoproteins 
Following the determination of the amino acid sequences for the JEV E TMDs, as well as the 
VSV-G TMD and C-tail, compilation of the complete amino acid sequences for the VSV/JEV 
chimeric glycoprotein constructs could take place (Figure 25). Subsequently, these full 
sequences were then used to enable the design of oligonucleotide primers necessary to carry 
out Q5 site-directed mutagenesis for cGP construction.  
Primer design was achieved through use of the NEBaseChanger program ①W in order to 
successfully produce effective primer sequences, the program requires the fulfilment of 
several criteria. Firstly, the amino acid sequences of the template (native JEV Beijing-1 
24SPprME) and desired (relevant cGP construct) proteins had to be reverse transcribed into 
nucleotide sequences, prior to entering into the NEBaseChanger system. The other parameters 
required were the nature of the mutagenesis i.e. insertion or substitution, and identification of 
the nucleotides which flank the mutagenic region. Following the completion of this 
information, NEBaseChanger is then able to generate specific forward and reverse primer 
sequences to enable the desired mutagenesis, and also offers important additional properties 
of each primer, such as the length in nucleotides, the GC% and the melting temperature (Tm). 
Furthermore, the program calculates a recommended paired annealing temperature (Ta) for 
the primers being used together in a mutagenesis reaction, which equals 3°C higher than the 
lowest Tm of the two primers.  Primer sequences and characteristics are given in greater detail 
in Tables 11 and 12, respectively.  
In chimeric glycoprotein construct #4, a duplicated first JEV E TM domain is present directly 
upstream of the appended VSV-G cytoplasmic tail. Unfortunately, this means that it cannot be 
feasibly generated using the Q5 site-directed mutagenesis kit, due to the fact that non-specific 
primer-binding and subsequent inaccurate amplification would occur. Therefore, it was 
decided that the best way to proceed for the momentum of this study was to cease pursuing 
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the production of this construct and prioritise the other chimeric glycoprotein constructs. It 
may be possible to achieve cGP construct #4 via an alternative cloning method, such as Gibson 
Assembly (New England Biolabs, MA, USA; Cat. No. #E5510S) ①W however, due to time 














































Table 11. Primer sequences employed in Q5 site-directed mutagenesis for the construction 
of JEV/VSV chimeric glycoproteins. The given primer names and their corresponding 
constructs are listed, along with the template plasmid and the full primer sequence, 
generated by the NEBaseChanger program. The colouration on each primer distinguishes the 
























GC content (%) 
Primer binding 








JEV_VSV_cGP#1_FW 61 20 67 71°C 
69°C 
 JEV_VSV_cGP#1_RV 63 17 58 66°C 
JEV_VSV_cGP#2_FW 60 15 45 58°C 
60°C 
 JEV_VSV_cGP#2_RV 59 14 44 57°C 
JEV_VSV_cGP#3.1_FW 58 21 67 71°C 
69°C 
 JEV_VSV_cGP#3.1_RV 66 17 44 66°C 
JEV_VSV_cGP#3.2_FW 61 20 67 71°C 
70°C 
 JEV_VSV_cGP#3.2_RV 78 17 38 67°C 
JEV_VSV_cGP#4_FW     
 JEV_VSV_cGP#4_RV     
JEV_VSV_cGP#5.1_FW 63 16 50 62°C 
65°C 
 JEV_VSV_cGP#5.1_RV 62 16 56 65°C 
JEV_VSV_cGP#5.2_FW 61 13 44 56°C 
59°C 
 JEV_VSV_cGP#5.2_RV 63 14 47 58°C 
Table 12. Characteristics of oligonucleotide primers used in Q5 site-directed mutagenesis to 
produce JEV/VSV chimeric glycoproteins. Each row presents a variety of properties corresponding to 
each mutagenic primer, including primer length, overall and primer binding site GC percentage, as 
well as the melting temperature and subsequent paired annealing temperature.  
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4.3.4 Q5 site-directed mutagenesis for the production of VSV/JEV chimeric glycoproteins 
Once the primers were successfully designed, their synthesis was ordered using Eurofins MWG 
Operon (details in section 4.2.1). After their arrival and reconstitution to the appropriate 
working concentration (see section 2.1.6), they were incorporated into mutagenesis PCR 
reaction mixtures, in an attempt to produce the candidate VSV/JEV chimeric glycoproteins.  
Initially, Q5 site-directed mutagenesis was carried out to produce cGP constructs #1, #3.1 and 
#5.1, as these mutagenic reactions required the standard pUC57-24SPprME plasmid as a 
template, unlike construct #2, #3.2 and #5.2, which require existing, successfully-mutated cGP 
construct plasmids as templates. The mutagenic PCR reactions were set up as described in 
Section 4.2.2. In these instances, the mutagenesis for both constructs #1 and #3.1 could be 
performed simultaneously, as they both required an annealing temperature of 69°C, whereas 
for construct #5.1, an annealing temperature of 65°C was necessary (Table 12). From here, 1µl 
of each amplified mutant PCR product was taken forward into the KLD reaction and 
subsequent transformation, before plating onto ampicillin-containing LB-agar plates. Resulting 
colony numbers and images of the streaked LB-amp plates can be observed in Figure 26. The 
three colonies residing on the VSV/JEV cGP #1 plate and the six present on the VSV/JEV cGP 
#5.1 plate were then subjected to colony PCR screening, to validate the presence of the 
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Figure 26. Transformant colony numbers of mutagenic pUC57-prME VSV/JEV chimeric 
glycoprotein candidate constructs. Following transformation of the cGP plasmid constructs 
and subsequent streaking onto LB-amp agar plates, the numbers of colonies present on each 
plate, after an overnight 37°C incubation, were recorded. Images of each of the antibiotic 
plates are also shown, to validate the identification of the distinct colonies.  
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4.3.5 Screening of potential mutant VSV/JEV chimeric glycoprotein plasmid clones 
The potential positive VSV/JEV cGP plasmid clones identified on the bacterial transformation 
plates subsequently underwent a colony PCR screening process, to calculate the size in 
nucleotide base pairs of the insert in the transformed, mutagenic plasmid, and thus ascertain if 
the mutagenesis to construct each chimeric glycoprotein has been successful. Each plated 
colony from constructs #1 and #5.1 was lysed, before mixing with a DreamTaq polymerase 
master mix and undergoing colony PCR, using ƚŚĞ①‘:s①?①?^ZE①?ƚŚermal cycling program 
(Table 7). Once complete, sample PCR products were run on a 1% (w/v) agarose gel at 120V, 
prior to UV visualisation. As can be seen from Figure 2.7, each of the three construct #1 
colonies (samples #1-3) successfully amplified a ~2.1kb DNA insert, and out of the six construct 
#5.1 colonies (samples #4-9), all of the samples expect #6 also appear to be positive, with 
strong amplification of the desired fragment. In addition to the experimental samples, a 
positive control (pUC57-24SPprME plasmid) and a negative control (empty pUC57 vector) were 
included on the agarose gel ①W interestingly, amplicon DNA was not apparent in the positive 
control lane. However, due to the convincing positive results observed in the vast majority of 
the experimental cGP lanes, a representative sample was taken forward for plasmid 
purification and Sanger sequencing, to check for successful mutagenesis and correct formation 






































1      2      3       4       5       L       6      7      8       9     +ve   -ve  
Figure 27. Gel electrophoresis image following colony PCR screening of candidate VSV/JEV 
chimeric glycoprotein constructs. Experimental samples #1-3 (for cGP construct #1) and #4-
9 (for cGP construct #5.1) were run in their corresponding, numbered lanes, alongside the 
GeneRuler 1kb DNA ladder (in lane L) and positive and negative controls (in lanes +ve and ①W
ve, respectively). Strong amplified DNA bands of a length of ~2.1kb, which equates to the 
approximate lengths of the cGP plasmid prME inserts, can be seen in lanes 1-5 and 7-9, with 
a faint PCR product of the same size also witnessed in lane 6.  
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4.3.6 Plasmid purification and Sanger sequencing of positive VSV/JEV chimeric glycoprotein 
clones 
On the basis of strongest amplicon production during colony PCR and the brightest bands 
visualised on the following gel image, samples #2 and #9 were selected for purification and 
sequencing.  These two sample colonies were picked from the re-streaked and incubated 
bacterial plate prepared during the colony PCR process, before overnight growth in an LB 
broth starter culture, pelleting by centrifugation and subsequent plasmid purification (as 
detailed in Section 2.1.4). Concentrations and purities of the pUC57-prME cGP plasmids were 
measured using the Nanodrop 2000 spectrophotometer (ThermoFisher Scientific, UK), with the 
resulting values presented in Table 13.  
cGP plasmid construct Concentration (ng/µl) Purity (A260/280) 
pUC57-prME cGP #1 201.9 1.81 




Each plasmid construct was then mixed with the M13 reverse primer and sent for sequencing, 
using the LIGHTrun Sanger sequencing system (GATC Biotech, Germany). Unfortunately, 
following the receipt of the sequencing results and analysis of each chromatogram, it was 
evident that the prME C-terminus of both the candidate cGP #1 and #5.1 plasmids was 
identical to that of the native pUC57-prME insert C-terminus, confirming that in fact the 
mutagenesis to create the VSV/JEV chimeric glycoproteins was unsuccessful. Therefore, as a 
consequence, further mutagenesis to complete the construction of cGP candidates #3 and #5, 
as well as to produce construct #2, was also unable to be carried out.   
Table 13. Measurement of pUC57-prME chimeric glycoprotein plasmid DNA concentration and 
purity. Prior to Sanger sequencing, the concentration and purity of each cGP plasmid construct was 
measured. Concentrations and purities are given in ng/µl and absorbance ratio of 260/280nm, 
respectively, alongside the corresponding plasmid construct name.   
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4.3.7 Selection of Kozak consensus sequences and subsequent mutagenic primer design 
In a bid to stimulate ribosomal activity and initiate translation of JEV viral RNA transcripts, thus 
considerably boosting downstream expression levels of prME proteins, the mutagenic 
insertion of three distinct, putative Kozak sequences was attempted. Out of the many short 
nucleotide stretches that have previously been defined as effective Kozak sequences, the three 
sequences decided upon to incorporate directly before the initial methionine (ATG) codon of 
the 15SP- or 24SP-prME genes were GTCAAA (Etheridge et al, 2014), CACAAA (Jackson et al, 
2011) and GCCACC (Babaie et al, 2011). This decision was made not only because of previous 
publications that have detailed the functional ability of these three sequences to initiate 
translation, but also because there is empirical evidence from previous studies carried out 
within the same laboratory group, indicating that each of these sequences have successfully 
contributed to high expression levels in the same batch of HEK293T/17 producer cells used in 
this study.    
In a similar fashion as with the chimeric glycoprotein primers, the design of mutagenic primers 
intended for the insertion of Kozak sequences was carried out using the NEBaseChanger 
program. Details of the nature and location of the mutation, as well as the template and 
desired sequences, were submitted to the program, resulting in the generation of six different 
forward primers, depending on the Kozak sequence being inserted, and also upon the length 
of the signal peptide upstream of the prME gene in the relevant construct. In each instance, 
ƚŚĞƐĂŵĞƌĞǀĞƌƐĞƉƌŝŵĞƌǁĂƐŐĞŶĞƌĂƚĞĚĂƐƚŚĞ①?①?ƚĞƌŵŝŶƵƐŽĨƚŚĞƉh①?①?-prME insert was 
unchanged and required no alteration in this series of mutations. The NEBaseChanger system 
also provided additional primer information and corresponding annealing temperatures for 
each downstream mutagenesis reaction (Table 14). All designed primers were subsequently 
ordered from Eurofins MWG Operon and reconstituted to the correct stock and working 
dilutions, prior to application in Q5 site-directed mutagenesis.  
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Kozak insertion mutagenesis primer characteristics 
Primer 
number 












































18 44 56 As 
Fwd  
Table 14. Sequences and properties of oligonucleotide primers used for the mutagenic 
insertion of Kozak sequences into pUC57-prME plasmids. Alongside each given primer name, 
the full primer sequence and relevant properties are displayed, such as the length in 
nucleotides, the percentage GC content, as well as the melting and resultant annealing 
temperatures. The red section on each coloured primer corresponds to the mutagenic region, 
whereas the green sections are where the primer binds.   
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4.3.8 Mutagenesis, transformation and screening of potential Kozak-mutated plasmids 
 To attempt the production of each of the six desired Kozak sequence insertions, Q5 site-
directed mutagenesis was carried out. The relevant template plasmids ①W either pUC57-
15SPprME or pUC57-24SPprME ①W were mixed with the Q5 polymerase master mix and the 
primers required to insert each candidate Kozak sequence, as detailed in Table 4.1. Based 
upon the recommendations given by the NEBaseChanger program, reactions involving forward 
Kozak primers #1, #3, #5 and #6 required an annealing temperature of 60°C, whereas for 
mutagenesis with forward primers #2 and #4, the recommended annealing temperature was 
58°C. All other temperatures and durations of the Q5 PCR thermal cycling program were 
identical for all Kozak mutagenesis, and are displayed in Table 5.  
 Subsequent to the mutagenic PCR reactions, 1µl of each PCR product was then carried 
forward into kinase-ligase-DpnI (KLD) treatment. Samples were incubated for a sufficient 
duration for the enzymes to take effect, before 2.5µl of each KLD-treated sample was 
transformed into 25µl aliquots oĨĐŽŵƉĞƚĞŶƚ,①?ɲE.coli cells, streaked onto ampicillin-
containing LB-agar plates and incubated overnight at 37°C. The resultant colony numbers 













Table 15. Transformant colony 
numbers of potential Kozak mutated 
pUC57-prME plasmid clones. 
Subsequent to transformation, 
streaking onto LB-ampicillin agar plates 
and overnight incubation, individual 
E.coli colonies potentially harbouring 
the desired Kozak mutant plasmids 
were counted and presented in a 
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In order to ascertain whether the colonies grown on the transformation plates possess the 
desired mutagenic plasmid with an inserted Kozak sequence, the 18 candidate colonies 
underwent colony PCR screening, using the M13 forward and reverse primers and amplifying 
with ƚŚĞ①‘:s①?①?^ZE①?ƚŚĞƌŵĂůĐǇĐůŝŶŐƉƌŽŐƌĂŵ①?dĂďle 7), before undergoing gel 
electrophoresis and UV visualisation. However, none of the prME inserts of the candidate 
Kozak plasmids were successfully amplified, as well as the positive control included on the gel 
(pUC57-24SPprME plasmid). Despite repeating this colony PCR experiment with a fresh 
preparation of the DreamTaq polymerase master mix, as well as altering the annealing 
temperature to stimulate improved primer binding to the PCR template, amplification of the 
desired ~2.1kb insert bands was not achieved. Therefore, restriction digest analysis was 
performed as an alternative screening process on a candidate colony from the potential 
pUC57-15SPprME-GTCAAAKoz, pUC57-15SPprME-GCCACCKoz and pUC57-24SPprME-





Restriction digest analysis was performed using EcoRI and XhoI restriction enzymes. In this 
instance, gel band lengths of ~2.7kb (pUC57) and ~2.1kb (Koz-prME) were desired. 
Furthermore, both conventional and FastDigest restriction enzymes were utilised in this 
reaction, for comparative purposes. Reaction mixtures for both sets of enzymes were prepared 
as detailed in Tables 8 and 9, before being placed in a thermocycler for incubation. Sample 
reactions #1-5, containing conventional enzymes, and samples #6-10, which included 
FastDigest enzymes, were incubated as described in Section 2.1.9. All samples were then run 
on an agarose gel (see Figure 28 for sample details), to assess the resulting DNA fragment 
lengths and quality of digestion. Both the conventional and FastDigest enzymes successfully 
digested the pUC57-24SPprME and Kozak mutant pUC57-prME plasmids, though a higher 
quality of digestion and clarity was observed for the FastDigest restriction enzymes. These data 
also confirm the presence of a prME insert in all of the mutagenic Kozak pUC57-prME 
plasmids, as bands of the approximate lengths of ~2.7kb and ~2.1kb were present in each of 
the experimental samples, as well as for the positive control. These DNA fragment lengths 
correspond to the known lengths of the pUC57 empty vector and the prME insert, respectively 
(Figure 28).   
From here, each of the three candidate colonies ①W pUC57-15SPprME-GTCAAAKoz, pUC57-
15SPprME-GCCACCKoz and pUC57-24SPprME-GCCACCKoz ①W were cultured, before plasmid 
purification and LIGHTrun Sanger sequencing took place, using the universal M13 forward 
primer. Unfortunately, once the sequencing results were returned and the chromatogram files 
were analysed, the mutagenesis was also revealed to be unsuccessful for the insertion of the 
Kozak consensus sequences upstream of the prME gene, as the aligned experimental 
ƐĞƋƵĞŶĐĞƐǁĞƌĞŝĚĞŶƚŝĐĂůĂƚƚŚĞ①?①?ƚĞƌŵŝŶƵƐƚŽƚŚĞŽƌŝŐŝŶĂů①?①?^W- and 24SP-prME genes, 
meaning that downstream studies to assess prME glycoprotein levels during JEV pseudotype 




   
L       1       2       3        4       5                         L       6       7       8       9      10   
Figure 28. Gel electrophoresis image following restriction enzyme digest screening of 
candidate Kozak insert mutagenic plasmids. Experimental samples #1 and #6 (for pUC57-
15SPprME-GTCAAAKoz), #2 and 7 (for pUC57-15SPprME-GCCACCKoz) and #3 and #8 (for 
pUC57-24SPprME-GCCACCKoz) were run in their corresponding, numbered lanes, alongside 
the GeneRuler 1kb DNA ladder (in lanes marked L) and positive (pUC57-24SPprME) and 
negative (uncut pUC57-24SPprME) controls (in lanes #4 and #9, and #5 and #10, respectively). 
All sample reactions containing restriction endonucleases successfully digested the plasmids, 
to achieve DNA fragment bands of ~2.7kb (pUC57) and #2.1kb (prME), indicating the presence 




The theme of this chapter was to explore various methods which could potentially increase the 
likelihood of producing functional-titre pseudotype viruses bearing the JEV envelope 
glycoproteins. There were two primary approaches to the experimental work presented in this 
chapter. Firstly, the attempted construction of VSV/JEV chimeric glycoproteins was explored, 
in a bid to induce an interaction between the JEV envelope proteins and the lentiviral gag-pol 
core proteins. This technique has been successfully employed previously to stimulate the 
assembly of other heterologous viral envelopes onto lentiviral cores, resulting in effective 
production and increased titre of pseudotype particles (Hu et al, 2007; Carpentier et al, 2011). 
Secondly, the presence of particular, short nucleotide stretches known as Kozak consensus 
sequences have been widely reported (Kozak, 1978; Kozak, 1986; Kozak, 2002; Nagakawa et al, 
2008). Kozak sequences, when located directly upstream of the starting methionine codon of a 
gene, serve to enhance the initiation of RNA translation, often resulting in a boost in protein 
expression levels. This mechanism could be harnessed to increase the intracellular expression 
of JEV viral envelopes for this study, and indeed, the three Kozak sequences selected for 
insertion into the pUC57-prME plasmid constructs ①W GTCAAA, CACAAA and GCCACC ①W have all 
been presented as effective translation initiators in recently published literature, for a variety 
of downstream applications (Babaie et al, 2011; Jackson et al, 2011; Etheridge et al, 2014).  
Unfortunately, the full effects of the VSV/JEV chimeric glycoprotein and the Kozak insertion 
mutant plasmid constructs could not be explored when applied to the production of JEV 
pseudotype viruses, as the Q5 site-directed mutagenesis utilised to perform the required 
nucleotide changes and form these genetic alterations was unsuccessful on both counts. The 
cause of the ineffective mutagenesis is currently unknown ①W however, following scrutiny of the 
protocols and methodologies used, it is possible that a failed KLD treatment could be 
accountable. An issue occurring at this step could mean that methylated template DNA was 
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not properly digested, and as a consequence, was carried forward to transformation and 
subsequent screening stages of the experiments. This eventuality may explain the sequencing 
results confirming that no mutagenesis took place, despite positive results in the previous 
colony PCR and restriction digest screening steps of the studies. Furthermore, false positive 
results may have occurred in screening stages involving colony PCR, due to non-specific primer 
binding, although methylated template DNA contamination seems more feasible.  
 The Q5 mutagenesis kit was used for the experiments detailed in this chapter because it had 
promptly and successfully been able to elongate the JEV C-terminal capsid signal peptide by 9 
residues, or 27 nucleotides, as shown in Chapter 3 of this thesis. Also, preliminary experiments 
using other similar site-directed mutagenesis kits had not been fruitful. However, a 
disadvantage to using the Q5 SDM kit is that there is a limited scope to optimise or 
ƚƌŽƵďůĞƐŚŽŽƚƚŚĞWZĂŶĚ<>ƐƚĂŐĞƐŽĨƚŚĞŬŝƚ①?ƐƉrotocols. This is due to the requirement of 
the NEBaseChanger program, which accurately designs oligonucleotide primers necessary to 
create the necessary insertion or substitution ①W it would be counter-intuitive to manipulate 
these sequences as the exact mutagenic sequence would not be incorporated into the PCR 
amplicon. Furthermore, other properties concerning the primer of the PCR thermal cycling 
program are recommended, such as the paired annealing temperature of the mutagenesis 
amplification. These recommendations are founded on detailed analysis of the primer 
sequence given by the same program, and are likely to produce an optimal result in 
downstream site-directed mutagenesis attempts. 
To conclude, if either of the approaches explored in this chapter resulted in the successful 
production of high-titre JEV pseudotype titres, it may enable their reliable utilisation in 
serological or virus biology-based study, whilst bypassing the considerable drawbacks of 
having to handle native, pathogenic JEV, and the high infrastructure and training expenses 




Lyophilisation of lentiviral pseudotype viruses for the development and 
distribution of a neutralisation assay-based diagnostic kit 
 
5.1 Preface 
The ability to effectively distribute and store assay reagents in a stable state is a vital aspect of 
the development of any assay, when the ambition is present to disseminate a diagnostic kit for 
clinical purposes, especially on an international or global scale. If the kit is designed to be 
utilised at the point of care, in a resource-deprived area and/or a region with a hot, arid or 
tropical climate, it is especially important that the reagents, in this instance pseudotype 
viruses, maintain a high level of storage stability and retention of virus titre. In this chapter, 
lyophilisation is explored as a means of preserving pseudotype viruses in medium- to long-
term storage, to enable their viability for cost-effective transit, end-point ambient incubation, 
reconstitution and use in downstream assays, with minimal detriment to their quality and 
efficiency. Unfortunately, since functional pseudotype viruses bearing JEV envelope 
glycoproteins were not successfully produced, a variety of high-titre RNA virus pseudotypes 
from different families were used as substitutes.  







5.2 Introduction  
In recent years, the rate of emergence and re-emergence of viral diseases has significantly 
increased, creating a concordant rise in the level of importance and impact on the global, 
clinical public health scale. Influenza (family Orthomyxoviridae, genus Influenzavirus A, species 
Influenza A virus) continues to be amongst the viruses with the highest propensity to cause 
morbidity and mortality in human populations ①W in 1997 and 2013 respectively, the H5N1 and 
H7N9 influenza subtypes caused notably severe outbreaks, and the highly transmissible H1N1 
virus caused a pandemic in 2009, fortunately mitigated by its low pathogenicity (Yuen et al, 
1998; WHO, 2010; Gao et al, 2013). The threat of influenza persists as novel subtypes, such as 
H6N1 and H10N8, cross species barriers to infect humans for the first time, and the recent 
emergence and discovery of H17N10 and H18N11 in Guatemalan bat reservoirs, which display 
a high level of diversity from other, more established influenza A subtypes (Tong et al., 2013; 
Wei et al., 2013; To et al., 2014). Similarly, rabies (family Rhabdoviridae, genus Lyssavirus, 
species Rabies virus) is a virus that possesses global ubiquity, with cases reported frequently 
on every continent except Antarctica. The lyssavirus is responsible for an annual mortality rate 
in excess of 60,000 people, of which the victims are primarily children and infants in resource-
deprived regions in Africa and Asia (WHO, 2013). Upon the onset of symptoms, rabies has an 
almost 100% case fatality rate, which is the highest of any known viral infection. Only very few 
patients have survived following the development of symptomatic pathology, with most of 
these cases resulting in a number of neurological sequelae (Jackson, 2013). Isolated outbreaks 
of Marburg virus (family Filoviridae, genus Marburgvirus, species Marburg marburgvirus) in the 
Democratic Republic of the Congo in 1999-2000, and then in Angola in 2004-2005, generated 
respective mortality rates of 83% and 90%, and more recent outbreaks in Uganda also act as a 
reminder that spillover events into human populations from unexpected, zoonotic viral 
sources can rapidly bring about serious public health concerns (Brauburger et al., 2012). 
Indeed, towards the end of 2014, the related Zaire ebolavirus, which is another prominent 
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member of the Filoviridae family, was the pathogen responsible for causing an outbreak which 
spread primarily through the West African countries of Guinea, Liberia and Sierra Leone, finally 
resulting in 28,652 cases throughout the next two years, with 40% of these proving fatal (Kaner 
and Schaack, 2016). Therefore, it is vitally important to consider options for monitoring the 
spread and curtailing the outbreak severity of such pathogenic viruses.   
Serological assays that are able to quantitatively measure the levels of antibody responses 
raised against immunogens, such as antigenic viral glycoproteins, allow for the experimental 
evaluation of novel vaccine and antiviral treatments, as well as permitting serosurveillance to 
track and monitor the epidemiological spread of viruses, which actively contributes towards 
international public health initiatives.   Serology compliments other branches of viral 
diagnostics, such as direct virus isolation or reverse transcription polymerase chain reaction 
(RT-PCR) diagnosis, through being able to retrospectively identify cases of acute viral infection 
once the transient viraemic stage has passed in the patient (Papenburg et al, 2011).  
Alongside their benefits, most conventional serological assays possess different disadvantages 
that have the propensity to negatively affect their reliability and efficiency.  
However, conventional serological assays possess drawbacks which detrimentally affect their 
efficiency. Importantly, most require the use of infectious wild-type virus, necessitating 
expensive, specialized biosafety level 3 or 4 (BSL-3 or -4) laboratories which are not readily 
available, especially in resource-limited areas. Hemagglutination inhibition (HI) assays, used 
routinely for influenza, suffer from variability caused by different erythrocytes and inhibitory 
factors, as well as low sensitivity. ELISA-based assays do not require the use of wild-type virus, 
but are also hindered by low sensitivity and cross-reactivity between samples. Furthermore, 
both HI and ELISA cannot differentiate between virus neutralising and non-neutralising 
antibody responses (as reviewed in Mather et al., 2013). Virus neutralisation assays, such as 
plaque reduction neutralisation test (PRNT) and fluorescent antibody virus neutralisation 
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(FAVN) assay, can measure virus neutralising antibody (VNAb) responses with high sensitivity 
and specificity levels but also require high biosafety for assay preparation, and in some cases 
are time-consuming and suffer from low-throughput (Cliquet et al., 1998; as reviewed in 
Mather et al., 2013).  
A potential solution to these issues is the utilisation of retroviral pseudotype viruses (PVs). PVs 
are composed of the structural and enzymatic core of one virus combined with heterologous 
envelope glycoproteins (Temperton et al, 2015). Manipulations to the genomic RNA of the 
lentiviral core create a replication-defective PV that encapsulates a quantifiable reporter gene.  
Transduction of a permissible target cell line is dependent upon the ability of the envelope 
glycoprotein to engage its cellular receptor in a process that mimics wild-type virus entry 
mechanisms. If this is successful, the reporter gene can be integrated into the host cell genome 
and subsequently expressed. Resultant levels of reporter protein in transduced cells can be 
measured, giving a readout equivalent to viral titre. Pseudotype virus neutralisation assays 
(PVNAs) attain comparable, if not higher, sensitivity and specificity results than many 
traditional serological assays (Desvaux et al., 2012).   
In order to maximise the utility of the pseudotype assay system, multiplexing of PVNAs has 
been demonstrated which permits simultaneous quantification of VNAb responses against 
several PVs (each harbouring a different reporter gene i.e. renilla and firefly luciferase, or GFP 
and RFP) in the same assay, sparing valuable reagents such as serum samples (Wright et al., 
2010). The flexibility of reporter genes that can be incorporated into PVs further customises 
the assay. Luciferase and GFP reporters enable highly quantitative readouts but require 
expensive reagents and/or equipment. However, infection by PVs that encapsulate lacZ 
①?ĞǆƉƌĞƐƐŝŶŐɴ-galactosidase) or secreted alkaline phosphatase (SEAP) reporter genes can be 
quantified by adding colorimetric substrates such as ONPG, CPRG or p-nitrophenyl phosphate 
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and measuring color change with an ELISA plate reader or by eye (Wright et al., 2009; Kaku et 
al., 2012).  
DƵůƚŝƉůĞǆŝŶŐ①?ĂƐǁĞůůĂƐƐĞůĞĐƚŝŶŐ①‘ůŽǁ-ĐŽƐƚ①?ƌĞƉŽƌƚĞƌŐĞŶĞƐ①?ĐŽŶƐŝĚĞƌĂďůǇƌĞĚƵĐĞƐƚŚĞĐŽƐƚ-per-
assay burden of the pseudotype platform. However, the high expenses associated in optimal 
transportation and storage can be an inhibitory obstacle in the international distribution of 
PVNAs. Despite pseudotype studies being conducted on field serum from resource-poor 
tropical countries, and reports of viruses that circulate in tropical regions being successfully 
pseudotyped (Wright et al., 2009; Kishishita et al., 2013), there appear to have been no 
published studies involving the carrying out of pseudotype neutralisation assays in tropical 
countries, especially in rudimentary laboratories without air-conditioning or access to reliable 
freezer units.  
The aim of this study was to ascertain the viability of lyophilising pseudotype viruses with a 
view to developing a PVNA-based kit. Pseudotype stability was monitored after subjection to 
environmental conditions likely experienced in the production, transit and usage of such a kit, 
especially to tropical countries. PV titres were also assessed subsequent to lyophilisation and 
immediate reconstitution, as well as incubating freeze-dried pellets at a variety of 
temperatures and humidities before reconstitution. 
5.3 Materials and Methods 
5.3.1 Viruses and cells 
The virus isolates pseudotyped in this study were influenza A/H5N1/Vietnam/1194/2004 strain 
(Genbank accession number ABP51976), rabies virus (RABV) strain Evelyn Rokitniki Abseleth 
(ERA; UniProtKB/Swiss-Prot code ABN11294) and the Lake Victoria strain of Marburg virus 
(MARV; Genbank accession number DQ447649).  Previously, the influenza HA gene and RABV 
G gene of these isolates were both sub-cloned into the pI.18 expression vector (Cox et al., 
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2002). The Marburg GP gene within the pCAGGS expression vector was a kind gift from 
Graham Simmons (Blood Systems Research Institute, San Francisco, CA, USA).   
Human embryonic kidney 293T clone 17 (HEK293T/17; ATCC CRL-11268) (Pear et al., 1993) 
cells were used for all transfections and as a target cell line for titration and neutralisation 
assays involving H5 pseudotype virus. Baby hamster kidney 21 cells (BHK-21; ATCC CRL-10) 
(Stoker and MacPherson, 1964) were used as a target cell line for RABV and MARV pseudotype 
virus assays. Both cell lines were cultured at 5% CO2 ŝŶƵůďĞĐĐŽ①?ƐDŽĚŝĨŝĞĚĂŐůĞDĞĚŝƵŵ
(DMEM) + GlutaMAX (Life Technologies, UK) supplemented with 15% foetal bovine serum 
(FBS) and 1% penicillin/streptomycin (Sigma Aldrich, UK). 
5.3.2 Serum samples 
For use in H5 PVNAs, a sample from a panel of ten sera extracted from chickens vaccinated 
with an inactivated, monovalent, adjuvanted H5N2 vaccine (A/chicken/Mexico/232/94/CPA 
strain) was selected. Previous studies have confirmed its seropositivity by HI (a titre of 1:1024 
with a homologous H5N2 test antigen) and PVNA, against an H5 A/Vietnam/1194/2004 
luciferase PV (Terregino et al., 2010; Molesti et al., 2013). To neutralise RABV pseudotypes, 
serum was used from a human subject vaccinated on days 0, 7 and 21 with the inactivated 
Rabipur vaccine (Novartis Vaccines, Germany).  
5.3.3 Production of pseudotype viruses 
The generation of all lentiviral pseudotype viruses was performed as detailed previously 
(Temperton et al., 2007; Wright et al., 2008).  24 hours prior to transfection, approximately 
4x106 HEK293T/17 cells were seeded into sterile 10 cm tissue culture dishes ①?EƵŶĐ①?dŚĞƌŵŽ
Scientific, UK). The HIV gag-pol plasmid, pCMV-②?①?①?①?①?(Zufferey et al., 1997) and the firefly 
luciferase reporter construct pCSFLW ①W (Capecchi et al., 2008) ďĂƐĞĚŽŶƉ,Z①?^/E-cPPT-SGW 
outlined in (Demaison et al., 2002) ①W were transfected simultaneously with either the influenza 
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HA, rabies G or Marburg GP expression vectors at a ratio of 1:1.5:1 (core:reporter:envelope) 
using the Fugene6 lipid-based reagent (Promega, UK). At 24 hours post-transfection, the cells 
were incubated with fresh media. For H5 transfections, exogenous recombinant 
neuraminidase from Clostridium perfringens (Sigma Aldrich, UK) was also added at this stage. 
Pseudotype supernatants were harvested at 48 hours after transfection and passed through a 
0.45µm pore filter (Millex®, Millipore, Billerica, MA, USA), before being prepared for 
lyophilisation. Remaining supernatant was aliquoted and stored at -80①?C.  
5.3.4 Lyophilisation of pseudotype viruses 
Individual samples of pseudotype virus were mixed with a sucrose-PBS cryoprotectant solution 
at a 1:1 v/v ratio to a 1M-0.1M range of molarities. Importantly, all lyophilisation was carried 
out in low surface-tension polypropylene microcentrifuge tubes (Caesa Lab, Canada), to 
prevent binding of the virus glycoproteins to the inside surface of the tubes, and subsequent 
loss of pseudotype titre, during freeze-drying. Once prepared, virus samples were pre-frozen 
at -80①?C. Immediately prior to lyophilisation, a second, pierced lid, made of standard 
polypropylene, was applied to each sample tube to allow for moisture release. All 
lyophilisation was carried out overnight in a FreeZone 2.5 litre freeze-drying chamber 
(Labconco, Kansas City, MO, USA) at a temperature of -50°C and a pressure of <0.133mBar. If 
the lyophilised pellets were stored for a sustained length of time after freeze-drying, the 
standard polypropylene pierced lid was removed from the sample tube, and the original low 
surface-tension polypropylene lid was replaced. Likewise, in the instances where the pellets 
were stored at a constant humidity as well as temperature, the sample tubes were kept in a 
sealed, humidified incubator unit, controlled by a humidistat. DMEM + GlutaMAX (with the 
same supplementation as for the cell culture) were attempted for all reconstitution of 




5.3.5 Pseudotype titration and neutralisation assays  
Titration and neutralisation assays were performed in 96-well plates and based upon 
previously described protocols (Temperton et al., 2007; Wright et al., 2009; Scott et al., 2012), 
but adapted for the use of reconstituted, lyophilised pseudotype. For titration assays, 1:2 serial 
dilutions of reconstituted pseudotype were incubated with 1x104 HEK293T/17 or BHK-21 cells 
for 48 hours before measuring relative luminescence units per ml (RLU/ml). For the 
neutralisation assay, serum samples were serially diluted (ranging from 1:40 to 1:81920) and 
incubated with 1x106 RLU of reconstituted pseudotype (as calculated from the titration assay) 
for 1hr at 37°C to permit antibody attachment to surface virus glycoproteins. 1x104 
HEK293T/17 or BHK-21 cells were then added to each well and incubated for 48 hours, prior to 
taking a chemiluminescent readout. In all instances, Bright-Glo luciferase assay reagent 
(Promega, UK) and a Glomax 96 luminometer (Promega, UK) were used to quantify luciferase 
reporter expression. 
5.3.6 Statistical analysis 
Pseudotype transduction titres were calculated by converting RLU readout values at a range of 
assay dilutions into RLU/ml, before determining the arithmetic mean and standard deviation. 
PVNA raw data was normalised as % neutralisation between mean values for a virus only 
control (equivalent to 0% neutralisation or 100% infection) and a cell only control (equivalent 
to 100% neutralisation or 0% infection), then IC50 and IC90 values were calculated using non-
linear regression analysis (log [inhibitor] vs normalised response ①W variable slope). All data 





5.4.1 Production of lentiviral pseudotypes 
High titre lentiviral pseudotype particles were generated bearing the envelope glycoproteins 
from influenza A/H5N1/Vietnam/1194/2004, rabies ERA and Marburg Lake Victoria strains. 
Transduction efficiency of the pseudotypes into HEK293T/17 cells (for influenza H5) and BHK-
21 cells (for RABV and MARV) was evaluated, and luciferase expression was observed at 
2.04x1010, 8.21x109 and 7.46x109 RLU/ml, respectively (Figure 29). All titration assays included 
ƚǁŽŶĞŐĂƚŝǀĞĐŽŶƚƌŽůƐ①P②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶ①?②?'①)①?ǁŚŝĐŚŝƐĂWsďĞĂƌŝŶŐŶŽǀŝƌĂůĞŶǀĞůŽƉĞ
glycoprotein, and a non-transduced cell only control.  
 
  
Figure 29: Infectivity of pseudotyped lentiviral vectors displaying influenza H5 A/Vietnam/1194/2004 
HA, RABV ERA G and MARV Lake Victoria GP glycoproteins. Pseudotype transduction titers are 
ĞǆƉƌĞƐƐĞĚĂƐŵĞĂŶ②?^ŽĨƌĞůĂƚŝǀĞůƵŵŝŶĞƐĐĞŶƚƵŶŝƚƐƉĞƌŵů①?Z>h①?ŵů①)①?②?ĞŶǀĞůŽƉĞŐůǇĐŽƉƌŽƚĞŝŶ①?
HEK293T/17 cell only and BHK-21 cell only negative controls are also shown. 
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5.4.2 Lyophilisation of lentiviral pseudotypes 
Next, pseudotype supernatants were mixed with a stepwise dilution series of sucrose-PBS 
solutions (1M, 0.5M, 0.25M, 0.1M) which acts as a cryoprotectant during lyophilisation. 
Supernatant was also lyophilised in pure PBS solution containing no sucrose, which is referred 
to as 0M sucrose-PBS. After overnight freeze-drying, lyophilised pellets were immediately 
reconstituted and transduction efficiency measured in a titration assay. Less than 1log10 of 
decrease in viral titre, measured in RLU/ml, was observed with H5, RABV and MARV 
pseudotypes at all cryoprotectant concentrations, when compared to their non-lyophilised 
counterparts (Figure 30A-C). Levels of titre retention are therefore sufficient for these 
lyophilised PVs to be taken forward into PVNA assays. As PV titre was retained following 
reconstitution of recently lyophilised pellets, regardless of sucrose-PBS concentration, freeze-























































Figure 30: Transduction retention of pseudotype viruses with (A) influenza H5 
A/Vietnam/1194/2004 HA, (B) RABV ERA G and (C) MARV Lake Victoria GP envelope glycoproteins 
following lyophilisation at a gradient of sucrose-PBS cryoprotectant molarities. Relative PV 
transduction titers are shown as mean ±SD of relative luminescent units per ml (RLU/ml). 
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5.4.3 Durability of lyophilised pseudotypes 
To ascertain the stability of PV aliquots stored in the freeze-dried state, individual lyophilised 
pellets in 1M, 0.5M and 0M cryoprotectant were incubated for varying durations at the 
following temperatures: -80°C, -20°C, +4°C, +20°C, +37°C/70% relative humidity (RH) and 
+37°C/95% RH. After 1, 2 and 4 weeks, freeze-dried pellets of PV were reconstituted and 
titrated as previously described (subsections 2.4 and 2.5) to calculate viral titre in RLU/ml. 
Generally, PV titre retention was high for all lyophilised H5 (Figure 31A-C), RABV (Figure 32A-C) 
and MARV (Figure 33A-C) samples that were stored at the lowest temperatures, but as the 
storage temperature increased, PV samples freeze-dried in the absence of cryoprotectant 
ĚĞŐƌĂĚĞĚƐŝŐŶŝĨŝĐĂŶƚůǇ①?ǁŝƚŚƚƌĂŶƐĚƵĐƚŝŽŶĞĨĨŝĐŝĞŶĐǇĚĞĐƌĞĂƐŝŶŐƚŽƚŚĂƚŽĨ②?'①?/ŶƚĞƌĞƐƚŝŶŐůǇ①?
relative humidity (RH) seems to play a role in viability of lyophilised PV pellets, with 1M- and 
0.5M-cryoprotected samples stored for 4 weeks generally retaining functional virus titre up to 







Figure 31: Effect of lyophilisation and pellet incubation on infectivity of H5 pseudotyped lentiviral 
vectors. Freeze-dried PVs displaying H5 A/Vietnam/1194/2004 HA were stored in either 1M, 0.5M or 0M 
sucrose-PBS cryoprotectant at a variety of temperatures and humidities for (A) 1 week, (B) 2 weeks and 
(C) 4 weeks before reconstitution and employment in a titration assay. Pseudotype transduction titres are 





Figure 32: Effect of lyophilisation and pellet incubation on infectivity of RABV pseudotyped lentiviral 
vectors. Freeze-dried PVs displaying RABV ERA G glycoproteins were stored in either 1M, 0.5M or 0M 
sucrose-PBS cryoprotectant at a variety of temperatures and humidities for (A) 1 week, (B) 2 weeks and (C) 
4 weeks before reconstitution and employment in a titration assay. Pseudotype transduction titres are 





Figure 33: Effect of lyophilisation and pellet incubation on infectivity of MARV pseudotyped lentiviral 
vectors. Freeze-dried PVs displaying MARV Lake Victoria GP glycoproteins were stored in either 1M, 0.5M 
or 0M sucrose-PBS cryoprotectant at a variety of temperatures and humidities for (A) 1 week, (B) 2 weeks 
and (C) 4 weeks before reconstitution and employment in a titration assay. Pseudotype transduction 




5.4.4 Reconstitution of lyophilised pseudotypes  
It is possible that reconstituting in supplemented DMEM results in an accumulation of soluble 
culture medium components in the pseudotype sample which may affect downstream 
employment in serological assays. To address this issue, we reconstituted H5, RABV and MARV 
pseudotypes (immediately after lyophilisation, in the presence of 0.5M sucrose-PBS) with 
distilled, nuclease-free H2O and DMEM (with supplementation described in subsection 2.1), 
before comparing their transduction ability into corresponding target cell lines with a titration 
assay (Figure 34). Levels of pseudotype titre retention were very similar with either 
reconstitution solution, indicating that possible culture medium nutrient accumulation when 
using DMEM to reconstitute lyophilised pseudotypes does not have an adverse effect on 
pseudotype infectivity. However, water could viably be used as an alternative solution for 
resuspension of freeze-dried pseudotypes, but it is uncertain whether this would detrimentally 
affect the health of the target cell lines in titration and neutralisation assays, due to insufficient 
volumes of fresh DMEM.   
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Figure 34. Influence of reconstitution solution on H5, RABV and MARV pseudotyped lentiviral 
vectors. Freeze-dried PVs with influenza H5 A/Vietnam/1194/2004 HA, RABV ERA G or MARV Lake 
Victoria GP envelope glycoproteins were reconstituted in either distilled, nuclease-free H2O or 
supplemented DMEM culture medium before utilisation in a titration assay. Pseudotype 
transduction titres are shown as mean ±SD of relative luminescent units per ml (RLU/ml). 
Unlyophilised pseudotype positive controls, and ②? envelope glycoprotein, HEK293T/17 cell only and 
BHK-21 cell only negative controls are also shown. 
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Table 16: Comparison of neutralising antibody titres against untreated and lyophilised pseudotyped 
lentiviruses. Half maximal inhibitory concentration (IC50) and 90% inhibitory concentration (IC90) 
values of confirmed antibody-positive antisera against H5 influenza and RABV pseudotypes before and 
after lyophilisation. VNAb titres were calculated using GraphPad Prism 5 software and are displayed as 
serum assay dilutions. Exact IC50 and IC90 values are also shown in parentheses. 
 
5.4.5 Neutralisation of pseudotypes post-lyophilisation 
The ability for lyophilised PVs to transduce target cells indicates that the influenza A, RABV and 
MARV envelope glycoproteins do not structurally deteriorate during the freeze-drying process, 
especially in the receptor-binding domains. However, in order to assess the structural integrity 
in the antigenic epitopes of the glycoproteins, neutralisation assays were also carried out using 
serum samples confirmed as antibody-positive against H5 and RABV strains. VNAb IC50 and IC90 
titres (the reciprocal of the highest serum dilution still able to confer 50% and 90% virus 
neutralisation) were compared between lyophilised and immediately reconstituted H5 and 
RABV pseudotypes, and their ①‘ĨƌĞƐŚ①?, unlyophilised counterparts, with no discernible reduction 














































It has been well-documented that retroviral pseudotypes are valid, reliable alternatives to 
wild-type virus for serological applications (Temperton et al, 2015). Advantageous qualities of 
the PVNA platform include the ability to conduct the assay in BSL-1 laboratories, as well as the 
ĂǀĂŝůĂďŝůŝƚǇƚŽƉĞƌĨŽƌŵŵƵůƚŝƉůĞǆĂƐƐĂǇƐĂŶĚŝŶĐŽƌƉŽƌĂƚĞ①‘ůŽǁ-ĐŽƐƚ①?ƌĞƉŽƌƚĞƌŐĞŶĞƐŝŶƚŽ
pseudoparticles, which all reduce the cost implications and increase the potential ubiquity of 
pseudotyping (Wright et al., 2009, 2010; Kaku et al., 2012).  However, the current necessity to 
store aliquots of PV supernatant at -80°C and to maintain the cold-chain during PV 
transportation present serious monetary obstacles for laboratories to acquire such reagents, 
especially if on a limited budget.  
Here, the viability of lyophilisation has been demonstrated as an alternative, cost-effective 
state for the storage and distribution of pseudotype viruses. In the presence of cryoprotectant, 
H5 influenza, rabies and Marburg PV supernatant retain very high levels of infectivity following 
freeze-drying and reconstitution.  Subsequent freeze-dried pseudotype pellets can generally 
withstand incubation for 4 weeks at a range of temperatures up to 37°C, and incubation in a 
①‘ƚƌŽƉŝĐĂůĐůŝŵĂƚĞ①?①?①?①?①?ĂŶĚ①?①?②?ƌĞůĂƚŝǀĞŚƵŵŝĚŝƚǇ①)ĨŽƌ①?ǁĞĞŬƐ①?ǁŚŝůƐƚŵĂŝŶƚĂŝŶŝŶŐĂǀŝƌĂůƚŝƚƌĞ
sufficient for employment in downstream neutralisation assays. This confirms the stability and 
glycoprotein integrity of lyophilised PVs throughout environmental conditions likely to be 
experienced within the production, dissemination and storage of a PVNA-based kit. 
Furthermore, both H5 influenza and rabies reconstituted pseudotypes were neutralised by 
VNAb-ƉŽƐŝƚŝǀĞƐĞƌƵŵƐĂŵƉůĞƐƚŽƚŚĞƐĂŵĞƉŽƚĞŶĐǇĂƐƚŚĞŝƌ①‘ĨƌĞƐŚ①?①?ƵŶůǇŽƉŚŝůŝƐĞĚĐŽƵŶƚĞƌƉĂƌƚƐ①?
indicating that antigenic epitopes on each virus glycoprotein do not structurally deteriorate 





With regard to the wider implications for PVNA-based serology kits, the findings reported in 
this study are also encouraging. The survival and usability of somatic cells after freeze-drying 
and reconstitution has already been established, with positive implications for many areas of 
biomedicine (Loi et al., 2008). Indeed, the opportunity to produce samples of pseudotype virus 
and candidate cell line as stable, dried pellets would considerably facilitate global distribution 
of a multi-component PVNA kit, at a fraction of the current expenditure for overseas shipping 
and storage on dry ice. Additionally, the high cost of purchasing frozen cell line ampoules from 
certified repositories can be avoided by incorporating lyophilised cells into such a kit. Overall, 
the utilisation of PVNA-based kits would significantly ameliorate logistic dilemmas surrounding 
vaccine evaluation and serological surveillance, especially for laboratories situated in resource-
poor countries where many emerging viral infections are prevalent. 
Virus lyophilisation as a stable means of storage is certainly not a novel phenomenon, with the 
process being acknowledged for decades (Tyrrell and Ridgwell, 1965). Studies involving wild-
type virus freeze-drying generally concur with this one in several aspects by, for instance, 
demonstrating the ability to store lyophilised foot and mouth disease virus at 4°C for 1 year 
(Fellowes, 1965) and freeze-dried poliovirus preparations at 37°C for 5 days (Berge et al., 
1971). Infectivity tests were also undertaken on pseudorabies virus lyophilised in a number of 
suspension media, with glutamate formulations mixed with sucrose or dextran proving the 
most cryoprotective (Scott and Woodside, 1976). Furthermore, the viability of freeze-dried 
viral vector formulations has been investigated for gene therapy applications. Retroviral 
vectors have recovered with more than 90% infectivity post-lyophilisation in the presence of 
sucrose cryoprotectant (Shin et al., 2010), with adenoviral vectors only showing negligible 
drops in titre following freeze-drying and storage at ambient temperatures (Croyle et al., 
2001). Likewise, lyophilsed influenza virosomes retained both structure and function after 12 
ǁĞĞŬƐ①?ƐƚŽƌĂŐĞĂƚ①?①?(Wilschut et al., 2007). In comparison, pseudotyped retroviral vectors 
rapidly decreased in titre following three to five freeze-thaw cycles (Higashikawa and Chang, 
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2001), which further reinforces how preferable lyophilisation is for employment in VNAb-
based serological kits.  
Relative humidity (RH) ①W the percentage saturation of water vapour in air ①W plays a pivotal role 
in storage stability of dried pseudotype pellets, with high RH levels proving detrimental to PV 
recovery and transduction potential. Certainly for wild-type influenza virus, it has been 
confirmed that both virus transmission and infectivity are significantly decreased in highly 
humid atmospheres, which could be an attributive factor for its seasonal fluctuation (Lowen et 
al., 2007; Noti et al., 2013). It has previously been postulated that viruses with a high lipid 
content are more sensitive to high RH (Assar and Block, 2001).  
Investigation of further parameters would be necessary before a robust, reliable PVNA-based 
kit could be trialled and clinically utilised. Firstly, existing data would need to be extrapolated 
by testing freeze-dried pellet storage stability over longer durations i.e. six months, one year 
and three years, as well as comparing other candidate suspending media to sucrose-PBS to 
ensure maximum efficiency of cryoprotection. Employing freeze-dried pseudotypes in PVNAs 
against larger panels of sera, before drawing comparisons against not only unlyophilised 
pseudotypes, but also established serological assays using live virus, would be vital to assess 
accordance in VNAb titres between assays. To increase PVNA kit flexibility and customisation, 
it would also be important to assess the sensitivity of other commonly used pseudotype virus 
cores to lyophilisation and subsequent stability studies. Another consideration is to accurately 
simulate conditions during an international transit journey, thus ascertaining the ability for 
lyophilised PVs to cope with harsh temperature and atmospheric fluctuations between, for 
example, an aeroplane cargo deck and tropical climate conditions.  
To conclude, in this study it is shown H5 influenza, rabies and Marburg pseudotype viruses can 
be stably stored in a lyophilised state for 4 weeks at temperatures up to 37°C, in the presence 
of at least 0.5M sucrose-PBS as a cryoprotectant, and retain much of their infectivity once 
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reconstituted and employed in virus neutralisation assays. This confirms the viability of 
producing a freeze-dried PVNA-based kit, which would considerably facilitate the execution of 
vaccine evaluation and sero-surveillance studies, especially in countries without access to BSL-
3/-4 containment laboratories or constant cold-chain storage facilities, and ultimately permit 






Final discussion and conclusions 
In this thesis, a wide variety of approaches were attempted to produce retroviral pseudotype 
viruses bearing the heterologous JEV prME glycoproteins, which could be utilised in several 
downstream applications, such as evaluation of novel vaccines and antiviral treatments, or 
ƐĞƌŽƐƵƌǀĞŝůůĂŶĐĞƐƚƵĚŝĞƐƚŽƚƌĂĐŬƚŚĞǀŝƌƵƐ①? geographical spread, ultimately in order to enhance 
the serological study and cell entry processes of the flavivirus.  
Chapter 1 of this thesis provides an introduction and literature review, which aims to help 
identify the importance of the data presented in subsequent chapters, in the context of the 
wider bank of literature in the discipline. This chapter outlines the clinical impact of JEV and of 
flaviviruses as a genus of viruses, before dissecting various stages of the JEV life cycle that are 
highly relevant to the body of work of this thesis. Furthermore, the role of pseudotype viruses 
as surrogates for their native, pathogenic counterparts is introduced, along with their 
advantages when compared with other surrogate virus particles used for flaviviral serology in 
low biosafety environments. Subsequently, Chapter 2 describes all of the general materials and 
methods routinely utilised throughout the studies which constitute the practical work of the 
following results chapters.  
As detailed in Chapter 3, the exploration of various experimental parameters was undertaken, 
related to the transfection and titration stages of JEV pseudotype virus production attempts. 
This work involved gauging JEV PV titres when manipulating target cell lines, transfected 
plasmid masses, use of low glucose culture media, plasmid-derived protease expression and 
employment of different transfection producer cell systems, before attempts to validate 
glycoprotein expression. Despite not being able to successfully generate functional JEV 
pseudotype preparations, the immunofluorescence experiment carried out in this chapter, 
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which indicates the intracellular retention of expressed prME protein at the endoplasmic 
reticulum membrane, was important in prompting the directions taken regarding the 
experiments conducted in the next chapter.  
The premise of Chapter 4 of this thesis was to increase the likelihood of JEV pseudotype 
production via genetic alteration of the prME plasmid constructs. This objective was 
attempted by construction of chimeric prME glycoproteins with mutagenic insertions or 
substitutions of the VSV-G transmembrane domain and/or cytoplasmic tail, in a bid to induce 
interactions between the JEV envelope proteins and the retroviral gag-pol core proteins; and 
also by mutagenesis to insert Kozak consensus sequences upstream of the prME gene, to 
augment the initiation of RNA translation and consequently boost intracellular expression 
levels of the JEV envelope glycoprotein. Although the mutagenesis in this chapter was not 
successful, meaning that the cGP and Kozak mutant constructs could not be employed in JEVpp 
production trials, aspects of the experimental design within this chapter represent an attempt 
to produce novel knowledge not currently present in the virological discipline. For example, 
following searches of current, relevant literature, it appears that panels of VSV-JEV chimeric 
glycoproteins with designs similar to those included in the results of this chapter have not 
been previously published.  
The data presented in Chapter 5 highlights the importance of maximising the utility and 
amenability of the pseudotype virus platform, particularly for laboratories in resource-
deprived areas. Confirmation that lentiviral pseudotype viruses bearing envelope glycoproteins 
from distinct RNA virus families can be lyophilised, stored at a variety of temperatures, 
humidities and durations, and then reconstituted to retain functional to high virus titres which 
can be effectively neutralised by positive serum samples, furthers our knowledge of the 
durability of pseudotype viruses and has important implications for the global distribution and 
storage of a PVNA-based kit package. 
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Throughout the laboratory work carried out for this project, several contingency strategies had 
to be followed, due to the inability to produce JEV PVs in previous experiments, meaning that 
the incorporation of JEV pseudotype viruses in downstream applications was unable to occur. 
A likely reason for the inability to produce retroviral pseudotypes bearing JEV glycoproteins is 
due to the mismatch in subcellular localisations of any expressed prME protein, which resides 
in the endoplasmic reticulum membrane, and HIV gag-pol cores, which directly exit the cell 
from the external plasma membrane, during viral assembly and budding. However, if 
generation of functional JEV pseudoparticles had been successful, they could be employed in a 
distinct range of downstream applications. For instance, comparative serology studies could be 
performed, where the results of a JEV PVNA were analysed alongside those of a more 
established serological assay, such as PRNT. If a high correlation between the two datasets was 
observed, this would indicate that the pseudotype-based neutralisation assay may be suitable 
for use in clinical serology studies, circumventing the requirement to handle pathogenic virus. 
Furthermore, pseudotyping of other flaviviruses, such as WNV and Zika viruses especially, but 
also other members such as TBEV, SLEV and MVEV, could be carried out, which could pave the 
way for the development of similar studies of these pathogens and potentially to develop a 
multiplexing system for flavivirus pseudotypes. Such a system enables the simultaneous 
screening of antibody samples against two viruses in the same sample well of an assay plate, 
saving both money and valuable reagents, such as experimental serum. Other subsequent 
applications for JEV pseudotype viruses include their utilisation to evaluate screening 
programs for novel antiviral treatments, and to aid the elucidation of potential cellular 
receptors for attachment and entry of the flavivirus into host target cells. Further 
considerations for the production of JEV PVs are discussed below.  
The utilisation of HIV and MLV structural and enzymatic proteins as backbones for JEV 
pseudoparticle production has been persistently fruitless throughout this project. Due to this, 
the exploitation of distinct pseudotyping cores for the generation of JEVpp should be explored.  
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Firstly, the employment of VSV as a pseudotyping core, primarily produced via ƚŚĞs^sȴ'①?
system in which the native VSV glycoprotein is replaced with a reporter gene, has also been 
successfully shown in combination with a variety of heterologous envelope glycoproteins, such 
as Nipah virus, Hantaan and Seoul hantaviruses, and the ER-budding SARS coronavirus (Kaku et 
al, 2009; Tamin et al, 2009; Ogino et al, 2003; Fukushi et al, 2006). Due to its success at 
pseudotyping other internal-budding RNA viruses, the VSV backbone system was viewed as a 
promising option for JEVpp generation. However, functional VSV-JEV pseudotype viruses have 
already been reported by one group (Tani et al, 2010), and routine application of the 
manipulated VSV genome necessitates containment level 2 practices (Whitt, 2010), requiring 
adherence to relatively stringent biosafety guidelines and official approval from institutional 
Health and Safety boards. Such laboratories are not readily available for the implementation of 
this project work.  
Also, human foamy virus (HFV) has been considered as a core for pseudotype flaviviruses, due 
to its regular use as a gene therapy vector (Mergia and Heinkelein, 2003). HFV is another 
member of Retroviridae, so by definition would be capable of reverse transcribing a reporter 
gene RNA dimer, meaning that the conventional multi-plasmid co-transfection system for 
pseudotype generation would not have to be drastically altered. Furthermore, this spumavirus 
possesses a unique morphology within the wider retrovirus family, as it buds from the 
endoplasmic reticulum rather than the plasma membrane. As HFV and JEV bud from the same 
membranous organelle, this could circumvent the issue of mismatched virus budding locations 
potentially experienced during HIV-JEVpp and MLV-JEVpp production (Mergia and Heinkelein, 
2003; Trobridge, 2009). 
As an alternative to VSV, the use of recombinant Newcastle disease virus (rNDV) as a viral 
vector expressing foreign JEV prME is being investigated, with co-operation from Dr Subbiah 
Elankumaran, University of Maryland (Huang et al, 2003; Zhao and Peeters, 2003; Wen et al, 
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2013). This process would involve the removal of the haemmaglutinin-neuraminidase (HN) and 
fusion (F) proteins from the full-length NDV genome and replacement with a luciferase (or 
other) reporter gene, to create an rNDV-ȴ,E①?&-Luc genome. This manipulated genome would 
then be cloned into a suitable DNA expression plasmid and transfected into pseudotype 
producer cells, alongside either the JEV 15SP- or 24SPprME plasmid construct. Additionally, 
this system functions under the transcriptional control of T7 RNA polymerase ①W this additional 
mandatory element can be introduced into HEK293T/17 producer cells via infection with a 
fowlpox-T7 helper virus, or alternatively by utilisation of BSR-T7 cells, which constitutively 
express the T7 RNA polymerase. An overview of the recovery systems available for 
recombinant NDV production from cDNA, which form the basis for the methodology to 
produce rNDV-JEV pseudotypes, can be found in Huang et al, 2003.  
Lastly, in collaboration with Professor Yvonne Perrie (Aston University, UK), another 
consideration to induce functional generation of JEV pseudotype viruses is via the exploitation 
of liposomes. Providing they were in the cleaved, mature conformation, recombinant prME 
glycoproteins of JEV could be incorporated into the external surface of liposomal vesicles. 
Upon introduction onto a producer cell monolayer either transiently transfected by, or 
constitutively expressing, a desired retroviral gag-pol and reporter gene, these liposomes 
could ƚŚĞŽƌĞƚŝĐĂůůǇĨƵƐĞĂŶĚŵĞƌŐĞǁŝƚŚƚŚĞĐĞůůƐ①?ƉůĂƐŵĂŵĞŵďƌĂŶĞƉŚŽƐƉŚŽůŝƉŝĚďŝůĂǇĞƌƐ①?
resulting in mature JEV envelope proteins coating the retroviral cores following budding and 
egress. If this approach was successful, it would circumvent the necessity for transfection of a 
prME plasmid, and subsequent expression, assembly and maturation, as a novel methodology 
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